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Abstract
Oleamide, an endocannabinoid-like mediator, is a fatty acid that
shares structural similarities with anandamide. Oleamide induces
cannabimimetic responses and is a potent vasodilator of rat small
mesenteric arteries. The cardiovascular actions of oleamide have
received relatively little attention in comparison to those of
anandamide, the prototypical endocannabinoid. The aim of this
study was to examine the vascular effects of oleamide in both health
and disease, making a comparison with those of anandamide.
This study demonstrated that oleamide caused vasorelaxation of the
rat isolated aorta. The vasorelaxant actions of oleamide were found
to be tissue dependent as oleamide did not evoke vascular
responses in the porcine mesenteric and coronary arteries.
Anandamide did not produce similar responses to oleamide in any of
these vessels, displaying marked differences between the two
compounds. Oleamide-induced vasorelaxation of the rat aorta was
abolished by capsaicin pre-treatment but this was independent of
sensory-nerve activity. This demonstrates a potential additional site
of action for oleamide and prompted further investigations into the
vascular actions of capsaicin. Oleamide also caused relaxation of
the rat perfused whole mesenteric arterial bed. This response was
diminished by a depolarising concentration of extracellular K+,
implicating the involvement of K+ channels.
Capsaicin evoked relaxation of both rat aortae and porcine coronary
arteries. The vasorelaxant effect of capsaicin was insensitive to
capsaicin pre-treatment and the presence of capsazepine, a TRPV1
antagonist. It was also found that the presence of capsaicin
inhibited the uptake of Ca2+ in depolarised porcine coronary arteries
and rat aortae on reintroduction of calcium. In porcine coronaries,
capsaicin abolished the contractile response to Bay-K 8644, a L-type
calcium channel activator. Therefore, it is proposed that capsaicin
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inhibits L-type calcium channels to drive vasorelaxation,
demonstrating a TRPV1-independent mechanism of action for
capsaicin.
Having described the vasorelaxation of Wistar aortae, the effects of
hypertension on the vascular actions of oleamide were determined.
Oleamide-induced vasorelaxation was significantly enhanced in
aortae from spontaneously hypertensive rats (SHR) compared to
those from normotensive Wistar Kyoto (WKY) controls. Oleamide
caused approximately 40% relaxation of the SHR aorta compared to
15% in the WKY isolated aorta. Similarly, responses to anandamide
were also increased in aortae from hypertension causing 30%
relaxation compared to 10% in arteries from normotensive controls.
Augmented vasorelaxation to oleamide and anandamide was
opposed by pre-treatment of vessels with capsaicin, an effect
independent of TRPV1 receptors. Inhibition of cyclooxygenase with
indomethacin potentiated responses to oleamide in WKY aortae to a
level comparable to responses in SHR aortae. Thus, this thesis
suggests that changes in the cyclooxygenase pathway are important
in regulating responses to oleamide in hypertension and may
represent an adaptive change in the early stages of established
hypertension in SHR rats.
In summary, this study provides further evidence of the
vasorelaxant nature of oleamide, which can be enhanced in arteries
from hypertension. Augmented responses in hypertension may
relate to alterations in the cyclooxygenase pathway during the early
stages of established hypertension in the SHR. This investigation
also documents the capsaicin-sensitive nature of oleamide
responses in aortic rings, which exists independently of sensory-
nerve mediated activity. The observation of a non-TRPV1 capsaicin-
sensitive mechanism may ultimately lead to the uncovering of an
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alternative mechanism of action for capsaicin in conduit arteries and
a novel site of action for oleamide.
Acknowledgements
iv
Acknowledgements
Firstly, I would like to thank Michael Randall and William Dunn for
their excellent supervision and guidance over the past years. I
would especially like to thank my parents for their constant love and
support, which has helped me immensely throughout my studies. I
would also like to thank my colleagues in E34, namely Amanda,
Emeka, Amjad, Jags and Laksh for all their help and for making the
lab a greatly more enjoyable experience. I would like to applaud
Michael Garle for all his hard work and expertise in making the lab
run smoothly. A massive thank-you goes to Marianne who has
made my time in Nottingham the best of my life. Finally, I would
like to acknowledge the BBSRC for funding this project.
Contents
v
Contents
Abstract ................................................................................... i
Acknowledgements.................................................................. iv
Contents ................................................................................. v
Publications ............................................................................xv
Abbreviations.........................................................................xvi
List of Figures ........................................................................xix
Chapter 1 General Introduction .................................................. 2
1.1 Fatty acid amides............................................................. 3
1.2 Synthesis and degradation of oleamide and anandamide....... 3
1.2.1 The biosynthesis of oleamide ....................................... 3
1.2.2 The biosynthesis of anandamide ................................... 7
1.2.3 Metabolism and uptake of anandamide and oleamide ...... 7
1.3 Evidence for oleamide as an endocannabinoid-like mediator 10
1.3.1 Cannabinoid receptor pharmacology ........................... 10
1.3.2 Oleamide as an endogenous ligand at CB1 receptors..... 13
1.3.3. In vitro effects of oleamide ....................................... 13
1.4 Interaction of oleamide and gap junctions ......................... 15
1.5 Cardiovascular effects of the endocannabinoid anandamide . 17
1.5.1 In vitro effects of anandamide.................................... 17
1.5.2 Anandamide and sensory-nerve activation ................... 18
1.5.3 Nitric Oxide release................................................... 19
Contents
vi
1.5.4 Vascular responses to anandamide and vasoactive
prostanoids ...................................................................... 22
1.5.5 Anandamide and the release of an EDHF ..................... 23
1.5.6 A novel non-classical cannabinoid receptor .................. 26
1.5 Hypotensive effects of endocannabinoids .......................... 30
1.6 Aims............................................................................. 32
Chapter 2 The vascular actions of oleamide in conduit arteries ..... 35
2.1 Introduction .................................................................. 35
2.2 Methods and Materials .................................................... 37
2.2.1 Animals ................................................................... 37
2.2.2 Preparation of aortic rings and experimental protocol .... 37
2.2.3 Preparation of porcine coronary arteries and mesenteric
arteries and experimental protocol ...................................... 40
2.2.4 Drugs and reagents .................................................. 42
2.2.5 Statistical analysis .................................................... 43
2.2.6 Isolation and culture of DRG neurones ........................ 43
2.2.7 Calcium imaging studies of DRG neurones ................... 45
2.3 Results ......................................................................... 46
2.3.1 Vascular responses to oleamide in the rat isolated aorta 46
2.3.2 Vascular responses to oleamide in the rat isolated aorta in
the presence of high extracellular K+ ................................... 47
2.3.3 Vascular responses to oleamide in the rat isolated aorta
after a 1h capsaicin pre-treatment ...................................... 48
2.3.4 Vascular responses to oleamide in the rat isolated aorta in
the presence of vanilloid receptor antagonists ...................... 49
Contents
vii
2.3.5 Vascular responses to oleamide in the rat isolated aorta in
the presence of COX-inhibition ........................................... 51
2.3.6 Vascular responses to oleamide in endothelium denuded
aortic rings ...................................................................... 52
2.3.7 Vascular responses to oleamide in the presence of URB597
in the rat isolated aorta ..................................................... 53
2.3.8 Vascular responses to oleamide in the presence of AM251
in the rat isolated aorta ..................................................... 54
2.3.9 Vascular responses to anandamide in the rat isolated aorta
...................................................................................... 55
2.3.10 Vascular responses to oleamide in porcine coronary
arteries............................................................................ 56
2.3.11 Vascular responses to anandamide in porcine coronary
arteries............................................................................ 57
2.3.12 Vascular responses to oleamide in porcine isolated
mesenteric arteries ........................................................... 58
2.3.13 Vascular responses to anandamide in porcine isolated
mesenteric arteries ........................................................... 59
2.3.14 Vascular responses to anandamide in the presence of L-
NAME in porcine isolated mesenteric arteries........................ 60
2.3.15 Vascular responses to anandamide in the presence of
indomethacin in porcine isolated mesenteric arteries ............. 61
2.3.16 Vascular responses to anandamide after a capsaicin pre-
treatment in porcine isolated mesenteric arteries .................. 62
2.3.17 Vascular responses to anandamide in endothelium-
denuded porcine mesenteric arteries ................................... 63
2.3.18 Effects of capsaicin and oleamide on calcium influx in rat
dorsal root ganglion neurones ............................................ 64
2.4 Discussion .................................................................. 65
Chapter 3 Enhanced vasorelaxant effects of oleamide and
anandamide in hypertension .................................................... 74
Contents
viii
3.1 Introduction .................................................................. 74
3.2 Methods and Materials .................................................... 78
3.2.1 Animals ................................................................... 78
3.2.2 Preparation of aortic rings and experimental protocol .... 78
3.2.3 Drugs and reagents .................................................. 80
3.2.4 Statistical analysis .................................................... 80
3.3 Results ......................................................................... 82
3.3.1 Vascular responses to oleamide and anandamide in
isolated aortae from SHR and WKY rats ............................... 82
3.3.2 Effects of AM251, a cannabinoid CB1 receptor antagonist,
on the vascular responses to oleamide in aortae from SHR and
WKY rats ......................................................................... 85
3.3.3 Effects of AM251, a cannabinoid CB1 receptor antagonist,
on the vascular responses to anandamide in aortae from SHR
and WKY rats ................................................................... 86
3.3.4 Effects of endothelial denudation on the vasorelaxant
responses to oleamide in SHR and WKY aortae ..................... 87
3.3.5 Effects of L-NAME on the vasorelaxant responses to
oleamide in SHR and WKY aortae........................................ 88
3.3.6 Effects of endothelial denudation on the vasorelaxant
responses to anandamide in SHR and WKY aortae................. 89
3.3.7 Effects of L-NAME on the vasorelaxant responses to
anandamide in SHR and WKY aortae ................................... 90
3.3.8 Effects of cyclooxygenase inhibition on the vasorelaxant
responses to oleamide in isolated aortae from SHR and WKY rats
...................................................................................... 91
3.3.9 Effects of cyclooxygenase inhibition on the vasorelaxant
responses to anandamide in isolated aortae from SHR and WKY
rats................................................................................. 94
Contents
ix
3.3.10 Effects of endothelial denudation on vascular responses
to oleamide in the presence of indomethacin in WKY aortae ... 95
3.3.11 Effects of the FAAH inhibitor, URB597, on vasorelaxant
responses to oleamide in aortae from SHR and WKY rats ....... 96
3.3.12 Effects of the FAAH inhibitor, URB597, on vasorelaxant
responses to anandamide in aortae from SHR and WKY rats... 97
3.3.13 Effects of capsaicin pre-treatment on the vasorelaxant
responses to oleamide in aortae from SHR and WKY rats ....... 98
3.3.14 Effects of capsaicin pre-treatment on vasorelaxant
response to anandamide in aortae from SHR and WKY rats .... 99
3.3.15 Vasorelaxant effects of capsaicin in aortae from SHR and
WKY rats ........................................................................100
3.3.16 Effects of the TRPV1 antagonist capsazepine and
ruthenium red on vasorelaxant responses to oleamide in aortae
from SHR and WKY rats ....................................................101
3.3.17 Effects of the TRPV1 antagonist capsazepine and
ruthenium red on vasorelaxant responses to anandamide in
aortae from SHR and WKY rats ..........................................104
3.4 Discussion .................................................................107
Chapter 4 Effects of hypertension on endothelium-dependent
vasorelaxation of the aorta .....................................................115
4.1 Introduction .................................................................115
4.2 Methods and Materials ...................................................118
4.2.1 Animals ..................................................................118
4.2.2 Preparation of aortic rings and experimental protocol ...118
4.2.3 Drugs and reagents .................................................119
4.2.4 Statistical analysis ...................................................120
4.3 Results ........................................................................121
Contents
x
4.3.1 Endothelium-dependent vasorelaxant responses to
carbachol in aortae from SHR and WKY rats ........................121
4.3.2 Effects of L-NAME on the vascular responses to
endothelium-dependent vasorelaxant carbachol in aortae from
SHR and WKY rats ...........................................................122
4.3.3 Effects of indomethacin on the vascular responses to
carbachol in aortae from SHR and WKY rats ........................123
4.3.4 Effects of capsaicin pre-treatment on the vascular
responses to endothelium-dependent vasorelaxant carbachol in
aortae from SHR and WKY rats ..........................................125
4.3.5 Effects of catalase, in the presence of L-NAME, on the
vasorelaxant responses to carbachol in aortae isolated from SHR
and WKY rats ..................................................................126
4.3.6 Effects of L-NAME, capsaicin pre-treatment and high
extracellular potassium on the vasorelaxant responses to
carbachol in SHR aortae ...................................................127
4.3.7 Effects of the gap junction inhibitor, carbenoxolone, on the
vasorelaxant responses to carbachol in SHR aortae ..............128
4.4 Discussion....................................................................130
Chapter 5 Effects of oleamide and anandamide in small mesenteric
arteries from spontaneously hypertensive rats ..........................137
5.1 Introduction .................................................................137
5.2 Methods and Materials ...................................................139
5.2.1 Animals ..................................................................139
5.2.2 Preparation of mesenteric arteries .............................139
5.2.3 Drugs and reagents .................................................141
5.2.4 Statistical analysis ...................................................141
5.3 Results ........................................................................142
Contents
xi
5.3.1 Vasorelaxant responses to oleamide in mesenteric arteries
isolated from SHR and WKY rats ........................................142
5.3.2 Vasorelaxant responses to anandamide in mesenteric
arteries isolated from SHR and WKY rats ............................143
5.3.3 Effects of L-NAME on the vasorelaxant responses to
anandamide in mesenteric arteries isolated from SHR and WKY
rats................................................................................144
5.3.4 Vasorelaxant responses to carbachol in mesenteric arteries
isolated from SHR and WKY rats ........................................145
5.3.5 Vasorelaxant response to capsaicin in mesenteric arteries
isolated from SHR and WKY rats ........................................146
5.4 Discussion....................................................................147
Chapter 6 Vasorelaxation to capsaicin and its effects on calcium
influx in arteries ....................................................................155
6.1 Introduction .................................................................155
6.2 Methods and Materials ...................................................159
6.2.1 Animals ..................................................................159
6.2.2 The vascular response to capsaicin in aortic rings and
porcine coronary artery ....................................................159
6.2.3 The effect of capsaicin on contractile responses to calcium
re-introduction ................................................................160
6.2.4 Drugs and reagents .................................................161
6.2.5 Statistical analysis ...................................................162
6.3 Results ........................................................................164
6.3.1 Vascular responses to capsaicin in rat isolated aortae ..164
6.3.2 Effects of capsaicin pre-treatment on capsaicin-induced
vasorelaxation of rat isolated aortae...................................165
Contents
xii
6.3.3 Involvement of TRPV1 receptors in capsaicin-induced
vasorelaxation of rat isolated aortae...................................166
6.3.4 Effects of ruthenium red on vasorelaxant responses to
capsaicin in the rat isolated aorta.......................................167
6.3.5 Effects of capsaicin on the contractile responses to calcium
re-introduction in rat isolated aortae ..................................168
6.3.6 Vascular effects of capsaicin in the porcine isolated
coronary artery................................................................169
6.3.7 Involvement of TRPV1 receptors in capsaicin-induced
vasorelaxation of porcine isolated coronary artery................170
6.3.8 Effects of capsaicin on the contractile response to calcium
re-introduction in porcine isolated coronary artery ...............171
6.3.9 Effects of 100µM capsaicin and the presence of vehicle on
the contractile response to calcium re-introduction in porcine
isolated coronary artery....................................................172
6.3.10 Involvement of TRPV1 receptors in the effects of
capsaicin on the contractile responses to calcium re-introduction
.....................................................................................173
6.3.11 Effects of capsaicin on contractile responses to the L-type
calcium channel activator Bay-K 8644 ................................174
6.3.12 Effects of oleamide on the contractile response to calcium
re-introduction in porcine isolated coronary artery ...............176
6.3.13 Effects of anandamide on the contractile response to
calcium re-introduction in porcine isolated coronary artery....177
6.4 Discussion....................................................................178
Chapter 7 Investigating the effects of oleamide in the perfused
mesenteric arterial bed ..........................................................187
7.1 Introduction .................................................................187
7.2 Methods.......................................................................190
7.2.1 Animals ..................................................................190
Contents
xiii
7.2.2 Perfused rat mesenteric arterial bed ..........................190
7.2.3 Drugs.....................................................................192
7.2.4 Statistical analysis ...................................................192
7.3 Results ........................................................................194
7.3.1 Vasorelaxant effects of oleamide in the perfused rat
mesenteric arterial bed.....................................................194
7.3.2 Involvement of gap-junctions in the vasorelaxant response
to oleamide in the perfused rat mesenteric arterial bed ........195
7.3.3 The involvement of potassium channels in the
vasorelaxant response to oleamide in the perfused rat
mesenteric arterial bed.....................................................195
7.3.4 Involvement of sensory nerves in the vasorelaxant
responses to oleamide in the perfused rat mesenteric arterial
bed ................................................................................196
7.3.5 Endothelium-dependent vasorelaxant of the perfused rat
mesenteric arterial bed.....................................................196
7.3.6 Endothelium-independent vasorelaxation of the perfused
rat mesenteric arterial bed................................................198
7.4. Discussion...................................................................199
Chapter 8 General Discussion..................................................204
8.1 General Discussion ........................................................204
8.1.1 Oleamide as a vasorelaxant ......................................204
8.1.2 Alternative mechanism of action for capsaicin .............205
8.1.3 Effect of hypertension on oleamide-induced responses .207
8.1.4 Effect of oleamide on EDHF-mediated vasorelaxation ...210
8.1.5 Conclusions ............................................................211
References ...........................................................................215
Contents
xiv
9. Appendices .......................................................................257
9.1 Appendix 1...................................................................257
9.1.1 Pre-contraction data for Chapter 2.............................257
9.1.2 Pre-contraction data for Chapter 3.............................258
9.1.3 Pre-contraction data for Chapter 4.............................262
9.1.4 Pre-contraction data for Chapter 5.............................263
9.1.5 Pre-contraction data for Chapter 6.............................264
9.1.6 Pre-contraction data for Chapter 7.............................264
Publications
xv
Publications
Hopps, J.J., Dunn, W.R., Randall, M.D., 2012. Enhanced
vasorelaxant effects of the endocannabinoid-like mediator, oleamide,
in hypertension. Eur J Pharmacol 684, 102-107.
Hopps, J.J., Dunn, W.R., Randall, M.D., 2012. Vasorelaxation
to capsaicin and its effects on calcium influx in arteries. Eur J
Pharmacol 681, 88-93.
Abbreviations
xvi
Abbreviations
2-AG 2-arachidonyl glycerol
anandamide N-arachidonylethanolamide
ANOVA analysis of variance
BACAT bile acid-coenzyme A:amino acid N-
acyltransferase
BKCa large conductance calcium-dependent
potassium-channels
CA1 cornu ammonis area 1
Ca2+ calcium ion
[Ca2+]i intracellular calcium
cAMP cyclic adenosine monophosphate
CB cannabinoid
CCl4 chemokine (C-C motif) ligand 4
cGMP cyclic guanosine monophosphate
CGRP calcitonin-gene related peptide
CNP C-type natriuretic peptide
CoA Coenzyme A
COX cyclooxygenase
CNS central nervous system
DMSO dimethyl sulphoxide
DRG dorsal root ganglia
DSE depolarisation-induced suppression of excitation
DSI depolarisation-induced suppression of inhibition
EDCF endothelium-derived contracting factor
EDHF endothelium-derived hyperpolarising factor
EDRF endothelium-derived relaxing factor
EET epoxyeicosatrienoic acids
eNOS endothelial nitric oxide synthase
EP1 prostaglandin E receptor 1
EP4 prostaglandin E receptor 4
EtOH ethanol
Abbreviations
xvii
FAAH fatty acid amide hydrolase
FABP fatty acid binding protein
FADH alcohol dehydrogenase
FALDH aldehyde dehydrogenase
GABA gamma-aminobutyric acid
GPCRs G-protein coupled receptors
*73Ǆ6 guanosine gamma thio-phosphate
h hour
HBSS Hank's balanced salt solution
H2O2 hydrogen peroxide
IP prostacyclin receptor
IP3 inositol trisphosphate
K+ potassium ion
KCl potassium chloride
KIR inward rectifier potassium-channel
L-NAME NG-nitro-L-arginine methyl ester
MGL monoacylglycerol lipase
min minute
mRNA messenger ribonucleic acid
NADA N-arachidonoyl dopamine
NAE N-acylethanolamines
Na+-K+ sodium-potassium pump
NAPE N-acylphosphatidylethanolamine
NAT N-acyltransferase
NH3 ammonia
NO nitric oxide
NOS nitric oxide synthase
OEA N-oleoyl-ethanolamine
OLDA N-oleoyl dopamine
oleamide cis-9-octadecenoamide
PAM peptidylglycine Į-amidating monooxygenase
PE phosphatidyl-ethanolamine
PGE2 prostaglandin E2
PGG2 prostaglandin G2
Abbreviations
xviii
PGH2 prostaglandin H2
PGI2 prostacyclin
PKA protein kinase A
PKG cGMP-dependent protein kinase
PLA phospholipase A
PLC phospholipase C
REM rapid eye movement
Rmax maximal response
RT-PCR reverse transcription polymerase chain reaction
S.E.M standard error of the mean
SHR spontaneously hypertensive rats
SNP sodium nitroprusside
TEA tetraethylammonium
THC tetrahydrocannabinol
TRPV1 transient receptor vanilloid type 1
WKY Wistar Kyoto
List of Figures
xix
List of Figures
Chapter 1 General Introduction .................................................. 2
Figure 1.1 Illustration of the proposed enzymatic pathway for the
biosynthesis of oleamide......................................................... 6
Chapter 2 The vascular actions of oleamide in conduit arteries ..... 35
Figure 2.1 Isometric tension set up. ....................................... 38
Figure 2.2 Representative trace of the response to oleamide in the
rat isolated aorta. ................................................................ 39
Figure 2.3 Representative trace of the response to anandamide in
a porcine mesenteric arterial segment.................................... 41
Figure 2.4 Vasorelaxant responses to oleamide and vehicle control
(DMSO) in rat aortic rings pre-contracted with methoxamine. ... 46
Figure 2.5 Vasorelaxant responses to oleamide in aortic rings from
Wistar rats contracted with high extracellular K+ (60mM). ........ 47
Figure 2.6 Vasorelaxant responses to oleamide in aortic rings from
Wistar rats pre-treated with capsaicin (10µM). ........................ 48
Figure 2.7 Vasorelaxant responses to oleamide in aortic rings from
Wistar rats pre-contracted with methoxamine in the presence of
capsazepine (5µM)............................................................... 49
Figure 2.8 Vasorelaxant responses to oleamide in aortic rings from
Wistar rats pre-contracted with methoxamine in the presence of
ruthenium red (10µM)..........................................................50
Figure 2.9 Vasorelaxant responses to oleamide in aortic rings from
Wistar rats pre-contracted with methoxamine in the presence of
indomethacin (10µM). .......................................................... 51
List of Figures
xx
Figure 2.10 Vasorelaxant responses to oleamide in endothelium
denuded aortic rings from Wistar rats pre-contracted with
methoxamine. ..................................................................... 52
Figure 2.11 Vasorelaxant responses to oleamide in aortic rings
from Wistar rats pre-contracted with methoxamine in the presence
of URB597 (1µM)................................................................. 53
Figure 2.12 Vasorelaxant responses to oleamide in aortic rings
from Wistar rats pre-contracted with methoxamine in the presence
of AM251 (1µM). ................................................................. 54
Figure 2.13 Vascular responses to anandamide in aortic rings from
Wistar rats pre-contracted with methoxamine. ........................ 55
Figure 2.14 Vascular responses to oleamide (10nM-30µM) and
vehicle control (DMSO) in porcine coronary arteries pre-contracted
with U46619. ...................................................................... 56
Figure 2.15 Vascular responses to anandamide in porcine coronary
arteries pre-contracted with U46619. ..................................... 57
Figure 2.16 Vascular responses to oleamide (10nM-10µM) and
vehicle control (DMSO) in porcine mesenteric arteries pre-
contracted with U46619. ...................................................... 58
Figure 2.17 Vasorelaxant responses to anandamide and vehicle
control (ethanol) in porcine mesenteric arteries pre-contracted
with U46619. ...................................................................... 59
Figure 2.18 Vasorelaxant responses to anandamide in porcine
mesenteric arteries pre-contracted with U46619 in the presence of
L-NAME (300µM). ................................................................ 60
List of Figures
xxi
Figure 2.19 Vasorelaxant responses to anandamide in porcine
mesenteric arteries pre-contracted with U46619 in the presence of
indomethacin (10µM). .......................................................... 61
Figure 2.20 Vasorelaxant responses to anandamide in porcine
mesenteric arteries pre-contracted with U46619 after a 1h
capsaicin pre-treatment (10µM). ........................................... 62
Figure 2.21 Vasorelaxant responses to anandamide in endothelial
denuded porcine mesenteric arteries pre-contracted with U46619.
......................................................................................... 63
Figure 2.22 Intracellular calcium increases in Wistar rat DRG
neurones in response to capsaicin (100nM) and oleamide (100µM)
expressed as a percentage of the response to KCl (60mM). ...... 64
Chapter 3 Enhanced vasorelaxant effects of oleamide and
anandamide in hypertension .................................................... 74
Figure 3.1 Representative trace of the response to oleamide in the
SHR aorta........................................................................... 78
Figure 3.2 Vasorelaxant responses to oleamide in aortic rings pre-
contracted with methoxamine from SHR and WKY rats. ............ 83
Figure 3.3 Vasorelaxant responses to anandamide in aortic rings
pre-contracted with methoxamine from SHR and WKY rats. ...... 84
Figure 3.4 Vasorelaxant responses to oleamide in the presence of
AM251 (1µM) in aortae from WKY and SHR rats. ..................... 85
Figure 3.5 Vasorelaxant responses to anandamide in the presence
of AM251 (1µM) in aortae from WKY and SHR rats................... 86
Figure 3.6 Vasorelaxation of endothelium denuded aortae from
WKY and SHR rats by oleamide. ............................................ 87
List of Figures
xxii
Figure 3.7 Vasorelaxant responses to oleamide in aortae from
WKY and SHR rats in the presence of L-NAME (300µM). ........... 88
Figure 3.8 Vasorelaxation of endothelial denuded aortae from WKY
and SHR rats by anandamide. ............................................... 89
Figure 3.9 Vasorelaxant responses to anandamide in aortae from
WKY and SHR rats in the presence of L-NAME (300µM). ........... 90
Figure 3.10 Vasorelaxant effects of oleamide in WKY and SHR
aortae in the presence of indomethacin (10µM). ...................... 92
Figure 3.11 Vasorelaxant responses to oleamide in the presence of
niflumic acid (1µM) in aortae from WKY and SHR rats. ............. 93
Figure 3.12 Vasorelaxant responses to anandamide in the
presence of indomethacin (10µM) in aortae from WKY and SHR
rats.................................................................................... 94
Figure 3.13 Vasorelaxant effects of oleamide in endothelium
denuded aortae from WKY rats in the presence of indomethacin
(10µM)............................................................................... 95
Figure 3.14 Vasorelaxant responses to oleamide in the presence of
URB597 (1µM) in aortae from WKY and SHR rats..................... 96
Figure 3.15 Vasorelaxant responses to anandamide in the
presence of URB597 (1µM) in aortae from WKY and SHR rats.... 97
Figure 3.16 Vasorelaxant responses to oleamide in aortic rings
from WKY and SHR rats after a 1h pre-treatment of vessels with
capsaicin (10µM). ................................................................ 98
Figure 3.17 Vasorelaxant responses to anandamide in aortic rings
from WKY and SHR rats after a 1h pre-treatment of vessels with
capsaicin (10µM). ................................................................ 99
List of Figures
xxiii
Figure 3.18 Vasorelaxation caused by capsaicin in aortae from
WKY and SHR rats. .............................................................100
Figure 3.19 Vasorelaxant effects of oleamide in WKY and SHR
aortae in the presence of capsazepine (5µM)..........................102
Figure 3.20 Vasorelaxant effects of oleamide in WKY and SHR
aortae in the presence of ruthenium red (10µM).....................103
Figure 3.21 Vasorelaxant effects of anandamide in WKY and SHR
aortae in the presence of capsazepine (5µM)..........................105
Figure 3.22 Vasorelaxant effects of anandamide in WKY and SHR
aortae in the presence of ruthenium red (10µM).....................106
Chapter 4 Effects of hypertension on endothelium-dependent
vasorelaxation of the aorta .....................................................115
Figure 4.1 Representative trace of the response to carbachol in
the SHR isolated aorta. .......................................................118
Figure 4.2 Vasorelaxant responses to carbachol in aortae from
WKY and SHR rats. .............................................................121
Figure 4.3 Vasorelaxant responses to carbachol in the presence of
L-NAME (300µM) in aortae from WKY and SHR rats. ...............122
Figure 4.4 Vasorelaxant responses to carbachol in the presence of
indomethacin (10µM) in aortae from WKY and SHR rats ..........124
Figure 4.5 Vasorelaxant responses to carbachol after a 1h pre-
treatment with capsaicin (10µM) of aortae from WKY and SHR rats.
........................................................................................125
Figure 4.6 Vasorelaxant responses to carbachol in the presence of
catalase (1000 units/ml) and L-NAME in aortae from WKY and SHR
rats...................................................................................127
List of Figures
xxiv
Figure 4.7 Vasorelaxant responses to carbachol in the presence of
high extracellular K+ (60mM) and L-NAME (300µM) in aortae from
SHR rats............................................................................128
Figure 4.8 Vasorelaxant responses to carbachol in the presence of
carbenoxolone (100µM) and L-NAME (300µM) from SHR rats ...129
Chapter 5 Effects of oleamide and anandamide in small mesenteric
arteries from spontaneously hypertensive rats ..........................137
Figure 5.1 Myograph set-up.................................................140
Figure 5.2 Representative trace of the response to anandamide in
a mesenteric artery segment from a SHR rat. ........................140
Figure 5.3 Vasorelaxant responses to oleamide in mesenteric
arteries isolated from WKY and SHR rats. ..............................142
Figure 5.4 Vasorelaxant responses to anandamide in mesenteric
arteries isolated from WKY and SHR rats. ..............................143
Figure 5.5 Vasorelaxant responses to anandamide in the presence
of L-NAME (300µM) in mesenteric arteries isolated from WKY and
SHR rats............................................................................144
Figure 5.6 Vasorelaxant responses to carbachol in mesenteric
arteries isolated from WKY and SHR rats. ..............................145
Figure 5.7 Vasorelaxant responses to capsaicin in mesenteric
arteries isolated from WKY and SHR rats ...............................146
Chapter 6 Vasorelaxation to capsaicin and its effects on calcium
influx in arteries ....................................................................155
Figure 6.1 Representative trace of the response to capsaicin in the
porcine coronary artery. ......................................................160
List of Figures
xxv
Figure 6.2 Representative trace of the contractile response to
calcium in the porcine coronary artery...................................161
Figure 6.3 Vasorelaxant responses to capsaicin and the vehicle
control (ethanol) in aortic rings pre-contracted with methoxamine
from Wistar rats. ................................................................164
Figure 6.4 Vasorelaxant responses to capsaicin in rat isolated
aortae pre-contracted with methoxamine after a 1h capsaicin
(10µM) pre-treatment. ........................................................165
Figure 6.5 Vasorelaxant responses to capsaicin in rat isolated
aortae pre-contracted with methoxamine in the presence of
capsazepine (1µM)..............................................................166
Figure 6.6 Vasorelaxant responses to capsaicin in rat isolated
aortae pre-contracted with methoxamine in the presence of
ruthenium red. ...................................................................167
Figure 6.7 Contractile responses in aortic rings from Wistar rats to
Ca2+ re-introduction in a Ca2+ free, high K+ buffer in the presence
of 30µM capsaicin. ..............................................................168
Figure 6.8 Vasorelaxant responses to capsaicin and the vehicle
control (ethanol) in porcine isolated coronary arteries pre-
contracted with U46619. .....................................................169
Figure 6.9 Vasorelaxant responses to capsaicin in porcine coronary
artery pre-contracted with U46619 in the presence of capsazepine
(10µM)..............................................................................170
Figure 6.10 Contractile responses in segments of porcine coronary
artery to Ca2+ re-introduction in a Ca2+ free, high K+ buffer in the
presence of 1µM, 10µM and 30µM capsaicin...........................172
List of Figures
xxvi
Figure 6.11 Contractile responses in segments of porcine coronary
artery to Ca2+ re-introduction in a Ca2+ free, high K+ buffer in the
presence of vehicle control, 30µM and 100µM capsaicin...........173
Figure 6.12 Contractile responses in segments of porcine coronary
artery to Ca2+ re-introduction in a Ca2+ free, high K+ buffer in the
presence of 30µM capsaicin and 10µM capsazepine.................174
Figure 6.13 Contractile responses of the porcine isolated coronary
arteries to the L-type calcium channel activator Bay-K 8644 in
presence of 1µM, 3µM, 10µM and 30µM capsaicin. ..................175
Figure 6.14 Contractile response in segments of porcine coronary
artery to Ca2+ re-introduction in a Ca2+ free, high K+ buffer in the
presence of 10µM oleamide..................................................176
Figure 6.15 Contractile responses in segments of porcine coronary
artery to Ca2+ re-introduction in a Ca2+ free, high K+ buffer in the
presence of 10µM anandamide. ............................................177
Chapter 7 Investigating the effects of oleamide in the perfused
mesenteric arterial bed ..........................................................187
Figure 7.1 Representative trace of the relaxant response to doses
of oleamide........................................................................192
Figure 7.2 Vasorelaxation to oleamide in the rat mesenteric
arterial bed contracted with methoxamine in the presence of L-
NAME and in the combined presence of L-NAME and
carbenoxolone....................................................................194
Figure 7.3 Vasorelaxation to oleamide in the rat mesenteric
arterial bed after a 1h pre-treatment with capsaicin and after
contraction with high extracellular potassium in the presence of L-
NAME................................................................................196
List of Figures
xxvii
Figure 7.4 Endothelium-dependent vasorelaxation to carbachol in
the rat mesenteric arterial bed contracted with methoxamine in
the presence of L-NAME, both L-NAME and carbenoxolone, and
both L-NAME and oleamide. .................................................197
Figure 7.5 Endothelium-independent vasorelaxation to SNP in the
rat mesenteric arterial bed contracted with methoxamine in the
presence of L-NAME and oleamide. .......................................198
8.1 General Discussion...........................................................204
Figure 8.1 Potential vascular mechanisms of action of oleamide.
........................................................................................213
Chapter 1 General Introduction
1
Chapter 1
General Introduction
Chapter 1 General Introduction
2
Chapter 1 General Introduction
Oleamide is an endogenous primary fatty acid amide originally
isolated from the cerebrospinal fluid of sleep-deprived cats (Cravatt
et al., 1995). Oleamide has been previously demonstrated to
induce a range of behavioural effects, including the tetrad of
responses used to characterise cannabimimetic activity. Indeed,
oleamide is an endogenous agonist at both rat and human
cannabinoid CB1 receptors (Leggett et al., 2004). Endogenous
cannabinoids, including the prototypical endocannabinoid
anandamide, have received a large amount of interest over the past
two decades. Since the isolation of anandamide from porcine brains
in 1992, it had been demonstrated to be a potent vasodilator of
isolated arteries and has been implicated in the pathophysiology of
several cardiovascular disease states. In contrast, the actions of
oleamide in the cardiovascular system have received comparatively
little interest, thus providing an exciting new area of research. To
date, oleamide has been shown to induce potent vasorelaxant
responses in rat isolated small mesenteric arteries (Hoi and Hiley,
2006; Sudhahar et al., 2009). The available literature describes a
clear over-lap in the underlying mechanisms of action responsible
for the vascular responses to oleamide and anandamide.
This investigation examined the cardiovascular actions of oleamide
in comparison to those of anandamide. Also, the vascular responses
to oleamide and anandamide were assessed in a rat model of
genetic hypertension, the spontaneously hypertensive rat (SHR).
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1.1 Fatty acid amides
Endogenous fatty acid amides represent an important and large
group of signalling molecules. Fatty acid amides are alkyl chains
comprising 16 or greater carbon atoms with a characteristic single
amide moiety and can be broadly categorised into two groups; the
primary and secondary fatty acid amides. A major group of the
secondary fatty amides are the N-acylethanolamines, of which
anandamide is the most well known and the prototypical
endogenous cannabinoid (CB1) receptor agonist (Devane et al.,
1992). The N-acylethanolamine group also includes N-palmitoyl-,
N-stearoyl-, and N-oleoylethanol-amine (Koga et al., 1997;
Mechoulam et al., 1998). Oleamide is one of five primary fatty acid
amides isolated from Human plasma (Arafat et al., 1989) and was
identified in the cerebrospinal fluid of sleep-deprived cats and
characterised as cis-9, 10-octadecenoamide (Cravatt et al., 1995).
After identification in the cerebrospinal fluid, oleamide has received
growing interest as a potentially important signalling molecule.
Oleamide has also been demonstrated to be present in rat plasma at
36-57nmol/L (Basile et al., 1999; Driscoll et al., 1999) 35nmol/L in
human plasma (Hanus et al., 1999) and 156nmol/L in the
cerebrospinal fluid of rats (Hanus et al., 1999). While the natural
occurrence of oleamide is apparent, the exact nature of the
biosynthetic pathway for oleamide has yet to be fully established.
1.2 Synthesis and degradation of oleamide and anandamide
1.2.1 The biosynthesis of oleamide
Sugiura et al. (1996) described the production of oleamide in brain
microsomes using oleic acid and ammonia as the starting substrates.
Similarly, the N18TG2 neuroblastoma cell line also has the ability to
synthesise oleamide from oleic acid (Merkler et al., 2004). The
favoured hypothesis for the biosynthesis of oleamide involves the
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formation of oleoylglycine that acts as the substrate for
peptidylglycine monooxygenase (PAM). The inhibition of PAM in
murine N18TG2 neuroblastoma cells blocks the formation of oleamide
and increases the production of the upstream substrate
oleoylglycine (Merkler et al., 2004). The murine N18TG2
neuroblastoma cell line had previously been demonstrated to
express PAM (Ritenour-Rodgers et al., 2000). Thus, Merkler et al.
(2004) present strong evidence that the PAM-pathway represents
the primary enzymatic route of biosynthesis for oleamide, with
oleoylglycine acting as an intermediate substrate. However, this
has not been replicated in other cell lines and it also presents
another problem as to how oleoylglycine is formed from oleic acid
and ammonia. Currently, a number of possible routes for the
formation of oleoylglycine have been proposed. Firstly, Burstein et
al. (2000) described an oxidative pathway for the formation of N-
acyl-glycines involving the actions of alcohol and aldehyde
dehydrogenases on oleoylethanolamide. Secondly, it has been
proposed that cytochrome c exists as an oleamide synthase (Driscoll
et al., 2007). Authors used oleoyl-CoA as a starting substrate
because all fatty acids appear to be activated as coenzyme
derivatives (Watkins et al., 1997). Driscoll et al. (2007) reported the
ability of the rat kidney to synthesise oleamide from oleoyl-CoA and
ammonia. In addition, evidence was presented that cytochrome c
catalysed the synthesis of oleamide using ammonia as a N-donor in
a manner that required hydrogen peroxide as a co-factor (Driscoll et
al., 2007). Therefore, cytochrome c may be acting directly on
oleoyl-CoA to catalyse the synthesis of oleamide. However, it is also
possible that cytochrome c is responsible for the production of
oleoylglycine that acts as the downstream substrate for PAM.
Indeed, Mueller and Driscoll (2007) detailed the in vitro formation of
oleoylglycine by cytochrome c from glycine and oleoyl-CoA.
Oleoylglycine and other fatty acid acyl glycines may have important
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signalling functions themselves, inducing hypothermia and
antinociception in animal models (Chaturvedi et al., 2006).
An alternative enzymatic route proposed for the production of
oleoylglycine is via a pathway analogous to that catalysed by bile
acid CoA:amino acid N-acyl transferases (BACAT) (Hiley and Hoi,
2007). OByrne et al. (2003) described the conjugation of fatty
acids to glycine in vitro and also conjugates of bile acids to glycine
by BACAT. It is unlikely that BACAT is the authentic enzyme for
oleoylglycine synthesis as activity for fatty acids was much lower
than for bile acids and it was active at saturated fatty acids, while
the proposed starting substrate oleic acid is monounsaturated
(OByrne et al., 2003).
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Figure 1.1
Figure 1.1 Illustration of the proposed enzymatic pathway for the
biosynthesis of oleamide. In summary, oleoylglycine may be
activated from its CoA-derivative, oleoyl-CoA, by a cytochrome c
complex with glycine as a necessary substrate and hydrogen
peroxide as a cofactor. Alternatively, cytochrome c could directly
convert oleoyl-CoA into oleamide using ammonia as substrate. It is
also possible that the sequential action of alcohol (FADH) and
aldehyde (FALDH) dehydrogenase on N-oleoyl-ethanolamide or the
action of a BACAT-like enzyme on oleoyl-CoA could provide another
route N-oleoylglycine production. Finally, the amidation of N-
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oleoylglycine forms oleamide. Figure 1.1 has been adapted from
Hiley and Hoi (2007) and Mueller and Driscoll (2009).
1.2.2 The biosynthesis of anandamide
Anandamide is produced on-demand from membrane bound
phospholipids as opposed to being released from intracellular stores.
A number of biosynthetic pathways have been proposed for the
generation of anandamide but the main pathway is considered to be
the transacylation-phosphodiesterase pathway (Di Marzo et al.,
1994; Sugiura et al., 1996b; 1996c; Cadas et al., 1997). This
pathway had originally been demonstrated to be responsible for the
synthesis of a range of NAEs (Schmid et al., 1990). The first step of
this process involves the formation of N-
acylphosphatidylethanolamine (NAPE) from membrane bound
phosphatidyl-ethanolamine (PE) (Natarjan et al., 1982; Cadas et al.,
1996). N-acyltransferase (NAT) catalyses the addition of a fatty
acid acyl to the amino head group of PE from glycerophospholipids,
including phosphatidylcholine, in an Ca2+ and cAMP-dependent
manner (Liu et al., 2006). The glycerophospholipids act as an acyl
donor from the Sn-1 position of the glycerol backbone (Jin et al.,
2007). The subsequent cleavage of NAPE by phospholipase D forms
anandamide and phosphatidic acid. Cadas et al. (1996)
demonstrated the Ca2+-dependent nature of NAT activity, while the
rate of the reaction is regulated by cAMP. Indeed, anandamide
production is induced in rat neurons by ionomycin, a Ca2+ ionophore
(Di Marzo et al., 1994).
1.2.3 Metabolism and uptake of anandamide and oleamide
The removal of anandamide is achieved by its transport into the
intracellular space where it is rapidly metabolised. Anandamide can
be metabolised by a number of different enzymatic pathways,
however, the primary route of degradation is via hydrolysis by fatty
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acid amide hydrolase (FAAH) to form arachidonic acid and
ethanolamide. The hydrolysis of anandamide was originally reported
in neuroblastoma cells and glioma cells (Deutsch and Chin, 1993)
but was also demonstrated in rat and porcine brain preparations
(Desarnaud et al., 1995; Ueda et al., 1995). Cravatt et al. (1996)
identified a membrane-bound hydrolytic enzyme in rat liver cells
capable of degrading oleamide into oleic acid. This same enzyme
also displayed the anandamide-hydrolysing activity outlined in
previous studies and was named FAAH, as it was predicted to act as
a general degradative enzyme for fatty acid amides (Cravatt et al.,
1995). FAAH is a member of a larger group of enzymes called the
amidase signature (AS) family and exists as two different isoforms,
FAAH-1 and FAAH-2 (Wei et al., 2006). FAAH-1 has greater affinity
for ethanolamides, like anandamide, and is considered to be the
primary enzymatic route for anandamide degradation (Wei et al.,
2006). FAAH-1 and -2 expression displays both tissue and species
specificity. FAAH-1 is highly expressed in the CNS compared to
FAAH-2, whereas FAAH-2 is more highly expressed in certain
peripheral tissues, including the heart, but is not expressed in
rodents for example (Wei et al., 2006).
Studies using FAAH-knockout mice have demonstrated the
importance of FAAH activity in the metabolism of anandamide. Mice
lacking FAAH exhibited an approximately 15-fold increase in brain
levels of anandamide compared to wild-type controls, (Cravatt et al.,
2001). FAAH-knockouts also had increased tolerance to pain, an
effect that was sensitive to CB1-receptor antagonism. In addition to
hydrolysis, anandamide can also be oxidised directly by the
cyclooxygenase (COX)-pathway (Yu et al., 1997; Ross et al., 2002;
Weber et al., 2004), lipoxygenase-enzymes (Hampson et al., 1995;
Ueda et al., 1995b) and cytochrome P450-dependent systems
(Snider et al., 2010; Bornheim et al., 1995).
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Before anandamide can be hydrolysed by FAAH situated on the
endoplasmic reticulum, it must first be transported across cell
membranes and through the cytosol. A number of mechanisms
have been proposed to facilitate this cellular uptake. A model of
passive diffusion across cell membranes has been put forward, but
the majority of the literature suggests the involvement of a
facilitated process involving transport proteins. Di Marzo et al.
(1994) demonstrated that the uptake of anandamide in cortical
neuron cultures is consistent with a carrier-mediated process,
namely that uptake is rapid and dependent on temperature and the
process is both saturable and selective. Two different forms of
facilitated transport of anandamide have been proposed. Firstly, a
membrane-bound carrier molecule exists to aid transport across the
plasma membrane or, alternatively, that intracellular binding
proteins exist to allow movement of anandamide through the cytosol
to the site of hydrolysis. In support of this second hypothesis,
several proteins have recently been identified that can bind and
transport anandamide (Kaczocha et al., 2009; Oddi et al., 2009; Fu
et al., 2012).
One of the proposed proteins involved in anandamide transport is a
fatty acid binding protein (FABP) (Kaczocha et al., 2009). Previously,
a plasma membrane fatty acid has been implicated in the transport
of different fatty acids in a range of studies (Berk et al., 1990; 1997;
Turcotte et al., 1999; Heather et al., 2006). Anandamide uptake
was upregulated by the over expression of FABP5 and FABP7 in
N18TG2 neuroblastoma cells and COS-7 cells, which are fibroblast-like
kidney cells derived from the monkey (Kaczocha et al., 2009).
Furthermore, the authors showed that an additional FABP agonist, in
this case oleic acid, attenuated the uptake of anandamide as did the
presence of a FABP inhibitor. Oddi et al. (2009) identified albumin
and Hsp70 as intracellular proteins capable of binding anandamide
by using a biotinylated anandamide analogue, enabling the isolation
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and detection of bound proteins by mass spectronomy. In addition,
a FAAH-like enzyme lacking hydrolytic activity has the ability to bind
and transport anandamide (Fu et al., 2012).
1.3 Evidence for oleamide as an endocannabinoid-like
mediator
1.3.1 Cannabinoid receptor pharmacology
The psychoactive nature of marijuana has long been known. Gaoni
DQG 0HFKRXODP  LVRODWHG Ʃ9-Tetrahydrocannabinol (THC) as
the main psychoactive ingredient of cannabis sativa. However, the
mechanisms of action responsible for inducing the powerful
psychological effects remained unknown for several decades.
Matsuda et al. (1990) cloned the first cannabinoid receptor (CB1)
from the rat brain after the development of selective THC analogues
had revealed the existence of cannabinoid binding sites in cerebral
cortex of rats (Devane et al., 1988). Subsequently a second
cannabinoid receptor (CB2) expressed in macrophages was identified
by sequence homology (Munro et al., 1993). With the discovery of
cannabinoid receptors it was hypothesised that an endogenous
factor active at these regions would exist. In 1992 anandamide was
the first endogenous cannabinoid to be discovered, isolated from the
porcine brain (Devane et al., 1992). Anandamide has been
demonstrated to bind to CB1 receptors with Ki values in the nM
range (Devane et al., 1992; Vogel et al., 1993; Mechoulam et al.,
1995; Adams et al., 1995; Hillard et al., 1995; Showalter et al.,
1996; Wise et al., 1996; Petitet et al., 1996). Anandamide exhibits
greater binding affinity at CB1 receptors compared to CB2 receptors,
with Lin et al. (1998) describing a Ki value 3-4 times greater at CB1
receptors. Subsequently at least four other endocannabinoids have
been isolated; 2-AG (Sugiura et al., 1995; Mechoulam et al., 1995),
noladin ether (Hanus et al., 2001), virodhamine (Porter et al., 2002)
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and N-arachidonyldopamine (NADA) (Bisogno et al., 2000; Huang et
al., 2002).
CB1 receptors are mainly located in the brain, with high regions of
expression in the telencephalon, brainstem, cerebellum, cerebral
cortex, spinal cord and dorsal root ganglia (DRG) (Herkenham et al.,
1990; 1991; Mailleux and Vanderhaeghe, 1992; Matsuda et al.,
1993; Westlake et al., 1994; Glass et al., 1997; Hohnmann and
Herkenham, 1999; Farquhar-Smith et al., 2000). CB2 receptors are
present in certain regions of the brain, while expression is high in
certain peripheral tissues, particularly immune cells. CB1-receptor
expression has also been described in the cardiovascular system
(Gebremedhin et al., 1999; Liu et al., 2000; Batkai et al., 2001;
Bonz et al., 2003; Batkai et al., 2004). Liu et al. (2000)
demonstrated the existence of functional CB1 receptors in human
endothelial cells from the aorta and hepatic artery. In vascular
endothelial cells from human cirrhotic livers the expression of CB1
receptors was upregulated by approximately 3-fold (Batkai et al.,
2001). Expression of CB1 receptors was also upregulated in the
heart and aortic endothelial cells from hypertensive rats (Batkai et
al., 2004). Similarly, CB1-receptor sites were located in human
arterial muscle (Bonz et al., 2003).
Both CB1 receptors and CB2 receptors are G protein-coupled
receptors (GPCRs), which comprise a large group of membrane
spanning receptors that initiate intracellular G-proteins to activate or
inhibit specific signalling cascades. The cannabinoid receptors couple
to the Gi/o protein, which acts to inhibit adenylyl cyclase and so
regulate intracellular cAMP levels (Vogel et al., 1993; Childers et al.,
1994; Deadwyler et al., 1995; Glass et al., 1997; Kern et al., 1999;
Glass and Northup, 1999; Childers et al., 2006). Activation of G
proteins via CB1 receptors decreases cAMP levels which can initiate a
range of downstream effects. Agonists at CB1 receptors function to
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close Ca2+ channels (Felder et al., 1993; Mackie et al., 1993;
Sugiura et al., 1997; Huang et al., 2001; Wang et al., 2003; Brown
et al., 2004), activate K+ channels (Mackie et al., 1995; McAllister et
al., 1999) and regulate neuronal gene expression (Collin et al., 1995;
Terranova et al., 1995; Gerdeman et al., 2002; Ade and Lovinger,
2007). The above effects on intracellular signalling induced by CB1-
receptor activation allow endocannabinoids to act as retrograde
signalling molecules.
Previous studies describe CB1-receptor mediated inhibition of N- and
P/Q-type Ca2+ channels (Mackie and Hille, 1992; Caulfield and
Brown, 1992; Twitchell et al., 1997; Huang et al., 2001; Liang et al.,
2004). Interestingly, Gebremedhin et al. (1999) reported that
anandamide and WIN-55,212, a synthetic cannabinoid, induced
vasorelaxation of cat cerebral arteries in a manner sensitive to CB1-
receptor inhibition. Also both cannabinoid agonists inhibited L-type
Ca2+ currents in isolated cerebral vascular smooth muscle cells,
which was identified as the predominant Ca2+ currents in that
preparation (Gebremedhin et al., 1999). The cannabinoid CB1
receptor antagonist rimonabant and Pertussis toxin both blocked the
inhibitory action of anandamide on L-type calcium currents. Thus,
providing a mechanism for anandamide-induced vascular effects via
CB1 receptors, although to date CB1-receptor expression has mainly
been located in endothelial cells of the vascular system.
Activation of K+ channels and inhibition of Ca2+ channels results in
decreased Ca2+-influx in neuronal cells and may cause a decrease in
neurotransmitter release, possibly underpinning the ability of
endocannabinoids to act as retrograde signalling molecules in the
regulation of several neuronal processes. For example,
endocannabinoid release from depolarised post synaptic cells can act
on pre-synaptic cells to activate CB1 receptors to inhibit Ca
2+-influx
and suppress GABA release from hippocampal CA1 pyramidal
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neurons (Ohno-Shosaku et al., 2002; Yoshida et al., 2002). This
action of suppressing GABA-release is termed depolarisation-
induced suppression of inhibition (DSI) (Glass and Nunthorpe, 1999).
Endocannabinoids also similarly act on pre-synaptic glutamatergic
terminals to suppress the release of the excitatory neurotransmitter
glutamate, in a process called depolarisation-induced suppression of
excitation (DSE) (Kreitzer and Regehr, 2001; Maejima et al., 2001)
that occurs in Purkinje cells and in dopaminergic cells (Melis et al.,
2004).
1.3.2 Oleamide as an endogenous ligand at CB1 receptors
Previous studies have demonstrated that oleamide is a full agonist
at CB1 receptors. The binding of both rimonabant and CP55,940 to
rat brain membranes was competitively inhibited by oleamide
(Leggett et al., 2004). CP55,940 is a synthetic cannabinoid and full
agonist of both CB1 and CB2 receptors and is more potent than THC
(Griffin et al., 1998; Thomas et al., 1998) CP55,940 binding to
human CB1 receptor cell membranes was similarly inhibited by
oleamide (Leggett et al., 2004). The authors also described
oleamide-evoked [356@ *73Ǆ6 ELQGLQJ and inhibition of forskolin-
stimulated cyclic AMP increases in a manner sensitive to rimonabant.
Cheer et al. (1999) similarly demonstrated competitive inhibition of
CP55,940 binding by oleamide.
1.3.3. In vitro effects of oleamide
Oleamide evokes a range of behavioural effects, many of which are
similar to those induced by anandamide (Mechoulam et al., 1997),
including the tetrad of effects used to characterise cannabinergic
activity. The characteristic tetrad of behavioural effects includes
hypoactivity, analgesia, hypothermia and catalepsy (Chaperon and
Thiebot, 1999).
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In rats and mice oleamide evokes hypothermia and hypomobility
(Mechoulam et al., 1997; Basile et al., 1999; Yang et al., 1999;
Fedorova et al., 2001; Huitron-Resendiz et al., 2001). Indeed,
oleamide produced approximately a 2°C drop in the core body
temperature of rats (Federova et al., 2001; Murillo-Rodriguez et al.,
2001). Oleamide also has analgesic properties, increasing the
resistance of rats to pain caused by a beam of light in the tail-flick
assay (Fedorova et al., 2001). Other studies report similar
analgesia, in addition to catalepsy, in response to oleamide in mice
(Mechoulam et al., 1997), although in the rat oleamide was not
cataleptic (Federova et al., 2001).
Oleamide levels in cerebrospinal fluid of rats correlates positively
with sleep-deprivation and has sleep-inducing properties (Cravatt et
al., 1995; Mendelson and Basile, 1999). A 6h period of sleep
deprivation caused a 4-fold increase in oleamide concentration in
cerebrospinal fluid of rats (Mendelson and Basile, 1999). Herrera-
Solis et al. (2010) demonstrated that both oleamide and
anandamide administered acutely and sub-chronically, resulted in
increased REM sleep, an effect that was blocked by the CB1 receptor
antagonist AM251. A range of other oleamide-induced behavioural
effects may also be a consequence of CB1 receptor activation.
Federova et al. (2001) demonstrated that the analgesic nature of
oleamide in the tail-flick assay was inhibited by rimonabant. In
addition, oleamide can upregulate appetite, a characteristic action of
cannabinoids (Dewey, 1986; Martinez-Gonzalez et al., 2004). The
importance of the endocannabinoid system in appetite regulation is
highlighted by rimonabant-induced weight loss in obese patients
(Leite et al., 2009).
While oleamide clearly demonstrates a range of cannabinoid-like
pharmacological effects, many are a product of oleamides
interaction with other neurotransmitter systems. Most notably,
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oleamide can interact with the GABAergic and serotonergic systems
(Huidobro-Toro and Harris, 1996; Thomas et al., 1997; Yost et al.,
1998). Federova et al. (2001) demonstrated that oleamide-induced
hypothermia and hypomotility was insensitive to rimonabant. The
action of oleamide on locomotion was blocked by the dopamine D2
receptor antagonist, while a GABA receptor antagonist reversed
hypothermia and analgesia (Federova et al., 2001). In CB1-
knockout mice, hypomotility and hypothermia induced by oleamide
remained intact (Lichtman et al., 2002).
1.4 Interaction of oleamide and gap junctions
Gap junctions are connecting structures between two cells that
facilitate cell-to-cell communication through the diffusion of ions and
small molecules (Nicholson, 2003; Martin and Evans, 2004). The
coupling of endothelial cells to endothelial cells and to smooth
muscle cells has previously been demonstrated and this is thought
to be important to vascular function (von der Weid and Beny, 1993;
Little et al., 1995; Yamamoto et al., 1998). Gap junctions consist of
two hemichannels, called connexons, themselves consisting of six
connexin subunits (Goodenough and Paul, 2003). Sandow and Hill
(2000) uncovered the existence of myoendothelial gap junctions in
rat mesenteric arteries using serial-section electron microscopy
techniques. They found an increased incidence of myoendothelial
gap junctions in smaller distal arteries in comparison to larger
proximal mesenteric arteries (Sandow and Hill, 2000). This
corresponds with reports that EDHF-mediated responses were
positively correlated with decreasing artery size in the rat
mesenteric arterial bed (Shimokawa et al., 1996). It has been
demonstrated that gap-junctional communication mediates EDHF
responses in mesenteric arteries from the rat, rabbit and guinea pig
and also in the rabbit iliac and rat hepatic arteries and in human
myometrial arteries (Chaytor et al., 1998; Taylor et al., 1998;
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Yamamoto et al., 1999; Edwards et al., 1999; Chaytor et al., 2001;
Griffith et al., 2002; Kenny et al, 2002; Chaytor et al., 2005).
Several studies have shown that oleamide can block gap-junctional
communication (Guan et al., 1997; Lerner et al., 1997; Boger et al.,
1998; Huang et al., 1998; Quist et al., 2000; Bannerman et al.,
2000; Boitano and Evans, 2000; Schiller et al., 2001; Krutovskikh et
al., 2002; Decrouy et al., 2004; Nagasawa et al., 2006). Indeed,
many studies have used oleamide as a pharmacological tool to
examine the importance of gap junctions in certain physiological
processes. Guan et al. (1997) reported that oleamide blocked
communication through gap junctions in rat glial cells, measured by
a decrease in electrical conductance and inhibition of dye transfer.
Oleamide also caused a decrease in one of the two phosphorylated
isoforms of Į1-connexin, the primary connexin expressed in glial
cells (Guan et al., 1997). However, oleamide did not inhibit Ca2+-
wave propagation between glial cells although classical gap-junction
blockers, such as 18ǃ-glycyrrhetinic acid, were able to (Guan et al.,
1997).
Interestingly, oleamide was used to block gap junctions in an
investigation examining the role of gap junctions in maintaining the
barrier function of porcine blood brain barrier endothelial cells
(Nagasawa et al., 2006). Oleamide inhibited the barrier property of
tight junction cells in the blood brain barrier. Whether, oleamide
actually plays a role in regulating the endothelial blood-brain barrier
is not known, however the high concentrations used in this instance
are probably not physiologically relevant. One physiological
importance of oleamides ability to block gap junctions may be in the
process of apotosis (Mueller and Driscoll, 2009). Mueller and
Driscoll (2009) proposed a model implicating oleamide in the
regulation of cell death. This is based on their observations that
cytochrome c can synthesise oleamide (Driscoll et al., 2007) and
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that cytochrome c is released from mitochondria during apotosis
(Liu et al., 1996; Kluck et al., 1997; Yang et al., 1997). It was
postulated that oleamide may act to close gap junctions to regulate
cell death and possibly prevent the spread of apotosis.
Indeed, Krutovskikh et al. (2002) reported that cell coupling through
gap junctions propagated the spread of apotosis in a cancerous rat
bladder cell line. In the presence of the gap-junction blocker ǃ-
glycyrrhetinic acid and in cells expressing a mutant connexin43 the
spread of cell death was decreased. Oleamide inhibited the spread
of Lucifer yellow dye in these cells and was used to assess the
importance of Ca2+-wave propagation, making use of its selectivity
on gap junction permeability described in previous studies (Guan et
al., 1997; Krutovskikh et al., 2002). However, oleamide itself had
no effect on the spread of cell death.
1.5 Cardiovascular effects of the endocannabinoid
anandamide
1.5.1 In vitro effects of anandamide
Anandamide has been shown to be a potent vasodilator of blood
vessels isolated from different species and vessel beds (reviewed
Randall et al., 2002). The mechanisms responsible for the
vasorelaxant properties of anandamide appear to be both tissue and
species specific. The earliest study showed that anandamide dilated
cerebral arteries from rabbits via the cyclooxygenase pathway as
the response was sensitive to the presence of indomethacin (Ellis et
al., 1995). Anandamide also induces vasorelaxation of rat
mesenteric arteries partly in a manner sensitive to non-selective
inhibition of the cyclooxygenase pathway with diclofenac (Fleming et
al., 1999). Anandamide has since been shown to cause
vasodilatation in a range of isolated vessels in a COX-independent
manner; basilar artery from the guinea pig (Zygmunt et al., 1999),
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bovine coronary artery (Pratt et al., 1998), rabbit aorta
(Mukhopadhyay et al., 2002), rat renal artery (Deutsch et al., 1997),
rat mesenteric artery (White and Hiley, 1997) perfused rat heart
(Fulton and Quilley, 1998; Randall and Kendall, 1997a), rabbit
mesenteric arteries (Chaytor et al., 1999) and the perfused rat
mesenteric arterial bed (Randall et al., 1996; Randall and Kendall,
1997b; Harris et al., 2002). A number of mechanisms have been
implicated in anandamide-induced responses that include sensory
nerve activity (Zygmunt et al., 1999), the release of nitric oxide
(Deutsch et al., 1997; Bilfinger et al., 1998), gap-junctional
communication (Chaytor et al., 1999; Harris et al., 2002), ATP-
sensitive K+ channels (Chataigneau et al., 1998), Ca2+activated K+
channels (Plane et al., 1997; Randall and Kendall, 1998) and EDHF-
mediated mechanisms (Chaytor et al., 1999; Harris et al., 2002;
OSullivan et al., 2004). The tissue specific nature of anandamide-
induced is probably best highlighted by OSullivan et al. (2004). The
authors demonstrated mechanistic differences underlying responses
between small resistance and large conduit rat mesenteric arteries.
In smaller arteries, anandamide-induced relaxation was attributed
to CB1-receptors and also to EDHF-mediated activity, which was
possibly facilitated by gap-junctions and coupled to a novel
endothelial cannabinoid receptor. Vasorelaxation of larger conduit
arteries was caused by CB1 receptors and sensory-nerve mediated
activity in an endothelium-independent manner (OSullivan et al.,
2004).
1.5.2 Anandamide and sensory-nerve activation
Zygmunt et al. (1999) suggested the involvement of sensory-nerve
mediated activity in anandamide-induced vasorelaxation.
Anandamide elicited vasorelaxation of rat isolated hepatic and small
mesenteric arteries and guinea-pig basilar artery, all of which were
sensitive to capsaicin pre-treatment designed to deplete vasoactive
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neuropeptides from perivascular sensory nerves (Zygmunt et al.,
1999). The vasorelaxant responses to anandamide were also
sensitive to CGRP receptor antagonism, characterising CGRP as the
neuropeptide released by activation of capsaicin-sensitive vanilloid
receptors by anandamide (Zygmunt et al., 1999). The capsaicin-
sensitive vanilloid receptor has been identified as the transient
receptor vanilloid type 1 (TRPV1) that functions as a non-selective
cation channel regulating permeability to Ca2+. Thus, the activation
of TRPV1 causes the increase in intracellular Ca2+ resulting in the
release of neuropeptides such as CGRP, substance P and tachykinins,
which can regulate vascular smooth muscle. In addition to capsaicin
and anandamide, TRPV1 is a target for a range of endogenous and
external agonists including lipoxygenase metabolites (Hwang et al.,
2000; Sexton et al., 2007), noxious heat (Brauchi et al., 2006) and
other fatty acid amides. N-oleoyl-ethanolamine (OEA), N-
arachidonoyl dopamine (NADA) and N-oleoyl dopamine (OLDA) have
all been shown to interact with vanilloid receptors (Huang et al.,
2002; Chu et al., 2003: Movahed et al., 2005; Sharkey et al., 2007).
Interestingly, the vasorelaxation of rat small mesenteric arteries
induced by oleamide also involved the activation of TRPV1 receptors
on sensory nerves. This response was attenuated by the TRPV1
antagonist capsazepine and the cation channel blocker ruthenium
red (Sudhahar et al., 2009).
1.5.3 Nitric Oxide release
The characterisation of endothelium-dependent vasorelaxation led to
the discovery of an endothelium-dependent relaxing factor (EDRF)
(Furchgott and Zawadzki, 1980). This study illustrated the
necessity of an intact endothelium in the vasorelaxation of isolated
arteries in response to acetylcholine, bradykinin and histamine
(Furchgott and Zawadzki, 1980). EDRF was subsequently identified
as nitric oxide (NO) (Ignarro et al., 1987a; 1987b; Palmer et al.,
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1987). NO had previously been demonstrated to be a potent
vasorelaxant in the bovine coronary artery, in which NO was shown
to activate soluble guanylate cyclase (Greutter et al., 1979; Ignarro
and Kadowitz, 1985).
It was proposed that a cytosolic endothelial enzyme was responsible
for the synthesis of an EDRF from L-arginine (Mayer et al., 1989).
Indeed, three isoforms of nitric oxide synthase (NOS) have been
isolated; neuronal-, endothelial-, and inducible-NOS. Neuronal nitric
oxide was identified from brain tissue (Bredt and Snyder, 1990) and
a version of this enzyme was found to be constitutively expressed in
endothelial cells of bovine aortae (Pollock et al., 1991). Endothelial
NOS is stimulated in response to calmodulin after an increase in
intracellular Ca2+ (Brendt and Snyder, 1990; Fostermann et al.,
1991; Michel et al., 1997). Endothelium-dependent relaxants and
shear stress both cause increases in endothelial cell Ca2+ and
release of NO (Koller et al., 1994; Fleming et al., 1998). Following
synthesis in the endothelium, NO is free to diffuse to the vascular
smooth muscle where it can activate guanylyl cyclase by binding to
its haem group (Gerzer et al., 1982; Ignarro et al., 1982; Wolin et
al., 1982). Activation of guanylyl cyclase upregulates the second
messenger 3´, 5´-cyclic guanosine monophosphate (cGMP), which
can stimulate cGMP protein kinases (PKG) (Lucas et al., 2000). PKG
can activate myosin light chain phosphatase, attenuating the
phosphorylation of myosin light chain to initiate the relaxation of
vascular smooth muscle (Surks et al., 1999; Torrecillas et al., 2000).
NO is continuously released from the endothelium (Vallance et al.,
1989; Stamler et al., 1994) and constitutes an important signalling
molecule regulating vascular tone. NO has been demonstrated to be
released in response to shear stress causing flow-dependent
vasodilatation (Buga et al., 1991). The importance of NO signalling
is further highlighted by studies showing that murine knockouts for
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endothelial NOS or cGMP activated protein kinases develop
hypertension (Huang et al., 1995; Pfeifer et al., 1998). NO has a
range of cardioprotective properties and down-regulation of NO
production has been implicated in the pathophysiology of a number
of cardiovascular disorders, including hypertension, diabetes and
hypercholesterolaemia (reviewed in Naseem, 2005).
Due to its importance as a vascular signalling molecule, NO was
proposed as a candidate mediating vasorelaxation to
endocannabinoids. In support of this, anandamide has been
demonstrated to elicit the release of NO (Deutsch et al., 1997;
Bilfinger et al., 1998; Poblete et al., 2005). Deutsch et al. (1997)
described anandamide-induced vasodilatation of perfused
juxtamedullary afferent arterioles from the rat kidney, which was
sensitive to inhibition of NO synthase with L-NAME and to
rimonabant. In perfused arterial segments from the kidney and in
cultured renal microvascular endothelial cells, anandamide
stimulated the release of NO (Deutsch et al., 1997). Similarly,
anandamide evoked endothelial NO release in the saphenous vein,
right atria and thoracic artery in a CB1-receptor mediated
mechanism (Bilfinger et al., 1998). The endocannabinoid 2-AG
elicited NO release in human saphenous vein via a process coupled
to CB1-receptor activation (Stefano et al., 2000). In a range of
immune cells 2-AG and anandamide caused the release of NO, again
via CB1 receptors (Stefano et al., 1996; 2000). In addition to being
able to evoke NO by stimulating endothelial CB1 receptors it has
been shown that the interaction of anandamide with TRPV1 may
also release NO. Perfusion of the rat mesenteric arterial bed with
anandamide stimulated an acute release of NO. This response to
anandamide was sensitive to antagonism of TRPV1 with capsazepine
and was also reduced by the presence of rimonabant or AM251
(Poblete et al., 2005). This TRPV1-dependent component of NO
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release corresponded with the endothelial expression of TRPV1
mRNA as measured using RT-PCR (Poblete et al., 2005).
1.5.4 Vascular responses to anandamide and vasoactive prostanoids
In addition to NO, the endothelium also releases vasorelaxant
prostanoids (Moncada et al., 1976; Moncada et al., 1979; Dusting et
al., 1977; Hong, 1980). The endothelium releases a number of
different vasoactive prostanoids; prostaglandin H2, I2 (prostacyclin),
D2, F2Į, E2 and thromboxane A2. These prostanoids are arachidonic
acid derivatives produced via the cyclooxygenase (COX) pathway.
The COX-pathway consists of COX-1 and COX-2 enzymes that are
expressed in the endothelium and vascular smooth muscle (De Witt
et al., 1983; Doroudi et al., 2000; Onodera et al., 2000; Kawka et
al., 2007). COX-enzymes convert arachidonic acid, liberated from
membrane phospholipids by phospholipases, into PGH2 and PGG2.
PGH2 produced by COX is subjected to further transformation by a
range of specific prostaglandin synthases. PGI2 synthase is highly
expressed in endothelial cells (Siegle et al., 1994; Tone et al., 1997;
Kawka et al., 2007) and as such prostacyclin is one of the most
abundant of the endothelium-derived prostanoids. Prostacyclin has
been demonstrated to be a potent vasodilator of blood vessels
(Bunting et al., 1976; Lamontagne et al., 1992; Jackson et al.,
1993), causing the relaxation of vascular smooth muscle by
interacting with IP receptors (Coleman et al., 1994). Other
endothelium-derived prostanoids, including PGH2 and thromboxane
A2, have been shown to cause vasoconstriction (Shirahase et al.,
1988; Ge et al., 1995; Rapoport and Williams, 1996; Gluais et al.,
2006).
Initial investigations implicated the COX-pathway in the vasodilator
actions of anandamide. Vasodilatation of rabbit cerebral arterioles
to both anandamide and THC was sensitive to inhibition of the COX-
pathway with indomethacin (Ellis et al., 1995). This suggests that
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metabolism of anandamide or its metabolites by COX results in
vasoactive prostanoid production. In rabbit mesenteric arteries and
sheep coronary arteries anandamide-induced vasorelaxation was
also sensitive to COX inhibition (Fleming et al., 1999; Grainger and
Boachie-Ansah, 2001). In addition, Herradon et al. (2007)
described an indomethacin-sensitive vasorelaxant response in rat
aortae to anandamide. Vasorelaxation of aortae was also
attenuated by the FAAH inhibitor URB597, a selective COX-2
inhibitor DFU, and an EP4 receptor antagonist. Taken together these
results predict the degradation of anandamide by FAAH to
arachidonic acid, which itself is metabolised by COX-2 to form a
vasoactive prostanoid, possibly prostaglandin E2, active at EP4
receptors to cause aortic vasorelaxation (Herradon et al., 2007).
In contrast to Herradon et al. (2007), it has been demonstrated that
aortic responses to THC, anandamide and NADA were augmented by
the presence of indomethacin (OSullivan et al., 2005). A picture
has emerged in subsequent studies in which the COX-pathway may
have a role in limiting the vascular actions of endocannabinoids in
some tissue preparations (Ho and Randall, 2007; Wheal et al.,
2010). Ho and Randall (2007) demonstrated that in mesenteric
vasculature from the rat the relaxant effects of anandamide and 2-
AG are regulated by the activity of COX and endocannabinoid
hydrolases. Vasorelaxant responses to anandamide were
potentiated by inhibition of COX-2 and FAAH. While, 2-AG-induced
relaxation was sensitive to inhibition of MGL and COX-1. Similarly,
indomethacin also potentiated relaxation to the endocannabinoid-
like fatty acid amide N-oleoylethanolamine in rat mesenteric arterial
beds (Wheal et al., 2010).
1.5.5 Anandamide and the release of an EDHF
As outlined above the endothelium is important in regulating local
vascular tone as it is the site for the synthesis and release of the
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vasodilators NO and prostacyclin (Dusting et al., 1977; Palmer et al.,
1987). The existence of another as yet unidentified vasoactive
mediator released by the endothelium has been demonstrated,
which functions independently of NO and prostacyclin release
(Taylor and Weston, 1988). This endothelium-dependent relaxant
factor is characterised by the hyperpolarisation of vascular smooth
muscle, is abolished by depolarising concentrations of K+ and is
sensitive to a specific combination of K+ channel blockers and hence
is known as endothelial dependent hyperpolarising factor (EDHF).
EDHF-mediated responses are blocked by the combination of
apamin and charybdotoxin (Zygmunt and Hogestatt, 1996; Corriu et
al., 1996). Apamin selectively blocks small conductance Ca2+-
activated K+ channels, while charybdotoxin is used to block both
intermediate and large conductance Ca2+-activated K+ channels.
This taken together with the fact that iberiotoxin, an inhibitor of
large conductance Ca2+-activated channels, does not replicate the
effects of charybdotoxin in blocking EDHF-mediated responses,
demonstrates that the EDHF response involves small and large Ca2+-
activated K+ channels (Zygmunt and Hogestatt, 1996). EDHF-
mediated responses involve activation of endothelial Ca2+-activated
K+ channels, caused by an increase in intracellular calcium in
response to ligand binding. The resulting efflux of K+ into the
intercellular space drives the hyperpolarisation of endothelial cells.
This hyperpolarisation is effectively passed on from the endothelium
to the vascular smooth muscle by an EDHF. A number of different
mechanisms and mediators have been proposed to be an EDHF,
including gap-junction communication (Chaytor et al., 1998; 2001;
Berman et al., 2002; De Vriese et al., 2002; Griffith et al., 2002;
Lang et al., 2007) K+ ions (Edwards et al., 1998; Coleman et al.,
2001), epoxyeicosatrienoic acids (Adeagbo and Henzel, 1998; Miura
and Gutterman, 1998; Fleming et al., 2001; Halcox et al., 2001),
hydrogen peroxide (Beny and von der Weid, 1991; Matoba et al.,
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2002; 2003; Shimokawa et al., 2005) and C-type natriuretic peptide
(Chauhan et al., 2003; Villar et al., 2007).
Various investigations have implicated EDHF-mediated mechanisms
in the vascular actions of anandamide. Chaytor et al. (1999)
described an endothelial component of the vasorelaxation of rabbit
superior mesenteric arteries to anandamide that was independent of
NO and prostanoid production. The anandamide-induced
endothelium-dependent relaxation was sensitive to the gap junction
inhibitor 18Į-glycyrrhetinic acid, the selective peptide gap-junction
inhibitor gap 27 and a concentration of rimonabant (10µM) sufficient
to block gap-junction communication (Chaytor et al., 1999). This
implicates gap-junctions and therefore EDHF-mediated mechanisms
in anandamide-induced relaxation of the rabbit mesenteric artery.
Randall and Kendall (1998) demonstrated vasorelaxation of the
perfused rat mesenteric arterial bed caused by anandamide, which
was sensitive to the combination of apamin and charybdotoxin,
supporting the possibility that a component of the anandamide
response is EDHF-mediated.
Similarly, the endothelium-dependent vasodilatation induced by
anandamide of murine mesenteric arteries was NO and COX-
independent but sensitive to the combination of apamin and
charybdotoxin (Jarai et al., 1999). The authors concluded that
cannabinoid-induced relaxation was mediated by a rimonabant-
sensitive endothelial receptor, distinct from the classical cannabinoid
receptors, which may be coupled to release of an EDHF (Jarai et al.,
1999). However, the effect of rimonabant on vasodilatation in the
CB-receptor knockout mice could be as a result of its ability to
inhibit gap-junctional communication. Harris et al. (2000) had
previously implicated the involvement of gap junctions in EDHF-
mediated relaxation of rat mesenteric arterial bed. The same group
also linked gap-junctional communication to the vasorelaxation of
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rat mesenteric arterial bed to anandamide, which was attenuated by
high concentrations of rimonabant and 18ǃ-glycyrrhetinic acid.
However, the response to anandamide was predominately
endothelium-independent and involved the activation of sensory
nerves, possibly through the release of NO as a neurotransmitter
(Harris et al., 2002).
Other studies failed to substantiate the effects of apamin and
charybdotoxin on anandamide-induced relaxation of arteries from
the rat mesenteric arterial bed. In isolated mesenteric arteries
vasorelaxation was sensitive to the inhibition of only large
conductance Ca2+-activated K+-channels (Plane et al., 1997) and
was insensitive to the combination of apamin and charybdotoxin
(White and Hiley, 1997).
In summary, anandamide has been demonstrated to elicit
endothelium dependent vasorelaxation via similar mechanism as
EDHF, possibly including the release of an EDHF. Although,
experiments using the same tissue type have yielded conflicting
results in relation to the involvement of K+-channels and gap-
junctions.
1.5.6 A novel non-classical cannabinoid receptor
A novel endothelial cannabinoid receptor distinct from both CB1 and
CB2 receptors, has been implicated in mediating the vasorelaxant
effects of cannabinoids. Investigations by Wagner et al. (1999)
described endothelium-dependent vasodilation to anandamide in the
rat mesenteric arterial bed that was attenuated by high
concentrations of rimonabant (1-5µM). Although, the authors
demonstrated that other potent cannabinoid-receptor agonists,
WIN-55212 and HU-210, failed to elicit vasodilatation. It was
postulated that a rimonabant-sensitive non-CB1/CB2 receptor
present on the endothelium was the target for anandamide (Wagner
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et al., 1999). However, it is possible that in the mesenteric
vasculature the sensitivity of anandamide responses to rimonabant
may be a result of its effects in blocking gap-junctional
communication at higher concentrations. Chaytor et al. (1999)
demonstrated that rimonabant (10µM) blocked dye transfer in COS-
7 cells and mimicked the effects of gap-junction inhibitors in
blocking anandamide-induced relaxation of rabbit mesenteric
arteries. Gap-junction inhibitors have also been shown to attenuate
vasorelaxation of rat mesenteric arterial bed to anandamide (Harris
et al., 2002).
Work by Jarai et al. (1999) presented further evidence supporting
the existence of a novel endothelial cannabinoid receptor. It was
demonstrated that abnormal cannabidiol (abn-cbd), which does not
bind to CB1 receptors, caused vasodilation of mouse mesenteric
vasculature that was inhibited by rimonabant (1µM). This was
replicated in CB1 and CB2 receptor knockout mice (Jarai et al., 1999).
It was proposed that the novel cannabinoid receptor was coupled to
EDHF-release as abn-cbd-induced vasodilation was blocked by the
combination of charybdotoxin and apamin (Jarai et al., 1999). As
discussed earlier, this is a well defined characteristic of the EDHF
response. The novel cannabinoid receptor has been reported to be
inhibited by cannabidiol and O-1918 (Jarai et al., 1999; Offertaler et
al., 2003). Subsequently, a number of studies have also implicated
the novel cannabinoid receptor in vasorelaxant responses.
Vasorelaxation of small resistance mesenteric arteries by
anandamide was sensitive to 0-1918 and reduced by the
combination of charybdotoxin and apamin (OSullivan et al., 2004).
Similarly, oleamide-induced relaxation of small mesenteric arteries
is also sensitive to 0-1918, rimonabant (3µM) and a combination of
charybdotoxin and apamin. Vasorelaxation of rat and rabbit aortae
is also partly mediated by a novel endothelial cannabinoid receptor
(Herradon et al., 2007; Mukhopadhyay et al., 2002).
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Figure 1.2
Figure 1.2 Summary of the mechanisms involved in vasorelaxation
that have been discussed in Chapter 1. Endothelium-dependent
agonists, such as acetylcholine and bradykinin, can activate GCRP to
upregulate protein kinases. Phospholipase C (PLC) can cause the
increase of intracellular calcium (Ca2+), which activates endothelial
nitric oxide synthase (eNOS) to produce nitric oxide (NO) that can
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diffuse to the smooth muscle to stimulate cGMP. Increase in
endothelial calcium can also stimulate intermediate and small
calcium-activated potassium channels driving the efflux of
potassium ions (K+) and the release of EDHF. Efflux of K+ can
activate inwardly rectifying potassium (KIR) and the sodium-
potassium (Na+-K+) pump. EDHF may include epoxyeicosatrienoic
acids (EETs) that can activate smooth muscle large conductance
potassium channels (bKca) to hyperpolarise smooth muscle,
hydrogen peroxide (H2O2) or C-type natriuretic peptide (CNP) that
can activate receptor-mediated increases in smooth muscle cGMP.
EDHF may be coupled to a novel endothelial cannabinoid receptor
(CBx) and in some cases hyperpolarisation is potentiated via
myoendothelial gap junctions. Phospholipase A (PLA) can liberate
arachidonic acid from the phospholipid bilayer, which can be
metabolised by the cyclooxygenase pathway (COX) to produce
prostaglandin (PGl2). PGl2 can act to increase cAMP levels in smooth
muscle cells by activating IP receptors. Activation of TRPV1
receptors on perivascular sensory nerves can release the
neuropeptide calcitonin gene related peptide (CGRP) that stimulates
the CGRP receptor to increase smooth muscle cAMP. The activation
of TRPV1 can also release NO. All these mechanisms result in the
relaxation of vascular smooth muscle causing vasorelaxation.
Figure 1.2 has been adapted from Randall et al. (2004), Luksha et al.
(2009) and Giles et al. (2012).
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1.5 Hypotensive effects of endocannabinoids
Endogenous cannabinoids and phytocannabiniods have received
growing interest because of their potential therapeutic use as
antihypertensive agents (reviewed; Pacher et al., 2005; Sarzani,
2008; Cunha et al., 2011). It has been postulated that
endocannabinoids may contribute to the hypotensive state of certain
pathophysiological diseases, including; haemorrhagic shock (Wagner
et al., 1997), endotoxic shock (Varga et al., 1998; Wang et al.,
2001; Liu et al., 2003; Batkai et al., 2004), cardiogenic shock
(Wagner et al., 2001) and liver cirrhosis (Batkai et al., 2001; Ros et
al., 2002; Domenicali et al., 2005). Recent research has implicated
an upregulated endocannabinoid system, involving increased CB1-
receptor expression and endocannabinoid production in liver
cirrhosis (Caraceni et al., 2010). Advanced liver cirrhosis is
associated with vasodilation of the mesenteric vasculature (Piscaglia
et al., 1997), which can contribute to portal hypertension by
enhancing portal inflow. Advanced cirrhosis is also associated with
systemic hypotension caused by vasodilation (Chu et al., 1997; Van
Roey et al., 1997). Research by Batkai et al. (2001) has suggested
that the endocannabinoid signalling system may contribute to
cirrhotic-induced low blood pressure. The hypotensive state of rats
with biliary cirrhosis and CCl4-induced cirrhotic model was
normalised by the CB1-receptor antagonist rimonabant (Batkai et al.,
2001). Circulating monocytes isolated from biliary cirrhotic rats and
human cirrhotic patients, when injected into normal rats elicited a
long-lasting hypotension but had no effect in rimonabant-treated
rats (Batkai et al., 2001). Monocytes from cirrhotic rats where
shown to have enhanced levels of anandamide by 2-3 fold when
compared to monocytes from healthy rats. Increased anandamide
levels correlated with greater expression of CB1-receptors in
endothelial cells from hepatic arteries (Batkai et al., 2001).
Chapter 1 General Introduction
31
The prototypical endocannabinoid, anandamide has been
demonstrated to cause hypotension in vivo (Varga et al., 1995;
1996) Intravenously administered anandamide elicits a triphasic
blood pressure response, characterised by an initial drop in blood
pressure, a subsequent pressor response, followed by a sustained
hypotension (Varga et al., 1995; 1996). The prolonged hypotension
is associated with reduced total peripheral resistance and reduced
cardiac contractility and is absent in CB1-receptor knockout mice
(Ledent et al., 1999) and in the presence of rimonabant (Lake et al.,
1997; Malinowska et al., 2001). However, the triphasic response
to anandamide including the prolonged phase of hypotension is
sensitive to the type of in vivo model used. Prolonged hypotension
in response to anandamide is either completely absent or greatly
attenuated in conscious models (Lake et al., 1997; Gardiner et al.,
2002). Gardiner et al. (2002) described complex pressor effects in
conscious rats, where transient pressor responses were
characterised by vasoconstriction in regional vascular beds, while
increasing doses of anandamide induced transient hypotension
followed by a prolonged period of hypertension. In contrast, a
biphasic response characterised by an initial transient drop in blood
pressure followed by prolonged hypotension has been reported in
conscious mice models (Ledent et al., 1999). Conscious CB1-
receptor knockout mice failed to respond to anandamide in the
characteristic biphasic manner, suggesting the hypotensive effects
of anandamide were mediated by cannabinoid receptors (Ledent et
al., 1999).
Smith and McQueen (2001) reported a dose-dependent drop in
blood pressure to anandamide administered to the vasculature of
the hindlimb of the anesthetised rat, results which were mimicked
by the vanilloid capsaicin. The blood pressure response evoked by
both anandamide and capsaicin was attenuated by capsazepine, a
competitive TRPV1 antagonist (Smith and McQueen, 2001). This
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suggests that cardiovascular responses to endocannabinoids can be
mediated by perivascular TRPV1 containing sensory nerves. This is
consistent with the observations of, Zygmunt et al. (1999) who
showed capsaicin-sensitive sensory nerves to be the driving
mechanism behind anandamide-induced vasorelaxation of rat
isolated arteries, via the release of the calcitonin gene related
peptide. In TRPV1 knockout mice the long lasting hypotensive
phase in response to anandamide remained intact, but the initial
transient drop in blood pressure was decreased.
1.6 Aims
The primary aim of this study was to examine the vascular actions
of the endocannabinoid-like mediator oleamide in comparison with
the more widely studied endocannabinoid, anandamide. It is
hypothesised that oleamide will demonstrate a similar vasorelaxant
profile to anandamide. To fulfil our aims several different methods
were used. Initially, the effects of oleamide in larger conduit vessels,
namely, the rat isolated aorta, porcine isolated coronary and
mesenteric arteries were examined as, to date, the actions of
oleamide have only been characterised in small resistance vessels.
Although a large body of research has characterised the
cardiovascular effects of anandamide in a number of models of
hypertension and implicated the endocannabinoid system in
hypertension, no investigation to date has described the responses
to oleamide in a model of hypertension. To achieve this, I
compared the vascular actions of oleamide and anandamide in
arteries from the spontaneously hypertensive rat model in
comparison to the normotensive control, the Wistar-Kyoto. As a
consequence of studies into the mechanisms driving vasorelaxation,
the vascular actions of the TRPV1 agonist capsaicin was
subsequently characterised in greater detail. The present study also
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characterised the vasodilator properties of oleamide in a whole
arterial bed preparation, the rat mesenteric arterial bed.
Chapter 2 The vascular actions of oleamide in conduit arteries
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Chapter 2 The vascular actions of oleamide in conduit
arteries
2.1 Introduction
Oleamide (cis-9, 10-octadecenoamide) is a fatty acid primary amide
that was originally isolated from the cerebrospinal fluid of cats
subjected to sleep deprivation (Cravatt et al., 1995). Being a fatty
acid amide, oleamide shares structural similarity with the
prototypical endocannabinoid anandamide, thus both act as a
substrate for fatty acid hydrolase (FAAH). Oleamide administered
in vivo demonstrates a similar profile of effects to anandamide.
Indeed, oleamide induces the tetrad of behavioural effects used to
denote cannabinoid-like activity. Oleamide causes hypomotility
(Basile et al., 1999; Fedorova et al., 2001), analgesia (Federova et
al., 2001), and hypothermia (Federova et al., 2001; Huitron-
Resendiz et al., 2001) in rat and mice models. A number of the in
vivo effects elicited by oleamide are sensitive to a blockade of CB1
receptors, for example, the analgesic effect of oleamide in the tail-
flick assay was abolished by rimonabant (Fedorova et al., 2001).
Oleamide also increases appetite (Huitron-Resendiz et al., 2001),
which is a classic cannabinoid-induced effect reflected in the success
of rimonabant in reducing body weight (Leite et al., 2006). In
addition oleamide has been shown to be an endogenous agonist of
both rat and human CB1 receptors (Legett et al., 2004).
Oleamide has recently been described as a potent vasodilator of rat
mesenteric resistance arteries. Hoi and Hiley (2006) reported that
oleamide-induced vasorelaxation involved sensory nerve-mediated
activity, activation of calcium activated K+-channels and was partly
dependent on an intact endothelium. Oleamide-induced responses
were also sensitive to O-1918, an antagonist of the putative
endothelial CB receptor (Hoi and Hiley, 2006). Sudhahar et al.
(2009) also implicated non-endothelial TRPV1 receptors and an O-
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1918 sensitive component, as well as endothelial CB1 receptors.
The literature describes a clear overlap of mechanisms involved in
responses to oleamide and anandamide.
While a large number of studies have investigated the vascular
effects of anandamide, oleamide has received little attention. With
this in mind the principal aim of this chapter was to characterise and
compare the vascular responses to oleamide and anandamide in
larger conduit arteries. The responses to oleamide in rat aortae,
porcine coronary arteries and porcine mesenteric arteries were
investigated.
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2.2 Methods and Materials
2.2.1 Animals
Wistar rats (250-350g; aged 12-18 weeks) were used during this
investigation. All rats used were housed at the Biomedical Services
Unit, University of Nottingham with a 12h light/dark cycle and in
temperature-controlled conditions. Porcine hearts and porcine
mesenteries were obtained from a local abattoir and transported in
ice-cold modified Krebs-Henseleit buffer solution (NaCl 118, KCl 4.7,
MgSO4 1.2, KH4PO 4.2, NaHCO3 25, D-glucose 10, CaCl2 2 (mM)).
2.2.2 Preparation of aortic rings and experimental protocol
The rats were stunned by a blow to the back of the head and killed
by cervical dislocation. This was followed by the removal of the
abdominal aorta. Subsequently, the aorta was cleared of all
connective tissue by blunt dissection and cut into segmental rings
(3mm-5mm). The aortic rings were placed between two metal wires,
with one being fixed and the other attached via thread to an
isometric transducer and placed into 50ml organ baths (Figure 2.1).
The organ baths were filled with modified Krebs-Henseleit buffer
solution (NaCl 118, KCl 4.7, MgSO4 1.2, KH4PO 4.2, NaHCO3 25, D-
glucose 10, CaCl2 2 (mM)) at 37°C and gassed (5% CO²/95% O²).
The aortic rings were allowed to equilibrate to an optimal baseline
tension of 9.8mN for 1h. Tension was measured by a Leitica force
transducer coupled to an ADInstruments MacLab recording system.
Chapter 2 The vascular actions of oleamide in conduit arteries
38
Figure 2.1
Figure 2.1 Isometric tension set up. A=pressure transducer,
B=thread, C=glass rod, D=gas inlet, E=connection to
thermocirculator, F=modified Krebs solution (50ml), G=organ bath,
H=organ bath drainage outlet, I=upper mounting hook, J=lower
mounting hook, K=gas delivery tube, L=tissue segment and
M=heated chamber.
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Vessels were pre-contracted with the Į1-adrenoceptor agonist
methoxamine (1-10µM) to achieve submaximal contraction prior to
the addition of oleamide (10nM-10µM) (Figure 2.2) or anandamide
(1nM-10µM), which were added cumulatively at 5 minute intervals
to construct concentration-response curves. Pre-contraction data
can be found in the appendices. Concentration-response curves
were started after a stable pre-contraction was established (after
approx 20 minutes). Pre-contraction data can be found in the results
section.
Figure 2.2
Figure 2.2 Representative trace of the response to oleamide in the
rat isolated aorta. A= 10nM, B=30nM, C=100nM, D=300nM,
E=1µM, F=3µM and G=10µM.
To investigate the role of sensory nerves, some vessels were
subjected to pre-treatment with 10µM capsaicin for 1h (Zygmunt et
al, 1999). Capsaicin pre-treatment was followed by a 20min wash-
out prior to methoxamine contraction. Experiments were also
performed in the presence of capsazepine (5µM), a TRPV1 receptor
antagonist (White et al., 2001). To further analyse sensory nerve
activity of aortae, concentration-response curves to capsaicin (1nM-
10µM) were constructed cumulatively. Experiments were also
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carried out in the presence of ruthenium red (10µM), a blocker of
capsaicin-activated cation channels (Harris et al., 2002).
The contribution of the endothelium was assessed by denuding
some vessels of endothelial cells. This was achieved by gentle
rubbing of the intimal surface with metal forceps. Endothelial
function was examined by addition of carbachol (10µM) after pre-
contraction by methoxamine. Vessels responding with less than
20% relaxation of induced tone to carbachol were deemed to be
lacking a functional endothelium. In some vessels, incubated with L-
NAME (300µM) to inhibit nitric oxide synthase, both control (n=7)
and treated (n=7) arteries were unresponsive to oleamide. In
other vessels indomethacin (10µM) was present to inhibit cyclo-
oxygenase (OSullivan et al., 2004). Some experiments were
carried out in the presence of high extracellular K+ (NaCl 62.5, KCl
59.4, MgSO4 1.2, KH4PO 1.2, NaHCO3 25, D-glucose 10, CaCl2 2
(mM)) to assess the role of hyperpolarising mechanisms in
responses to oleamide. In some experiments the role of cannabinoid
CB1 receptors was examined by incubation with AM251 (1µM) a
cannabinoid CB1 receptor antagonist (OSullivan et al., 2005). Some
experiments were carried out in the presence of URB597 (1µM), a
fatty acid amide hydrolase (FAAH) inhibitor (Ho and Randall, 2007).
2.2.3 Preparation of porcine coronary arteries and mesenteric
arteries and experimental protocol
Proximal coronary arteries were removed from the hearts and first
order mesenteric arteries removed from mesenteries and stored in a
refrigerator over-night at 4°C in pre-gassed Krebs-Henseleit buffer
solution having been cleaned thoroughly of connective tissue by
blunt dissection and cut into segments of 3-5mm. Porcine arteries
were stored in the refrigerator no longer than 24h.
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Porcine coronary and mesenteric arteries were placed onto two
metal wires, with one being fixed and the other attached via thread
to an isometric transducer measuring tension and placed into 50ml
organ baths (Figure 2.1). The organ baths were filled with modified
Krebs-Henseleit buffer solution at 37°C and gassed steadily (5%
CO²/95% O²). Porcine coronary arteries and mesenteric arteries
were equilibrated to 49mN. Tension was measured by a Leitica
force transducer coupled to an ADInstruments MacLab recording
system. Porcine coronary and mesenteric arteries were pre-
contracted with U46619 (1-70nM), a thromboxane mimetic, prior to
the construction of concentration-response curves to oleamide
(10nM-10µM) and anandamide (1nM-10µM) (Figure 2.3) to achieve
a submaximal contraction of 50-80% of maximal KCl (60mM)
response. To investigate the role of sensory nerves in the response
to anandamide, porcine mesenteric arteries were subjected to pre-
treatment with 10µM capsaicin for 1h (Zygmunt et al., 1999).
Capsaicin pre-treatment was followed by a 20min wash-out period,
prior to pre-contraction. In porcine mesenteric arteries,
concentration-responses curves to anandamide were also
constructed in the presence L-NAME (300µM), indomethacin (10µM)
and in endothelial denuded vessels.
Figure 2.3
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Figure 2.3 Representative trace of the response to anandamide in a
porcine mesenteric arterial segment. A=1nM, B=3nM, C=10nM,
D=30nM, E=100nM, F=300nM, G=1µM, H=3µM and I=10µM.
2.2.4 Drugs and reagents
Oleamide (cis-9-Octadecenoamide), anandamide
(arachidonylethanolamide) and AM251 (N-(piperidin-1-yl)-5-(4-
iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-
carboxamide) were purchased from Tocris Co. (UK). Capsaicin (8-
Methyl-N-vanillyl-trans-6-nonenamide), capsazepine (N-[2-(4-
chlorophenyl)ethyl]-1,3,4,5-tetrahydro-7,8-dihydroxy-2H-2-
benzazepine-2-carbothioamide), methoxamine hydrochloride (Į-(1-
Aminoethyl)-2,5-dimethoxybenzyl alcohol hydrochloride), U46619
(9,11-Dideoxy-9a,11a-methanoepoxy prostaglandin F2Į), ruthenium
red (ammoniated ruthenium oxychloride), L-NAME (NG-Nitro-L-
arginine methyl ester hydrochloride), indomethacin (1-(4-
Chlorobenzoyl)-5-methoxy-2-methyl-3-indoleacetic acid), URB597
(cyclohexylcarbamic acid 3'-carbamoyl-biphenyl-3-yl ester) and
carbachol ((2-Hydroxyethyl) trimethylammonium chloride
carbamate) were all purchased from Sigma Chemicals Co. (UK).
Anandamide, capsaicin, indomethacin and capsazepine were
dissolved in ethanol at stock concentrations of 10 mM and
methoxamine at 1mM. DMSO (Dimethyl sulfoxide) was used to
dissolve stock solutions of oleamide and AM251 at 10 mM and
URB597 at 1 mM. All other drugs were dissolved using distilled
water. All dilutions were made using distilled water. L-NAME,
indomethacin, AM251 and capsazepine were incubated for
approximately 20 minutes before pre-contraction of vessels with
methoxamine. Ruthenium red was incubated for 30 minutes, while
URB597 was incubated for 10 minutes before pre-contraction.
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2.2.5 Statistical analysis
All responses are expressed as mean percentage vasorelaxation with
the associated standard error of the mean (S.E.M). The GraphPad
Prism 5.0 software (San Diego, CA) was used to plot mean data as
sigmoidal concentration-response curves using a sigmoidal equation
[Y=Bottom+ (Top-Bottom)/(1+10((LogEC50-X)*Hillslope)), when
X=logarithm of agonist concentration and Y=response from Bottom
to Top in a sigmoidal shape]. The curves were used to determine
potency (pEC50) and maximal response (Rmax) values. Potency
(pEC50) is the negative log of agonist concentration that reduced
methoxamine-induced contraction by 50%. The maximal response
relates to the maximum percentage vasorelaxation of methoxamine-
induced pre-contraction. Statistical significance was determined
using two-tailed unpaired Students t-test between two data sets or
one-way ANOVA when comparing multiple data-sets. One-way
ANOVA was followed by a Bonferroni post hoc carried out as
appropriate. Statistical significance was determined using one-way
ANOVA unless stated otherwise in the figure legend. P-values <0.05
were considered significant.
2.2.6 Isolation and culture of DRG neurones
Dorsal root ganglion (DRG) neurons are used as a model for primary
afferent nociceptors and have a high expression of TRPV1 receptors.
DRG cells were therefore used as a tool to investigate the effects of
oleamide on TRPV1 receptors. The following protocol was carried
out by Paul Millns of the University of Nottingham. DRG neurons
were isolated from Wistar rats (250g-350g) (Lindsay, 1988) and
after the rats were killed as previously described.
After being killed as previously described the rat was sprayed with
70% alcohol. The skin was cut to expose the underlying muscle and
vertebral column. Incisions were made either side of the vertebral
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column and spinous processes were then removed from the dorsal
surface of the exposed spine. After this cleaning of the spinal
column it was removed from the animal. Muscle and connective
tissue was then cleaned from the vertebral column before it was
placed in Hanks balanced saline solution (HBSS) containing HEPES
(20mM). Using fine-pointed scissors a ventral strip of bone (3-4mm)
was removed from the ventral roof of the vertebral column. An
incision to the mid-line of the spinous processes allowed the
bisection of the spinal column. Following the gentle removal of the
spinal cord the DRGs were exposed. Approximately 30-40 DRGs
were cut from the central and peripheral trunks using microsurgery
scissors and watch-makers forceps and placed in HBSS with HEPES
(0.1M) and washed once.
Ganglia were cultured in agreement to the methodology outlined in
Millns et al. (2006). DRG neurons were incubated (37°C/5% CO2)
for 90min in 5mL neurobasal medium (Invitrogen, Paisley, UK)
containing collagenase (2.5mg/mL) and 10% horse serum. Isolated
ganglia were washed in phosphate-buffered saline (5mL) with
porcine trypsin (2.5mg/mL) and incubated for 30 min (37°C/5%
CO2). Thereafter, ganglia were washed and triturated. The
subsequent cell suspension was layered on a 16% bovine serum
albumin solution (4mL), which was centrifuged allowing the removal
of the supernatant. The remaining cell sediment was suspended
again in neurobasal medium (1mL) and made up to 1.5mL with glial
cell line-derived neurotrophic factor (50ng/mL), nerve growth factor
(25pg/mL), L-glutamate (2mM), penicillin (200 units/mL),
streptomycin (200ng/mL) and with horse serum. Cell suspension
was pipetted onto 13mm glass cover slips and incubated (37°C/5%
CO2) overnight.
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2.2.7 Calcium imaging studies of DRG neurones
Fura-2AM is a calcium sensitive dye and loading cells with Fura-2AM
allows intracellular Ca2+ concentrations to be visualised using
imaging techniques as the excitation wavelength of Fura-2AM alters
upon binding of calcium. After being grown overnight DRG cells were
washed three times with a Ca2+ buffer and a 2.5µL Fura-2AM
solution (5µM) in 450µL Ca2+ buffer (NaCl 145, KCl 5, CaCl2 2,
MgSO4·7H2O 1, HEPES 10, glucose 10 (mM)) with 50µL horse serum
and then incubated (37°C) in the dark. After at least 30mins DRG
cells were again washed three times with a Ca2+ buffer to remove
excess Fura-2AM and left for 15mins. The intracellular calcium
concentrations of 30-40 cells from individual neurones were
analysed using an Improvision imaging system. The n numbers
used in the results section represent the number of cells used. Cells
were isolated from six different animals. Intracellular calcium was
estimated as the ratio of fluorescence intensities emitted at 340nm
and 380nm excitation wavelengths (measured at 500nm). Cells
were imaged using an inverted microscope with a high sensitivity
camera attached. Excitation wavelengths were altered by a filter
wheel attached to the microscope. Cover slips with DRG cells were
attached to a Perspex chamber using vacuum grease. This formed a
well that was then attached to a heated platform (30°C) and DRG
neurons were perfused (2ml/min) with Ca2+-buffer. Cover slips
containing DRG cells were then superfused (2ml/min) with capsaicin
(100nM) and oleamide (100µM) for 60s. Responses to oleamide and
capsaicin alone were expressed as a percentage of the response to
high KCl (60mM)(60s) and data are expressed as mean ± standard
error of the mean (SEM). Perfusion of DRGs with KCl results in
calcium-influx caused by depolarisation and was used as a control
response during the experiments. DRGs that demonstrated an
increase from basal in the ratio of peak fluorescence that was less
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than 0.2 in response to KCl were excluded from the study for being
non-viable.
2.3 Results
2.3.1 Vascular responses to oleamide in the rat isolated aorta
Oleamide caused concentration-dependent vasorelaxation of aortic
rings isolated from Wistar rats (Rmax=20.7±2.5%, pEC50=6.64±0.37,
n=10) (Figure 2.4). DMSO (0.15% of final bath volume) did not
cause a vascular response.
Figure 2.4
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Figure 2.4 Vasorelaxant responses to oleamide and vehicle control
(DMSO) in rat aortic rings pre-contracted with methoxamine. Mean
data with bars indicating S.E.M are displayed.
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2.3.2 Vascular responses to oleamide in the rat isolated aorta in the
presence of high extracellular K+
Vasorelaxant responses to oleamide (Rmax=16.9±2.2%,
pEC50=7.27±0.54, n=5) in rat aortae were unaffected by a high
concentration of extracellular K+ (60mM) (Rmax=15.9±2.1%,
pEC50=6.73±0.45, n=8) (Figure 2.5).
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Figure 2.5 Vasorelaxant responses to oleamide in aortic rings from
Wistar rats contracted with high extracellular K+ (60mM). Mean data
with bars indicating S.E.M are displayed. Experiments were
analysed using Students t-test.
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2.3.3 Vascular responses to oleamide in the rat isolated aorta after
a 1h capsaicin pre-treatment
Oleamide caused vasorelaxant responses in aortae such that, at
10µM, relaxation was 14.0±2.8% (n=11) and this response was
abolished after pre-treatment of vessels with capsaicin (n=11)
(Figure 2.6).
Figure 2.6
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Figure 2.6 Vasorelaxant responses to oleamide in aortic rings from
Wistar rats pre-treated with capsaicin (10µM). Mean data with bars
indicating S.E.M are displayed.
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2.3.4 Vascular responses to oleamide in the rat isolated aorta in the
presence of vanilloid receptor antagonists
Vasorelaxant responses to oleamide in rat aortic rings
(Rmax=20.7±2.5%, pEC50=6.64±0.37, n=10) were unaffected by the
TRPV1 antagonist capsazepine (5µM) (Rmax=26.7±4.0%,
pEC50=6.80±0.51, n=7) (Figure 2.7). Similarly, oleamide-induced
vasorelaxation (Rmax=21.9±3.6%, pEC50=6.03±0.35, n=7) was
unaffected by the cation channel blocker ruthenium red (10µM)
(Rmax=24.1±4.8%, pEC50=5.66±0.33, n=7) (Figure 2.8).
Figure 2.7
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Figure 2.7 Vasorelaxant responses to oleamide in aortic rings from
Wistar rats pre-contracted with methoxamine in the presence of
capsazepine (5µM). Mean data with bars indicating S.E.M are
displayed.
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Figure 2.8
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Figure 2.8 Vasorelaxant responses to oleamide in aortic rings from
Wistar rats pre-contracted with methoxamine in the presence of
ruthenium red (10µM). Mean data with bars indicating S.E.M are
displayed.
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2.3.5 Vascular responses to oleamide in the rat isolated aorta in the
presence of COX-inhibition
Vasorelaxation induced by oleamide in rat aortic rings
(Rmax=19.7±4.6%, pEC50=5.85±0.44, n=8) was unaffected by
indomethacin (10µM) (Rmax=31.0±9.6%, pEC50=5.30±0.34, n=8)
(Figure 2.9)
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Figure 2.9 Vasorelaxant responses to oleamide in aortic rings from
Wistar rats pre-contracted with methoxamine in the presence of
indomethacin (10µM). Mean data with bars indicating S.E.M are
displayed.
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2.3.6 Vascular responses to oleamide in endothelium denuded aortic
rings
Vasorelaxation elicited by oleamide in rat aortic rings
(Rmax=14.5±6.0%, pEC50=6.04±1.02, n=6) was comparable to the
vasorelaxation of endothelial denuded vessels (Rmax=13.8±1.5%,
pEC50=6.32±0.25, n=6) (Figure 2.10).
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Figure 2.10 Vasorelaxant responses to oleamide in endothelium
denuded aortic rings from Wistar rats pre-contracted with
methoxamine. Mean data with bars indicating S.E.M are displayed.
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2.3.7 Vascular responses to oleamide in the presence of URB597 in
the rat isolated aorta
Vasorelaxation induced by oleamide in rat aortic rings
(Rmax=10.2±3.5%, pEC50=5.88±0.50, n=7) was unaffected by the
presence of URB597 (1µM) (Rmax=13.0±2.0%, pEC50=6.36±0.28,
n=8) (Figure 2.11).
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Figure 2.11 Vasorelaxant responses to oleamide in aortic rings from
Wistar rats pre-contracted with methoxamine in the presence of
URB597 (1µM). Mean data with bars indicating S.E.M are displayed.
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2.3.8 Vascular responses to oleamide in the presence of AM251 in
the rat isolated aorta
Vasorelaxation induced by oleamide in rat aortic rings
(Rmax=10.5±4.4%, pEC50=5.61±0.43, n=7) was unaffected by the
presence of AM251 (1µM) (Rmax=11.6±4.3%, pEC50=5.75±0.48,
n=6) (Figure 2.12).
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Figure 2.12 Vasorelaxant responses to oleamide in aortic rings from
Wistar rats pre-contracted with methoxamine in the presence of
AM251 (1µM). Mean data with bars indicating S.E.M are displayed.
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2.3.9 Vascular responses to anandamide in the rat isolated aorta
Anandamide (1nM-10µM) failed to elicit any response in rat isolated
aortic rings (n=8) (Figure 2.13).
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Figure 2.13 Vascular responses to anandamide in aortic rings from
Wistar rats pre-contracted with methoxamine. Mean data with bars
indicating S.E.M are displayed.
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2.3.10 Vascular responses to oleamide in porcine coronary arteries
Oleamide (10nM-30µM) and DMSO (0.15% of final bath volume)
failed to elicit any response in isolated porcine coronary arteries
(n=6) (Figure 2.14).
Figure 2.14
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Figure 2.14 Vascular responses to oleamide (10nM-30µM) and
vehicle control (DMSO) in porcine coronary arteries pre-contracted
with U46619. Mean data with bars indicating S.E.M are displayed.
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2.3.11 Vascular responses to anandamide in porcine coronary
arteries
Anandamide failed to elicit a vascular response in porcine isolated
coronary arteries (n=5) (Figure 2.15).
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Figure 2.15 Vascular responses to anandamide in porcine coronary
arteries pre-contracted with U46619. Mean data with bars indicating
S.E.M are displayed.
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2.3.12 Vascular responses to oleamide in porcine isolated
mesenteric arteries
Oleamide did not cause a significant vasorelaxant response in
porcine isolated mesenteric arteries compared to DMSO (0.15% of
final bath volume) (Figure 2.16).
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Figure 2.16 Vascular responses to oleamide (10nM-10µM) and
vehicle control (DMSO) in porcine mesenteric arteries pre-contracted
with U46619. Mean data with bars indicating S.E.M are displayed.
Experiments were analysed using Students t-test.
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2.3.13 Vascular responses to anandamide in porcine isolated
mesenteric arteries
Anandamide and capsaicin caused concentration-dependent
vasorelaxation of porcine mesenteric arteries, such that at 10µM,
anandamide elicited relaxation of 53.1±13.4% (n=6) (Figure 2.17).
At the same concentration the vehicle control (0.15% of final bath
volume) did not cause vasorelaxation.
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Figure 2.17 Vasorelaxant responses to anandamide and vehicle
control (ethanol) in porcine mesenteric arteries pre-contracted with
U46619. Mean data with bars indicating S.E.M are displayed.
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2.3.14 Vascular responses to anandamide in the presence of L-
NAME in porcine isolated mesenteric arteries
The vasorelaxant response to 10µM anandamide, 34.2±8.3% (n=8)
in porcine mesenteric arteries was abolished in the presence of L-
NAME (300µM) (Figure 2.18). Arteries in the presence of L-NAME
were noticeable more sensitive to U46619, with a range of 1-10nM
always sufficient to pre-contract vessels.
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Figure 2.18 Vasorelaxant responses to anandamide in porcine
mesenteric arteries pre-contracted with U46619 in the presence of
L-NAME (300µM). Mean data with bars indicating S.E.M are
displayed. Experiments were analysed using Students t-test.
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2.3.15 Vascular responses to anandamide in the presence of
indomethacin in porcine isolated mesenteric arteries
The vasorelaxant response to 10 µM anandamide, was 31.6±8.5%
(n=10), was not significantly affected by indomethacin, 16.0±6.1%
(n=10) (Figure 2.19).
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Figure 2.19 Vasorelaxant responses to anandamide in porcine
mesenteric arteries pre-contracted with U46619 in the presence of
indomethacin (10µM). Mean data with bars indicating S.E.M are
displayed. Experiments were analysed using Students t-test.
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2.3.16 Vascular responses to anandamide after a capsaicin pre-
treatment in porcine isolated mesenteric arteries
The vasorelaxant response to anandamide, 23.0±5.3% (n=6), was
unaffected by a 1h pre-treatment of vessels with capsaicin,
15.4±7.4%, (n=6) (Figure 2.20).
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Figure 2.20 Vasorelaxant responses to anandamide in porcine
mesenteric arteries pre-contracted with U46619 after a 1h capsaicin
pre-treatment (10µM). Mean data with bars indicating S.E.M are
displayed. Experiments were analysed using Students t-test.
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2.3.17 Vascular responses to anandamide in endothelium-denuded
porcine mesenteric arteries
Vasorelaxation of porcine mesenteric arteries by 10µM anandamide,
17.5±5.8% (n=7), remained similar in endothelium denuded vessels,
such that vasorelaxation by 10µM was 13.1±3.6% (n=8) (Figure
2.21).
Figure 2.21
-9 -8 -7 -6 -5 -4
-10
0
10
20
30
40
50 control (n=7)
+ minus endothelium (n=8)
Log [Anandamide] (M)P
e
rc
e
n
ta
ge
R
e
la
x
a
tio
n
(%
)
Figure 2.21 Vasorelaxant responses to anandamide in endothelial
denuded porcine mesenteric arteries pre-contracted with U46619.
Mean data with bars indicating S.E.M are displayed. Experiments
were analysed using Students t-test.
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2.3.18 Effects of capsaicin and oleamide on calcium influx in rat
dorsal root ganglion neurones
Capsaicin produced a marked increase in intracellular calcium that
was 121±5. % (n=244) of the response elicited by KCl. Conversely,
oleamide produced a small increase in intracellular calcium, which
was 10.3±6.6% (n=244) of the KCl response (Figure 2.22).
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Figure 2.22 Intracellular calcium increases in Wistar rat DRG
neurones in response to capsaicin (100nM) and oleamide (100µM)
expressed as a percentage of the response to KCl (60mM).
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2.4 Discussion
The primary aim of this chapter was to characterise the vascular
effects of the endocannabinoid substance oleamide and make a
comparison to those of anandamide in large conduit arteries. A
major finding of the current study is that oleamide demonstrated
vasorelaxant properties in the rat isolated aorta, eliciting
approximately 20% relaxation. However, oleamide failed to cause
any vascular response in porcine mesenteric and coronary arteries.
The magnitude of the vasorelaxant response to oleamide in the rat
aorta is similar to the responses reported elsewhere to other
cannabinoids. OSullivan et al. (2005) described relaxations to
DQDQGDPLGH Ʃ9-tetrahydrocannabinol (THC) and N-
arachidonoyldopamine (NADA), all of which caused approximately
20% relaxation of aortic rings. However, the present study
demonstrated that anandamide did not cause vasorelaxation of
aortae. This is also in contrast to Herradon et al. (2007), who
reported a 35% relaxation to anandamide (10nM-100µM) compared
to vehicle. Possible explanations for this discrepancy are that the
lower concentration of anandamide examined here compared to
OSullivan et al. (2005) (10µM vs. 30µM) and using ethanol as a
solvent may blunt anandamide-induced responses (Herradon et al.,
2007).
The present chapter has described a small vasorelaxant effect in rat
aortae to oleamide of approximately 20%, which is a considerably
reduced response to oleamide compared to previously reported
effects in small resistance vessels. Hoi and Hiley (2006) reported
approximately 100% relaxation of pre-constricted small mesenteric
arteries, while Sudhahar et al. (2009) described a 60% vasorelaxant
response to oleamide. It is therefore possible that small resistance
vessels are more sensitive to the effects of oleamide than larger
conduit vessels. This is further demonstrated by the lack of a
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response to oleamide in porcine coronary arteries. Indeed,
differences in the reactivity to anandamide exist between conduit
and resistance arteries (OSullivan et al., 2004). OSullivan et al.
(2004) demonstrated that in small resistance arteries anandamide
elicited greater vasorelaxation compared to conduit mesenteric
arteries. Anandamide caused 90% relaxation of pre-constricted
third order mesenteric arteries compared to 35% of the superior
mesenteric artery. The authors also reported differences between
conduit and resistance vessels in the underlying mechanisms
involved in vasorelaxation. Anandamide-induced vasorelaxation of
large mesenteric arteries was predominately mediated by non-
endothelial vanilloid and CB1 receptors, while in smaller mesenteric
arteries responses involved an EDHF component (OSullivan et al.,
2004). This chapter presents results that similarly demonstrate
oleamide and anandamide have limited vasodilator actions in larger
conduit vessels.
Anandamide can induce vasorelaxation through the activation of
TRPV1 receptors in rat hepatic and mesenteric arteries and in guinea
pig basilar arteries (Zygmunt et al., 1999). Activation of TRPV1
receptors on perivascular sensory nerves elicits the release of
various neuropeptides, including CGRP, to cause vasorelaxation.
Indeed, anandamide-induced relaxation of rabbit aortae is partly
dependent on non-endothelial TRPV1 activation, a response that is
also sensitive to the CGRP antagonist CGRP8-37 (Mukhopadhyay et
al., 2002). Past studies have also implicated sensory nerve-
mediated mechanisms in oleamide-induced vasorelaxation (Hoi and
Hiley, 2006; Sudhahar et al., 2009). With this in mind it was
hypothesised that relaxation of rat aortae was mediated by sensory
nerves or TRP channels. Indeed, in the rat aorta oleamide-induced
vasorelaxation was sensitive to capsaicin pre-treatment designed to
desensitise perivascular sensory nerves. In Chapter 3, augmented
responses to oleamide and anandamide in the isolated aorta from
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the spontaneously hypertensive rat (SHR) model of hypertension
were normalised by capsaicin pre-treatment. Previous reports have
implicated sensory-nerve mediated mechanisms in regulating the
enhanced responses to endocannabinoids in hypertensive models (Li
et al., 2003; Wang et al., 2005; Wheal and Randall, 2009).
The sensitivity of oleamide-induced responses to capsaicin pre-
treatment suggests the involvement of perivascular sensory nerves
and the release of neuropeptides. However, when using additional
techniques to elucidate the involvement of TRPV1, including the
competitive antagonist capsazepine and the cation channel blocker
ruthenium red, oleamide-induced responses remained intact. This
clearly shows that vasorelaxation to oleamide is occurring
independently of TRPV1 activation but is sensitive to capsaicin. The
results also are consistent with an alternative mode of action for the
vascular effects of capsaicin. Indeed, Chapter 6 provides evidence
that capsaicin can inhibit the influx of calcium through L-type
calcium channels.
There is a growing body of evidence that demonstrates that
capsaicin can also regulate smooth muscle function by TRPV1
independent mechanisms. Several studies have reported that
capsaicin can inhibit calcium channels or activate potassium
channels in order to facilitate relaxation (Lo et al., 1995; Ellis et al.,
1997; Zhu et al., 1997; Sim et al., 2001; Yeon et al., 2001). Sim et
al. (2001) reported that capsaicin dose-dependently inhibited
spontaneous contractions in antral circular myocytes of the guinea
pig stomach. It was proposed that capsaicin inhibited this
spontaneous contraction by direct intracellular inhibition of voltage-
operated Ca²+ channels (Sim et al., 2001). In smooth muscle cells
of the rat aorta the inhibition of voltage-dependent L-type Ca²+
channels was reported to be the main mechanism driving capsaicin-
induced relaxation (Lo et al, 1995). Yeon et al. (2001) described a
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capsaicin-induced relaxation of the rabbit coronary artery, which
was proposed to be due to the activation of the delayed rectifier K+
channel. In human bronchi smooth muscle and equine tracheal
smooth muscle capsaicin-induced relaxation was mediated by
charybdotoxin-sensitive large conductance Ca²+ activated K+
channels (Ellis et al., 1997; Zhu et al., 1997). Gupta et al. (2007)
reported that capsaicin-induced relaxations in isolated human and
porcine arteries were not facilitated via CGRP or Neurokinin1
receptors, indicating responses were independent of neuropeptides
release. In addition, responses to capsaicin were independent of NO,
vanilloid receptors, voltage-sensitive calcium channels, K+ channels
or cAMP mediated mechanisms. Based on this the authors
concluded that non-specific mechanisms were involved in capsaicin
responses. In the present chapter, it should not be ruled out that
capsaicin may persist after the wash-out period and may block
additional sites. For example, it is possible that capsaicin could
block a novel cannabinoid receptor which mediates oleamide-
induced vasorelaxation.
The present chapter also investigated the effects of oleamide on
calcium influx in DRG neurones. Capsaicin (100nM) was shown to
evoke large increases in [Ca2+]i. The increase in [Ca
2+]i is mediated
by TRPV1 receptor activation (Caterina et al., 1997). Anandamide
has previously been demonstrated to enhance calcium influx in
HEK293 cells expressing recombinant TRPV1 and in rat DRG
neurones in a capsazepine sensitive manner (Smart et al., 2000).
Similarly, the anandamide analogues methanandamide and
palmitoylethanolamide also facilitated calcium influx (Smart et al.,
2000). As discussed above TRPV1 has also been implicated in the
vascular actions of oleamide (Hoi and Hiley, 2006; Sudhahar et al.,
2009). Thus, experiments were designed to examine whether
oleamide mimicked the effects of capsaicin at TRPV1. Oleamide
(100µM), unlike capsaicin, did not cause a marked increase in
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intracellular calcium and this would suggest that it is not a potent
activator of TRPV1. This strengthens the conclusion that in the rat
aortae oleamide is not causing relaxation through TRPV1 receptors.
Oleamide (100µM) caused a small decrease in capsaicin-induced
calcium influx. Previous studies have demonstrated cannabinoid
mediated inhibition of calcium influx elicited by capsaicin in rat DRG
neurones (Millns et al., 2001; Sagar et al., 2005). Intracellular
increases of calcium in response to capsaicin were attenuated by
HU210 and this inhibitory action was abolished by the CB1
antagonist rimonabant (Millns et al., 2001). The cannabinoid
arachidonyl-2-2choroethylamide also inhibited capsaicin-induced
increases in [Ca2+]i in DRG neurones from sham-operated and
neuropathic Sprague-Dawley rats and was similarly sensitive to
rimonabant (Sagar et al., 2005). Therefore, it is possible that at
concentrations used in DRG neurones oleamide is inhibiting
responses to capsaicin, possibly via CB1 receptors.
Oleamide is a selective agonist of both rat and human CB1 receptors
(Leggett et al., 2004). Leggett et al. (2004) demonstrated that
oleamide could competitively inhibit binding of CB1 agonists and
antagonists and also upregulate the binding of [356@*73Ǆ6 WR UDW
brain regions. Oleamide also inhibited forskolin-stimulated cAMP
accumulation in mouse neuroblastoma cells (Leggett et al., 2004). A
range of behavioural effects induced by oleamide are sensitive to
CB1 antagonism (Federova et al., 2001). Also, CB1-receptor
activation has been implicated in oleamide-induced vasorelaxation
of mesenteric resistance arteries (Sudhahar et al., 2009). Sudhahar
et al. (2009) demonstrated that the presence of the CB1 antagonist
AM251 caused a rightward shift in oleamide-induced relaxation.
Therefore, it was an obvious step to investigate the involvement of
CB1 receptors in the vascular responses to oleamide in rat aortae.
However, in the present study AM251 had no effect on the small
vasorelaxant effect caused by oleamide. In past studies examining
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the vasorelaxant effects of anandamide in the rat aorta, responses
were independent of CB1 receptor activation (OSullivan et al., 2005;
Herradon et al., 2007). Therefore, it is unlikely that oleamide is
mediating its vascular effects in rat aorta through CB1. Moreover,
vasorelaxant responses to oleamide in isolated aorta from SHR and
and the normotensive Wistar Kyoto (WKY) control described in
Chapter 3 were insensitive to AM251 presence.
As detailed in the methods, in both the control vessels and those
treated with L-NAME oleamide failed to elicit a vasorelaxant
response in the Wistar aorta. The disappearance of the
vasorelaxant effect of oleamide is not without precedent. Previously,
Hoi and Hiley (2006) found a large variability in the sensitivity of
mesenteric arteries to oleamide from rat to rat. The authors
reported that in approximately 30% of the rats used oleamide
elicited less than 20% vasorelaxation of pre-constricted tone,
compared to the 100% relaxation in vessels from responsive rats
and unresponsive vessels were removed from the analysis.
Interestingly, mesenteric arteries classed as low-responding to
oleamide also responded poorly to anandamide in comparison to
mesenteric arteries in which oleamide was efficacious (Hoi and Hiley,
2006). This supports our findings that there is variability in the
responses to oleamide, with some aortae being completely
unresponsive. The reasons for this are unknown but may reflect
seasonal or underlying genetic differences.
The involvement of the COX-pathway in regulating the vascular
responses to oleamide in WKY aortae has been discussed elsewhere
(Hopps et al., 2012). Ho et al. (2007) described that the local
activity of endothelial COX and FAAH was acting to blunt
anandamide-induced vasodilator responses in small mesenteric
arteries from rats. In cerebral arteries vasodilatation by
anandamide and THC was abolished by indomethacin, implicating
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the production of prostanoids in endocannabinoid responses (Ellis et
al., 1995). Herradon et al. (2007) described an indomethacin-
sensitive anandamide-induced vasorelaxation of rat aortae that was
also sensitive to inhibition of FAAH. The response was driven by a
COX-2 derived prostanoid active at endothelial prostaglandin EP4
receptors. Other studies have also implicated the COX-pathway in
responses to endocannabinoid (Pratt et al., 1998; Fleming et al.,
1999; Grainger and Boachie-Ansah, 2001). In the present study
indomethacin did not affect relaxation of the rat aortae to oleamide
or the anandamide-induced vasorelaxation of porcine mesenteric
arteries. This is in contrast to studies reported by OSullivan et al.
(2005) in which indomethacin potentiated vasorelaxation to
anandamide, THC and NADA in isolated aortae. Chapter 3 discusses
the potentiation by indomethacin of oleamide-induced responses in
WKY aortae.
Anandamide-induced vasorelaxation of porcine mesenteric arteries
was abolished in the presence of the NO synthase inhibitor L-NAME.
This demonstrates that anandamide can induce the release of NO,
which acts to relax vascular smooth. Other studies have reported
anandamide-induced release of NO (Deutsch et al., 1997; Poblete et
al., 2005). Anandamide was shown to dilate perfused
juxtomedillary afferent arterioles, which was sensitive to the
presence of L-NAME and rimonabant (Deutsch et al., 1997). The
authors also demonstrated the CB1-mediated release of NO in
response to anandamide in perfused renal arterial segments.
Interestingly, the vasorelaxant response to anandamide in porcine
mesenteric arteries was not dependent on an intact endothelium.
This would suggest that the NO released by anandamide is derived
from a non-endothelial source. A hypothesis could be that
anandamide is causing the release of neuronal NO. For example, in
endothelium-denuded mesenteric arteries from the guinea pig it was
demonstrated that electrical field stimulation induces vasodilatation
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(Gyoda et al., 1995). This response was attenuated with nitro-L-
arginine and so was mediated by non-endothelial NO. Neuronal NO
release induced by electrical field stimulation in SHR mesenteric
arteries was increased by endogenous prostacyclin, demonstrating a
regulatory role for neuronal NO in the vasomotor response (Ferrer et
al., 2004). In the human sigmoid colon circular muscle capsaicin-
induced relaxation was mediated by NO, as described by its
sensitivity to the presence the NO synthase inhibitor L-NOARG
(Bartho et al., 2002).
In summary, this chapter has demonstrated the vasorelaxant
properties of oleamide in rat aortae. However, the vasorelaxant
nature of oleamide was tissue dependent and oleamide did not
affect isolated porcine coronary and mesenteric arteries. This
chapter also reports differences between the mechanisms of action
between oleamide and anandamide as the two substances did not
elicit similar responses in any of the vessels tested. Oleamide-
induced responses were regulated by an unidentified capsaicin-
sensitive TRPV1-independent mechanism. Thus, results may
suggest an additional site of action for oleamide.
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Chapter 3 Enhanced vasorelaxant effects of oleamide and
anandamide in hypertension
3.1 Introduction
Endogenous cannabinoids and phytocannabinoids have recently
received growing interest, partly because of their potential
therapeutic use as antihypertensives (reviewed; Pacher et al., 2005;
Sarzani, 2008; Cunha et al., 2011). In males, long-term smoking of
marijuana has been linked to hypotensive effects that are
diminished by rimonabant, a cannabinoid CB1 receptor antagonist
(Gorelick et al., 2006). The hypotensive effects of THC have been
replicated in rat models, in which depressor effects are increased in
spontaneously hypertensive rats compared to normotensive controls
(Kosersky, 1978). Key evidence suggesting that the
endocannabinoid system is a potentially important target for the
treatment of hypertension comes from clinical trials of rimonabant.
The clinical trials were designed to study the impact of rimonabant
on weight loss in obese patients. Patients treated with rimonabant
experienced significant weight loss (Despres et al., 2005). In
addition, CB1 receptor antagonism caused a decrease in blood
pressure in obese patients with high blood pressure (Van Gaal et al.,
2005; Pi-Sunyer et al., 2006; Rucker et al., 2007; Ruilopea et al.,
2008), by a magnitude such that mortality associated with
hypertension would be significantly decreased (Lewington et al.,
2002). The decrease in blood pressure was presumably secondary to
the weight loss caused by appetite suppression by antagonism of
centrally located CB1 receptors. However, treatment with
rimonabant led to a number of adverse effects, including depression
and increased anxiety (Leite et al., 2009). Despite these adverse
effects, the case-study of rimonabant clearly highlights that
inhibition of the central endocannabinoid system may result, albeit
indirectly, in reductions in blood pressure.
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It has been postulated that endocannabinoids may contribute
towards the hypotensive state of certain pathophysiological diseases,
including; haemorrhagic shock (Wagner et al., 1997), endotoxic
shock (Varga et al., 1998; Wang et al., 2001; Liu et al., 2003;
Batkai et al., 2004), cardiogenic shock (Wagner et al., 2001; 2003)
and liver cirrhosis (Batkai et al., 2001; Ros et al., 2002; Domenicali
et al., 2005). Recent research has implicated an upregulated
endocannabinoid system, involving increased CB1 expression and
endocannabinoid production, in hepatic cirrhosis (Caraceni et al.,
2010). Batkai et al. (2001) demonstrated that, in a rat model of
cirrhosis, which is also hypotensive, the injection of rimonabant
increased blood pressure. There was also an upregulation of CB1
receptor expression in endothelial cells isolated from the vasculature
(Batkai et al., 2001). Circulating monocytes from patients with
chronic liver cirrhosis caused a decrease in blood pressure when
injected into rats, characterised by increased levels of anandamide
(Batkai et al., 2001). This further highlights the potential value of
the endocannabinoid system in the regulation of blood pressure
under pathophysiological conditions.
Both endocannabinoids and cannabinoids elicit enhanced depressor
responses in animal models of hypertension in comparison to
normotensive controls (Kosersky 1978; Lake et al., 1997; Batkai et
al., 2004b; Li et al., 2003; Wang et al., 2005; Wheal et al., 2007).
Batkai et al. (2004b) described enhanced depressor effects of
anandamide in the anesthetised SHR compared to normotensive
Wistar Kyoto rats (WKY). Increased depressor responses in the SHR
were associated with the upregulation of aortic and cardiac CB1
receptor expression (Batkai et al., 2004). The depressor effect of
anandamide in the SHR does not appear dependent on anaesthesia
(Wheal et al., 2007). The TRPV1 receptor has also been implicated
in the depressor effects of anandamide (Li et al., 2003; Wang et al.,
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2005). Li et al. (2003) demonstrated that methanandamide, a
stable analogue of anandamide, caused enhanced depressor effects
in SHR rats, which was partially mediated by TRPV1 and CB1
receptors. The antihypertensive effect of anandamide was
attenuated by capsazepine and in the mesenteric vasculature of the
SHR there was an upregulation of CGRP receptor expression
compared to the WKY (Li et al., 2003). Hence, anandamide-induced
hypotension may be elevated in the SHR due to the activation of
TRPV1 receptors on perivascular sensory nerves causing the release
of CGRP. In conscious rats made hypertensive through a high salt
diet, anandamide also caused enhanced hypotensive effects (Wang
et al., 2005). The decreases in blood pressure induced by
methanandamide were attenuated in the presence of either
capsazepine or rimonabant (Wang et al., 2005). The blockade of
both TRPV1 and CB1 receptors in combination completely abolished
cardiovascular responses to methanandamide. The mesenteric
vasculature from the high salt diet model of hypertension was
associated with increased expression of TRPV1 receptors compared
to the normotensive controls (Wang et al., 2005). Wang et al.
(2007) demonstrated that methanandamide elicited a greater
release of CGRP in arteries from hypertensive rats. In addition,
plasma levels of anandamide were upregulated in rats made
hypertensive by a high salt diet (Wang et al., 2007). It was
postulated that anandamide levels are upregulated in order to limit
blood pressure increases in high salt rat model through the
activation of TRPV1 receptors and the subsequent release of CGRP
(Wang et al., 2007).
The vasorelaxant properties of anandamide were also found to be
enhanced in some isolated blood vessels from models of
hypertension in comparison to vessels from normotensive controls.
In a rat model of hypertension, where animals acquire hypertension
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through chronic nitric oxide synthase inhibition with L-NAME,
anandamide produced enhanced vasorelaxant effects in perfused
mesenteric arterial beds (Mendizabel et al., 2001; Tep-Areenan et
al., 2002; Wheal et al., 2007). Wheal and Randall (2009)
demonstrated enhanced vascular responses to anandamide in two
models of hypertension; the SHR and the L-NAME induced model of
hypertension. In aortic rings from SHR rats the enhanced
vasorelaxant response to anandamide was mediated by
endothelium-dependent mechanisms which were independent of NO
and CB1 receptors (Wheal and Randall, 2009). Wheal and Randall
(2009) similarly demonstrated greater relaxation of mesenteric
arteries in the L-NAME model of hypertension and that the enhanced
effects of anandamide were absent after pre-treatment of vessels
with capsaicin, suggesting increased sensory nerve-mediated
activity in hypertension. This is contradictory to previous research
that showed capsazepine affected anandamide-induced responses
equally in mesenteric beds from hypertensive and normotensive rats
(Mendizabel et al., 2001). Interestingly, Wheal and Randall (2009)
did not test the sensitivity of the anandamide response to
capsazepine and Mendizabel et al. (2001) did not examine the
effects of capsaicin pre-treatment.
In light of the research implicating the endocannabinoid system in
hypertension, the hypotensive and antihypertensive nature of
anandamide, and the vasorelaxant properties of oleamide, it is
necessary to characterise the vascular effects of oleamide in
hypertension, and compare with those of anandamide. The aim of
this chapter was to investigate oleamide-induced vascular effects in
isolated vessels from the SHR model of hypertension and compare
them to the effects produced by anandamide.
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3.2 Methods and Materials
3.2.1 Animals
Male spontaneously hypertensive rats (SHR) and normotensive
Wistar Kyoto (WKY) rats (Charles River UK) (250-350g; aged 12-18
weeks) were used during this investigation. All rats used were
housed at the Biomedical Services Unit, University of Nottingham
with a 12h light/dark cycle and in temperature-controlled conditions.
3.2.2 Preparation of aortic rings and experimental protocol
The rats were killed and aortae removed and set-up following the
protocols outlined in Chapter 2.
Vessels were pre-contracted with the Į1-adrenoceptor agonist
methoxamine (1-10µM) to achieve submaximal (~70%) contraction
prior to the addition of oleamide (10nM-10µM) (Figure 3.1) or
anandamide (1nM-10µM), which were added cumulatively at 5
minute intervals to construct concentration-response curves.
Figure 3.1
Figure 3.1 Representative trace of the response to oleamide in the
SHR aorta. A= 10nM, B=30nM, C=100nM, D=300nM, E=1µM,
F=3µM and G=10µM.
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To investigate the role of sensory nerves, some vessels were
subjected to pre-treatment with 10µM capsaicin for 1h (Zygmunt et
al., 1999). Capsaicin pre-treatment was followed by a 20 minute
wash-out prior to methoxamine contraction. Experiments were also
performed in the presence of capsazepine (5µM), a TRPV1 receptor
antagonist (White et al., 2001). To further analyse any differences
in sensory nerve activity between SHR and WKY rats concentration-
response curves to capsaicin (1nM-10µM) were constructed
cumulatively. Experiments were also carried out in the presence of
ruthenium red (10µM), a blocker of capsaicin-activated cation
channels (Harris et al., 2002).
The contribution of the endothelium was assessed by denuding
some vessels of endothelial cells. This was achieved by gentle
rubbing of the intimal surface with metal forceps. Endothelial
function was examined by addition of carbachol (10µM) after pre-
contraction with methoxamine. Vessels responding with less than
20% relaxation of induced tone to carbachol were deemed to be
lacking a functional endothelium. To inhibit nitric oxide synthase
some vessels were incubated with L-NAME (300µM), while in other
vessels indomethacin (10µM) was present to inhibit cyclo-oxygenase
(OSullivan et al., 2004). Concentration-response curves to
oleamide were also carried out in the presence of niflumic acid
(10µM), a selective COX-2 inhibitor (Wheal et al., 2010). In some
experiments the role of cannabinoid CB1 receptors was examined by
incubation with AM251 (1µM) a cannabinoid CB1 receptor antagonist
(OSullivan et al., 2005). Some experiments were carried out in the
presence of URB597 (1µM), a fatty acid amide hydrolase (FAAH)
inhibitor (Ho and Randall, 2007).
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3.2.3 Drugs and reagents
Oleamide, anandamide and AM251 were obtained from Tocris Co.
(UK). All other drugs used in this investigation were purchased from
Sigma Chemicals Co. (UK). Anandamide, capsaicin and capsazepine
were dissolved in ethanol at stock concentrations of 10 mM. DMSO
was used to dissolve oleamide and AM251 at 10 mM and URB597 at
1mM. All other drugs were dissolved in distilled water. L-NAME,
indomethacin, AM251 and capsazepine were incubated for
approximately 20 minutes before pre-contraction of vessels with
methoxamine. Ruthenium red and niflumic acid were incubated for
30 minutes, while URB597 was incubated for 10 minutes before pre-
contraction.
3.2.4 Statistical analysis
All responses are expressed as mean percentage vasorelaxation with
the associated standard error of the mean (S.E.M). The GraphPad
Prism 5.0 software (San Diego, CA) was used to plot mean data as
sigmoidal concentration-response curves using a sigmoidal equation
[Y=Bottom+ (Top-Bottom)/(1+10((LogEC50-X)*Hillslope)), when
X=logarithm of agonist concentration and Y=response from Bottom
to Top in a sigmoidal shape]. The curves were used to determine
potency (pEC50) and maximal response (Rmax) values. Potency
(pEC50) is the negative log of agonist concentration that reduced
methoxamine-induced contraction by 50%. The maximal response
relates to the maximum percentage vasorelaxation of methoxamine-
induced pre-contraction. Statistical significance was determined
using two-tailed unpaired Students t-test between two data sets or
one-way ANOVA when comparing multiple data-sets. One-way
ANOVA was followed by a Bonferroni post hoc carried out as
appropriate. Statistical significance was determined using one-way
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ANOVA unless stated otherwise in the figure legend. P-values <0.05
were considered significant.
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3.3 Results
3.3.1 Vascular responses to oleamide and anandamide in isolated
aortae from SHR and WKY rats
Oleamide caused concentration-dependent vasorelaxation of aortic
segments from both SHR and WKY rats. Maximal relaxation was
significantly (P<0.001) greater in SHRs (Rmax=40.3±3.5%, n=6)
compared to that in aortae from WKY rats (Rmax=15.7±3.9%, n=6)
(Figure 3.2). The potency of oleamide was comparable between
aortae from SHR and WKY rats.
In aortic rings from SHR and WKY rats, anandamide also caused
concentration-dependent vasorelaxation and maximal relaxation was
significantly greater (P<0.001) in SHRs (Rmax=31.7±3.4%, n=10
SHR) compared to WKY rats (Rmax= 11.8±0.5%, n=10 WKY rats),
while the potency of anandamide was similar between strains
(pEC50=5.85±0.45, n=10 WKY rats; pEC50=6.36±0.28, n=10 SHR)
(Figure 3.3).
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Figure 3.2
-8 -7 -6 -5 -4
-10
0
10
20
30
40
50
60 WKY (n=5)
SHR (n=6)
Log [Oleamide] (M)
Pe
rc
e
n
ta
ge
R
e
la
x
a
tio
n
(%
)
Figure 3.2 Vasorelaxant responses to oleamide in aortic rings pre-
contracted with methoxamine from SHR and WKY rats. Mean data
with bars indicating S.E.M displayed.
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Figure 3.3
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Figure 3.3 Vasorelaxant responses to anandamide in aortic rings
pre-contracted with methoxamine from SHR and WKY rats. Mean
data with bars indicating S.E.M displayed.
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3.3.2 Effects of AM251, a cannabinoid CB1 receptor antagonist, on
the vascular responses to oleamide in aortae from SHR and WKY
rats
The vasorelaxant responses caused by oleamide (Rmax=27.6±3.5%,
pEC50=6.05±0.25, n=8) were unaffected by the CB1 receptor
antagonist AM251 (1µM) in SHR aortae (Rmax=37.3±3.5%, pEC50=
6.32±0.22, n=6). Similarly, responses to oleamide
(Rmax=13.1±3.2%, pEC50= 5.80±0.40, n=6) were unaffected in
aortae from WKY rats in the presence of AM251 (1µM)
(Rmax=15.8±1.7%, pEC50=5.90±0.21, n=4) (Figure 3.4).
Figure 3.4
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Figure 3.4 Vasorelaxant responses to oleamide in the presence of
AM251 (1µM) in aortae from WKY and SHR rats. Mean data with
bars indicating S.E.M displayed.
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3.3.3 Effects of AM251, a cannabinoid CB1 receptor antagonist, on
the vascular responses to anandamide in aortae from SHR and WKY
rats
Anandamide-induced vasorelaxation of aortae from both WKY
(Rmax=12.3±1.6%, pEC50=6.71±0.31, n=6) and SHR rats
(Rmax=36.0±2.3%, pEC50=6.76±0.19, n=6) was unaffected by the
CB1 receptor antagonist AM251 (1µM) (Rmax=7.7±1.1%,
pEC50=7.18±0.44, n=6 WKY; Rmax=43.5±2.7%, pEC50=6.87±0.17,
n=6 SHR) (Figure 3.5).
Figure 3.5
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Figure 3.5 Vasorelaxant responses to anandamide in the presence of
AM251 (1µM) in aortae from WKY and SHR rats. Mean data with
bars indicating S.E.M displayed.
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3.3.4 Effects of endothelial denudation on the vasorelaxant
responses to oleamide in SHR and WKY aortae
The vasorelaxant effects of oleamide in both WKY (Rmax=13.1±3.2%,
pEC50=5.80±0.40, n=6) and SHR (Rmax=27.6±3.5%,
pEC50=6.05±0.25, n=8) arteries were unaffected by endothelial
denudation (Rmax=10.8±2.2%, pEC50=6.20±0.44, n=6 WKY;
Rmax=23.2±5.0%, pEC50=5.72±0.32, n=9 SHR) (Figure 3.6).
Figure 3.6
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Figure 3.6 Vasorelaxation of endothelium denuded aortae from WKY
and SHR rats by oleamide. Mean data with bars indicating S.E.M
displayed.
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3.3.5 Effects of L-NAME on the vasorelaxant responses to oleamide
in SHR and WKY aortae
The vasorelaxation caused by oleamide in aortae from WKY
(Rmax=13.9±4.5%, pEC50=6.05±0.71, n=5) and SHR
(Rmax=40.3±3.5%, pEC50=6.49±0.22, n=6) rats was unaffected by
L-NAME (300µM) (Rmax=14.6±1.7%, pEC50=5.96±0.18, n=6 WKY;
Rmax=40.8±3.7%, pEC50=6.14±0.19, n=6 SHR) (Figure 3.7).
Figure 3.7
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Figure 3.7 Vasorelaxant responses to oleamide in aortae from WKY
and SHR rats in the presence of L-NAME (300µM). Mean data with
bars indicating S.E.M displayed.
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3.3.6 Effects of endothelial denudation on the vasorelaxant
responses to anandamide in SHR and WKY aortae
Anandamide did not cause any vascular responses in isolated aortae
from WKY rats. Anandamide-induced vasorelaxation of aortic
segments from SHR rats (Rmax=26.4±2.8%, pEC50=6.97±0.29, n=7)
was unaffected by removal of the endothelium (Rmax= 19.3±1.8%,
pEC50=6.24±0.20, n=7) (Figure 3.8).
Figure 3.8
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Figure 3.8 Vasorelaxation of endothelial denuded aortae from WKY
and SHR rats by anandamide. Mean data with bars indicating S.E.M
displayed.
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3.3.7 Effects of L-NAME on the vasorelaxant responses to
anandamide in SHR and WKY aortae
Anandamide failed to induce vasorelaxation in WKY aortae.
However, vasorelaxation of SHR aortae by anandamide
(Rmax=31.7±3.7%, pEC50=6.36±0.28, n=10) was unaffected by L-
NAME (Rmax=32.2±3.0%, pEC50=6.28±0.21, n=7) (Figure 3.9).
Figure 3.9
-9 -8 -7 -6 -5 -4
-10
0
10
20
30
40
50
60 WKY (n=10)
WKY+ L-NAME (n=6)
SHR (n=10)
SHR+ L-NAME (n=7)
Log [Anandamide] (M)P
e
rc
e
n
ta
ge
R
e
la
x
a
tio
n
(%
)
Figure 3.9 Vasorelaxant responses to anandamide in aortae from
WKY and SHR rats in the presence of L-NAME (300µM). Mean data
with bars indicating S.E.M displayed.
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3.3.8 Effects of cyclooxygenase inhibition on the vasorelaxant
responses to oleamide in isolated aortae from SHR and WKY rats
Vasorelaxation to oleamide in SHR arteries (Rmax=40.3±3.5%,
pEC50=6.49±0.22, n=6) was unaffected by 10µM indomethacin
(Rmax=28.7±3.8%, pEC50=5.90±0.28, n=6) (Figure 3.10). In
contrast in aortae from WKY control rats vasorelaxation to oleamide
was significantly (P<0.001) enhanced in the presence of 10µM
indomethacin, such that relaxation at 10µM oleamide was
37.3±3.6% (n=7) compared to a relaxation of 15.5±4.5% (n=6) at
this concentration in the absence of indomethacin (Figure 3.10).
Vasorelaxation to oleamide in both WKY (Rmax=13.1±6.2%,
pEC50=5.65±0.57, n=6) and SHR aortae (Rmax=43.3±4.4%,
pEC50=6.04±0.18, n=6) was unaffected by the COX-2 inhibitor
niflumic acid (10µM) (Rmax=22.9±11.3%, pEC50=5.40±0.58, n=6
WKY; Rmax=41.2±6.6%, pEC50=5.86±0.27, n=5 SHR) (Figure 3.11).
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Figure 3.10
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Figure 3.10 Vasorelaxant effects of oleamide in WKY and SHR aortae
in the presence of indomethacin (10µM). Mean data with bars
indicating S.E.M displayed.
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Figure 3.11
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Figure 3.11 Vasorelaxant responses to oleamide in the presence of
niflumic acid (10µM) in aortae from WKY and SHR rats. Mean data
with bars indicating S.E.M displayed.
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3.3.9 Effects of cyclooxygenase inhibition on the vasorelaxant
responses to anandamide in isolated aortae from SHR and WKY rats
In aortae from SHR rats the vasorelaxant responses caused by
anandamide (Rmax=36.0±2.3%, pEC50=6.76±0.19, n=6 SHR) were
significantly reduced in the presence of indomethacin such that
Rmax=19.9±2.8% (n=6) (Figure 3.12), although potency was
unaffected (pEC50=7.49±0.51, n=6). In aortae from WKY rats the
relaxant responses (Rmax=12.1±1.5%, pEC50=6.86±0.28, n=6)
were completely abolished (Figure 3.12).
Figure 3.12
-9 -8 -7 -6 -5 -4
-10
0
10
20
30
40
50
60 WKY (n=6)
WKY + indomethacin (n=6)
SHR (n=6)
SHR + indomethacin (n=6)
Log [Anandamide] (M)
Pe
rc
e
n
ta
ge
R
e
la
x
a
tio
n
(%
)
Figure 3.12 Vasorelaxant responses to anandamide in the presence
of indomethacin (10µM) in aortae from WKY and SHR rats. Mean
data with bars indicating S.E.M displayed.
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3.3.10 Effects of endothelial denudation on vascular responses to
oleamide in the presence of indomethacin in WKY aortae
The enhanced vasorelaxant responses in WKY aortae to oleamide in
the presence of 10µM indomethacin were abolished by the removal
the endothelium (Figure 3.13).
Figure 3.13
-8 -7 -6 -5 -4
-10
0
10
20
30
40
50
60 WKY (n=6)WKY + indomethacin
+ endothelial denudation (n=6)
WKY + indomethacin (n=7)
Log [Oleamide] (M)
Pe
rc
e
n
ta
ge
R
e
la
x
a
tio
n
(%
)
Figure 3.13 Vasorelaxant effects of oleamide in endothelium
denuded aortae from WKY rats in the presence of indomethacin
(10µM). Mean data with bars indicating S.E.M displayed.
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3.3.11 Effects of the FAAH inhibitor, URB597, on vasorelaxant
responses to oleamide in aortae from SHR and WKY rats
Vasorelaxation to oleamide in both WKY (Rmax=6.3±3.7%,
pEC50=5.64±0.56 n=7) and SHR (Rmax=43.2±7.1%;
pEC50=6.13±0.32, n=6) aortae was unaffected by URB597 (1µM)
(Rmax=6.3±5.3%, pEC50=5.60±0.66, n=7 WKY; Rmax=37.3±5.8%,
pEC50=5.87±0.25, n=6 SHR) (Figure 3.14).
Figure 3.14
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Figure 3.14 Vasorelaxant responses to oleamide in the presence of
URB597 (1µM) in aortae from WKY and SHR rats. Mean data with
bars indicating S.E.M displayed.
Chapter 3 Enhanced vasorelaxant effects of oleamide and anandamide in
hypertension
97
3.3.12 Effects of the FAAH inhibitor, URB597, on vasorelaxant
responses to anandamide in aortae from SHR and WKY rats
Vasorelaxation to anandamide in both WKY (Rmax=16.2±3.3%,
pEC50=6.50±0.44, n=8) and SHR (Rmax=25.3±3.3%;
pEC50=6.84±0.45, n=6) aortae was unaffected by URB597 (1µM)
(Rmax=13.6±3.0%, pEC50=6.37±0.38, n=8 WKY; Rmax=31.0±2.9%,
pEC50=7.01±0.34, n=6 SHR) (Figure 3.15).
Figure 3.15
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Figure 3.15 Vasorelaxant responses to anandamide in the presence
of URB597 (1µM) in aortae from WKY and SHR rats. Mean data with
bars indicating S.E.M displayed.
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3.3.13 Effects of capsaicin pre-treatment on the vasorelaxant
responses to oleamide in aortae from SHR and WKY rats.
Vasorelaxation to oleamide was significantly (P<0.001) reduced in
the SHR arteries after pre-treatment with capsaicin for 1h
(Rmax=9.8±1.5%, n=5, SHR), compared to the control value given
above. The potency of the oleamide as a vasorelaxant was
unaffected. Pre-treatment with capsaicin caused maximal responses
to oleamide in the SHR to become comparable to the responses in
WKY rats such that relaxation at 10µM oleamide was 9.5±2.0%
(n=5) compared to a relaxation of 7.6±2.8% (n=6) (Figure 3.16).
Figure 3.16
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Figure 3.16 Vasorelaxant responses to oleamide in aortic rings from
WKY and SHR rats after a 1h pre-treatment of vessels with capsaicin
(10µM). Control SHR and WKY data from Figure 3.2 included as a
comparison and displayed as a dashed line. Mean data with bars
indicating S.E.M displayed.
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3.3.14 Effects of capsaicin pre-treatment on vasorelaxant response
to anandamide in aortae from SHR and WKY rats
After pre-treatment with capsaicin the maximal response to
anandamide was significantly (P<0.05) reduced (Rmax=19.5±1.6%,
n=7, SHR), and its potency was also significantly (P<0.01)
increased (pEC50=8.44±0.55, n=7, SHR) (Figure 3.17). Importantly,
capsaicin pre-treatment caused the maximal responses to
anandamide in SHR to become comparable with responses in the
WKY (Rmax=22.1±3.6%, n=7) (Figure 3.17).
Figure 3.17
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Figure 3.17 Vasorelaxant responses to anandamide in aortic rings
from WKY and SHR rats after a 1h pre-treatment of vessels with
capsaicin (10µM). Control SHR data from Figure 3.3 included as a
comparison and displayed as a dashed line. Mean data with bars
indicating S.E.M displayed.
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3.3.15 Vasorelaxant effects of capsaicin in aortae from SHR and
WKY rats
The vasorelaxant responses to capsaicin were comparable in aortic
rings from both SHR and WKY rats such that at 10µM capsaicin
vasorelaxation in SHR aortae was 30.4±5.3% (n=9) compared to
38.0±9.2% (n=8) (Figure 3.18).
Figure 3.18
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Figure 3.18 Vasorelaxation caused by capsaicin in aortae from WKY
and SHR rats. Mean data with bars indicating S.E.M displayed.
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3.3.16 Effects of the TRPV1 antagonist capsazepine and ruthenium
red on vasorelaxant responses to oleamide in aortae from SHR and
WKY rats
The responses to oleamide in WKY arteries (Rmax=6.3±3.7%,
pEC50=5.64±0.56, n=7) and SHR arteries (Rmax=43.2±7.1%,
pEC50=6.13±0.33, n=6) were unaffected by capsazepine
(Rmax=20.3±7.5%, pEC50=5.34±0.47, n=7 WKY; Rmax=37.7±5.5%,
pEC50=6.27±0.35, n=6 SHR) (Figure 3.19). Vasorelaxation to
oleamide in aortic rings from both WKY (Rmax=6.3±3.7,
pEC50=5.64±0.56, n=7) and SHRs (Rmax=43.2±7.1%,
pEC50=6.13±0.33, n=6) was unaffected by 10µM ruthenium red
(Rmax=10.3±2.6%, 5.68±0.30, n=7 WKY; Rmax=42.6±6.35%,
pEC50=5.71±0.23, n=6 SHR) (Figure 3.20). In the presence of
capsazepine some vessels from WKY rats were less sensitive to
methoxamine. A range of 1µM-100µM of methoxamine was used to
pre-contract these vessels.
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Figure 3.19
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Figure 3.19 Vasorelaxant effects of oleamide in WKY and SHR aortae
in the presence of capsazepine (5µM). Mean data with bars
indicating S.E.M displayed.
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Figure 3.20
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Figure 3.20 Vasorelaxant effects of oleamide in WKY and SHR aortae
in the presence of ruthenium red (10µM). Mean data with bars
indicating S.E.M displayed.
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3.3.17 Effects of the TRPV1 antagonist capsazepine and ruthenium
red on vasorelaxant responses to anandamide in aortae from SHR
and WKY rats
The vasorelaxant effects of anandamide in aortae from WKY rats
(Rmax=16.2±3.3%, pEC50=6.50±0.44, n=8) were unaffected by 5µM
capsazepine (Rmax=19.7±7.6%, pEC50=7.56±0.34, n=7) (Figure
3.21). Similarly, vasorelaxation of SHR arteries (Rmax=25.3±3.3%,
pEC50=6.84±0.45, n=6) was unaffected by 5µM capsazepine
(Rmax=30.9±4.1%, pEC50=6.77±0.39, n=5) (Figure 3.21). The
vasorelaxant effects of anandamide were unaffected in the presence
of 10µM ruthenium red in both WKY and SHR arteries
(Rmax=10.9±1.9%, pEC50=6.13±0.29, n=7 WKY; Rmax=29.6±3.9%,
pEC50=7.15±0.52, n=5 SHR) (Figure 3.22).
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Figure 3.21
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Figure 3.21 Vasorelaxant effects of anandamide in WKY and SHR
aortae in the presence of capsazepine (5µM). Mean data with bars
indicating S.E.M.
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Figure 3.22
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Figure 3.22 Vasorelaxant effects of anandamide in WKY and SHR
aortae in the presence of ruthenium red (10µM). Mean data with
bars indicating S.E.M displayed
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3.4 Discussion
The principal finding of this chapter was that the vasorelaxant
responses to the endocannabinoid-like substance, oleamide are
substantially enhanced in the aorta isolated from the SHR model of
hypertension and that this may be related to alterations in
prostanoid metabolism. This study was designed as a comparison
between the effects of the prototypical endocannabinoid,
anandamide, with those of oleamide in hypertension. A clear finding
from this study was that the enhanced effects of both oleamide and
anandamide in SHR aortae were capsaicin-sensitive. Indeed,
previous studies have associated increased sensory nerve activity
with models of hypertension (Li et al., 2003; Li and Wang, 2003;
Wang et al., 2005). The magnitude of the vasorelaxant responses
to oleamide in aortae from the hypertensive strain are comparable
to those caused by anandamide, approximately 30-40% relaxation
of induced tone.
Anandamide is known to cause vasorelaxation via stimulating
vanilloid receptors on sensory nerves (Zygmunt et al., 1999).
Furthermore, sensory nerves via TRPV1 activation are also involved
in vasorelaxation caused by oleamide in small mesenteric arteries
from normotensive Wistar rats (Sudhahar et al., 2009). In Chapter
2, oleamide-induced vasorelaxation of aortae was found to be
sensitive to capsaicin pre-treatment. In a previous study, in the L-
NAME-induced model of hypertension, the enhanced vasorelaxant
effects of anandamide in mesenteric beds were normalised by
capsaicin pre-treatment and so were ascribed to an upregulation of
sensory-nerve mediated activity (Wheal and Randall, 2009). This
could possibly be explained by an increase in TRPV1 expression in
the mesenteric vasculature in hypertensive rats (Wang et al., 2005).
Wheal and Randall (2009) described the effects of two different
models of hypertension on the vasorelaxant effects of anandamide.
Chapter 3 Enhanced vasorelaxant effects of oleamide and anandamide in
hypertension
108
In support of the current findings anandamide-induced
vasorelaxation was enhanced in aortae from SHR rats, this
endothelium-dependent effect of anandamide was insensitive to
capsaicin pre-treatment of aortae (Wheal and Randall, 2009).
However, in mesenteric arterial beds from SHR rats, anandamide
was less potent as a vasorelaxant and was associated with impaired
NO-dependent relaxations (Wheal and Randall, 2009). This
contradicts earlier reports by Li et al. (2003) that demonstrated
enhanced depressor responses to methanandamide in SHRs was
partly due to activation of sensory nerves. The enhanced depressor
effect was associated with increased CGRP expression in the
mesenteric vasculature that presumably increased vascular
sensitivity to methanandamide in the SHR (Li et al., 2003).
In the present study the enhanced responses to both oleamide and
anandamide were sensitive to capsaicin pre-treatment and the
resulting responses were comparable to those in the normotensive
controls. This is clearly consistent with the proposal that the
enhanced responses in the SHR arteries are due to increased
sensory nerve activity. However, when additional pharmacological
approaches were used, including the TRPV1 antagonist capsazepine
and the non-selective cation channel blocker, ruthenium red, the
enhanced responses were unaffected. This suggests that although
the mechanism underlying the enhanced responses to
endocannabinoids is capsaicin-sensitive, it does not appear to
involve TRPV1 channel activation or sensory nerves. Indeed, the
vasorelaxant responses to capsaicin alone were comparable between
the hypertensive and normotensive strains. This may suggest that
there is comparable sensory nerve activity between the strains or
alternatively that capsaicin is acting via mechanisms distinct from
the sensory nerve-mediated pathway. Indeed, the previous chapter
describes studies conducted with arteries from Wistar rats that
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demonstrate that capsaicin inhibits responses to oleamide in a
sensory nerve independent manner. Chapter 6 demonstrates that
capsaicin itself causes vasorelaxation possibly via the direct or
indirect inhibition of calcium influx through L-type calcium channels.
Increased CB1 expression was the original hypothesis for the
augmented responses to oleamide in SHR aortic segments. This
was based on literature showing that the aortic endothelium from
SHRs is associated with greater CB1 expression (Batkai et al., 2004),
coupled with the ability of oleamide to act as an endogenous CB1
receptor agonist (Leggett et al., 2004). The involvement of CB1
receptors has been reported in oleamide-induced vasorelaxation of
small mesenteric arteries (Sudhahar et al., 2009). Anandamide is
also a partial agonist at CB1 receptors (Pertwee, 2005) and in
anesthetised mice anandamide induces hypotensive effects, which
are absent in CB1 receptor knock-out models (Ledent et al., 1999).
In anesthetised rats anandamide also reduces blood pressure in a
CB1 receptor dependent manner (Malinowska et al., 2001). Batkai
et al. (2004) reported enhanced depressor responses to anandamide
in hypertension, effects that were blocked by CB1 antagonism. In
addition, CB1 antagonists were found to cause pressor responses in
SHR rats (Batkai et al., 2004). However, in the present study, the
enhanced vasorelaxation to both oleamide and anandamide was
unaffected by the presence of the CB1 receptor antagonist, AM251,
and are therefore independent of CB1 receptor activation. While,
Batkai et al. (2004) described increased expression of CB1 in the
aortic endothelium, the augmented vasorelaxation of SHR aortae by
anandamide reported elsewhere was similarly insensitive to the
presence of AM251 (Wheal and Randall, 2009). Many of the
vascular effects of anandamide in previous studies occur
independently of CB1 receptors. In isolated aortae from Wistar rats,
vasorelaxant responses to anandamide and NADA were insensitive
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to CB1 receptor antagonism (OSullivan et al., 2005; Herradon et al.,
2007).
The presence of indomethacin increased the vasorelaxant effects of
oleamide in normotensive aortae, such that they were comparable
to those from SHR. This clearly highlights the importance of the
cyclooxygenase pathway in regulating the responses to oleamide.
In addition to these findings, other studies have shown that COX-
inhibition potentiates the vasorelaxant responses to
endocannabinoids (Ho and Randall, 2007). Ho and Randall (2007)
described relaxant responses to the endocannabinoids, anandamide
and 2-AG, in small mesenteric arteries from wistar rats. The
anandamide-induced responses were augmented by the presence of
the COX-2 inhibitor nimesulide and also URB597. The relaxant
responses to 2-AG were similarly increased by indomethacin and
flurbiprofen, which is more potent at COX-1, and were augmented
by an inhibitor of both FAAH and MGL (Ho and Randall, 2007). Ho
and Randall (2007) suggest a regulatory action of the FAAH, MGL
and COX pathways limits endocannabinoid-induced vasorelaxation.
With COX-1 implicated in 2-AG-induced responses and COX-1 in
anandamide induced responses. It is important to note that
anandamide can be hydrolysed by FAAH into arachidonic acid
metabolites that can be further metabolised by the COX-pathway
(Fowler et al., 2007), or alternatively can be directly metabolised by
cyclo-oxygenase enzymes into vasoactive prostanoids. Interestingly,
vasorelaxant responses to anandamide and NADA in the Wistar rat
isolated aorta were also enhanced by the inhibition of the COX
pathway (OSullivan et al., 2005). This suggests that the regulation
of endocannabinoid-induced responses by the COX pathway may be
widespread in the normotensive vasculature. The increased
responses to anandamide and 2-AG in the presence of COX-
inhibition in mesenteric arteries was dependent on an intact
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endothelium (Ho and Randall, 2007). Similarly, in the present study
the enhanced response to oleamide in WKY aortae in the presence
of indomethacin was absent in endothelium denuded vessels.
Vasorelaxation of perfused mesenteric arterial beds by N-
oleoylethanolamine, an endocannabinoid-like substance, is also
augmented by the presence of indomethacin (Wheal et al., 2010).
It is unlikely that oleamide is a direct substrate for an upregulated
COX-pathway. Therefore, metabolism of oleamide could act to limit
vasorelaxation in aortic rings from normotensive rats and so
accounting for the enhanced effects in SHR aortae. Inhibition of the
COX-pathway with indomethacin would then remove the modulation
of vasorelaxation to oleamide in the WKY and responses are
normalised between the two strains. Alternatively, it is possible that
vasoconstrictor prostanoids are being released in WKY aortae in
response to oleamide and removal of these prostanoids would
enhance vasorelaxation. A possible example of this mechanism in
action is in the vasorelaxation of rat mesenteric arterial beds by N-
oleoylethanolamine, which was sensitive to capsaicin pre-treatment
and potentiated by indomethacin. The effect of indomethacin on N-
oleoylethanolamine-induced responses was replicated by
flurbiprofen and vapiprost, a thromboxane A2 receptor antagonist
(Wheal et al., 2010). This suggests that the release of
vasoconstrictive prostanoids via COX-1 acting at thromboxane A2
limits N-oleoylethanolamine-induced responses.
The production of any vasoconstrictor prostanoids is unlikely to be
coupled to FAAH-dependent metabolism of oleamide as the
responses were unaffected by the presence of URB597.
Furthermore, oleic acid, which is the metabolite of FAAH-
degradation of oleamide, is an unlikely substrate for COX-enzymes.
The upregulation of responses to oleamide is independent of COX-2
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as the presence of niflumic acid had no effect on the vasorelaxant
response to oleamide in WKY aortic rings.
The current study shows enhanced vasorelaxant responses to
anandamide in aortae from SHR rats, which is consistent with the
responses reported in Wheal and Randall (2009). In both strains
the anandamide-induced responses were sensitive to the presence
of indomethacin, used to inhibit the cyclo-oxygenase pathway. This
is consistent with the actions of anandamide reported in the isolated
aorta from the normotensive wistar rat (Herradon et al., 2007).
Herradon et al. (2007) described a vasorelaxant effect of
anandamide that was sensitive to both FAAH and COX-inhibition. It
was suggested that the production of the COX-2 derived
prostaglandin E2 was involved in the vasorelaxant response to
anandamide. In the present study, any production of vasoactive
prostanoids is independent of FAAH-mediated degradation of
anandamide as vasorelaxation persists in the presence of URB597.
It is possible that anandamide could be metabolised directly by
COX-2 (Yu et al., 1997). It can be concluded that the cyclo-
oxygenase pathway is an important mechanism underlying
anandamide-induced responses in both strains. However, in the
presence of indomethacin, vasorelaxation to anandamide continued
to be greater in SHR aortae and so is not the result of an
upregulated cyclo-oxygenase pathway. It is also possible that
indomethacin may be able to augment responses to oleamide
independently of the COX-pathway. One hypothesis to explain the
augmented responses which occurs in the SHR that are uncovered in
the WKY arteries following COX inhibition could be that oleamide
mobilises endogenous arachidonic acid. The liberated arachidonic
acid could then enter the COX pathway. It could be that COX-
dependent metabolism of arachidonic acid to opposing
vasoconstrictor prostanoids occurs in the WKY arteries to limit
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vasorelaxation and that this modulation is absent or impaired in SHR
arteries. In this respect it has been shown previously that
vasorelaxation to N-oleoylethanolamine, which cannot be
metabolised to arachidonic acid, is also enhanced by COX inhibition
and antagonism of thromboxane receptors (Wheal et al., 2010).
This is consistent with increased vasoconstrictor prostanoid activity
opposing vasorelaxation.
In conclusion, this chapter reports greatly enhanced vasorelaxant
effects of the endocannabinoid-like substance oleamide and
anandamide in aortae from the SHR model of hypertension. The
augmented responses to both oleamide and anandamide were both
abolished by capsaicin pre-treatment but are independent of TRPV1
receptor activity. An important finding was that vasorelaxant
responses to oleamide are normalised by the presence of
indomethacin in aortae. Therefore, the COX-pathway is an
important component in regulating oleamide-induced vasorelaxation
in normotensive aortae and this is lost in hypertension. It is
possible that this is an adaptive change to modulate the rise in
blood pressure.
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Chapter 4 Effects of hypertension on endothelium-dependent
vasorelaxation of the aorta
4.1 Introduction
Certain pathological conditions including hypertension (Taddei et al.,
1996; Hedner et al., 1997; Khder et al., 1998; Park et al., 2001)
and diabetes (reviewed in De Vriese et al., 2000; Balletshofer et al.,
2000; Stehouwer et al., 2002; Park et al., 2008; Matsumoto et al.,
2010) are associated with altered endothelial function. In the past,
research has demonstrated that endothelium-dependent
vasorelaxation is blunted in aortae isolated from SHR rats compared
to normotensive controls (Luscher and Vanhoutte, 1986; Auch-
Schwelk et al., 1990; Yang et al., 2002; Gluais et al., 2005). The
endothelial dysfunction associated with hypertension is mediated by
the production of endothelium-derived contracting factors (EDCF) as
opposed to the absence or attenuation of a relaxing factor (Luscher
and Vanhoutte, 1986). Luscher and Vanhoutte (1986)
demonstrated that endothelium dependent relaxation of SHR aortae
from rats ages 30-34 weeks was normalised by the presence of
indomethacin, thus implicating the production of COX-derived
vasoconstrictive prostanoids. EDCF mediated responses in SHR
aortae correlates with an upregulated endothelial COX-1 expression
(Ge et al., 1995; Tang and Vanhoutte, 2008). Gluais et al., (2005)
demonstrated that aortae from 1-year old SHRs released increased
amounts of prostacyclin, which can act as a vasoconstrictor under
certain conditions. Endothelium-dependent contractions are also
sensitive to the presence of TP-receptor antagonists (Auch-Schwelk
et al., 1990; Kato et al., 1990; Yang et al., 2002) present on
vascular smooth muscle (Yang et al., 2003). The association
between hypertension and endothelial function has also been
demonstrated in patients with essential hypertension (Hedner et al.,
1997; Khder et al., 1998; Kimura et al., 1999) and in other models
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of hypertension, including in renal mass reduction rats (Kimura and
Nishio, 1999).
Therefore, according to the literature, endothelial dysfunction in
hypertension may be related to the increased release of COX-
derived vasoconstrictive prostanoids, including prostacyclin,
diffusing to the vascular smooth muscle to activate TP-receptors.
However, Wheal and Randall (2009) reported enhanced
endothelium-dependent vasorelaxation of SHR aortae to carbachol.
Authors used aortae from 20-week old SHRs and other
investigations also report intact or enhanced endothelial function in
rats that are younger than those used in Luscher and Vanhoutte
(1986) and represent an earlier stage of established hypertension.
In rats 12-15 weeks of age, it was shown that mesenteric
vasodilatation induced by carbachol was comparable between SHR
and WKY rats. In similarly aged SHRs (11-13 weeks) EDHF-
mediated responses in the caudal artery were intact (Sandow et al.,
2003). Another clear demonstration of intact endothelial function in
younger SHRs was reported by Radaelli et al. (1998). In SHRs aged
12 weeks pressor responses induced by the inhibition of nitric oxide
synthase were enhanced compared to WKY rats, possibly suggesting
augmented NO activity in the hypertensive strain. Interestingly, in
6 week old SHRs that were pre-hypertensive pressor responses
were similar between the two strains (Radaelli et al., 1998). In 8-
12 week SHRs an increase in the activity of vascular NOS was
reported that correlated with greater amounts of plasma NO
metabolites (Vaziri et al., 1998). In addition, endothelium-
dependent renal vasodilatation induced by acetylcholine remained
intact and responses to arachidonic acid were enhanced in SHRs
aged 13-15 weeks (Pomposiello et al. 2001). In (mREN-2)-27
transgenic rat model of hypertension intact responses to carbachol
in mesenteric arterial beds were also described (Randall and March,
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1998). However, the inhibition of NO production or EDHF
attenuated responses to a greater degree in normotensive controls
in comparison to hypertensive rats (Randall and March, 1998). This
points to the augmentation of the compensatory relationship
between NO and EDHF in the transgenic model of hypertension.
Similarly, to results presented in Chapter 3, Wheal and Randall
(2009) also described augmented responses to anandamide in SHR
aortae. In light of these differences and the similarity of
anandamide-induced responses with Wheal and Randall (2009), it is
necessary to characterise the endothelial-function in SHR aortae.
Moreover, in Chapter 3 the COX-pathway was an important factor in
limiting oleamide-induced vasorelaxation in normotensive aortae.
This presents the possibility that a difference exists between the
endothelial function of WKY and SHR aortae.
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4.2 Methods and Materials
4.2.1 Animals
Male SHR and WKY rats (Charles River UK) (250-350g; aged 12-18
weeks) were used during this investigation. All rats used were
housed at the Biomedical Services Unit, University of Nottingham
with a 12h light/dark cycle and in temperature-controlled conditions.
4.2.2 Preparation of aortic rings and experimental protocol
The rats were killed, aortae removed and set-up following the
protocols outlined in Chapter 2. Endothelium-dependent relaxation
was investigated by constructing concentration-response curves for
carbachol (1nM-10µM) in SHR (Figure 4.1) and WKY aortae.
Figure 4.1
Figure 4.1 Representative trace of the response to carbachol in the
SHR isolated aorta. A=1nM, B=3nM, C=10nM, D=30nM, E=100nM,
F=300nM, G=1µM, H=3µM and I=10µM.
The vasorelaxant effects of carbachol were also examined in the
presence of L-NAME (300µM), indomethacin (10µM), catalase (1000
units/ml) or after a 1h capsaicin (10µM) pre-treatment. Catalase
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was used in order to establish to contribution of hydrogen peroxide
to carbachol responses in SHR aortae. The contribution of gap
junctions to carbachol responses was also investigated by
constructing concentration-response curves for carbachol (1nM-
10µM) in SHR aortae in the presence of carbenoxolone (100µM)
alone and together with L-NAME (300µM). The effect of a
depolarising concentration of extracellular potassium (60mM) (Hoi
and Hiley, 2006), alone and in combination with L-NAME and a 1h
capsaicin pre-treatment, on carbachol concentration-response
curves was also examined in order to determine the importance of
K+ channels in responses in SHR aortae. These experiments were
performed in an attempt to characterise a NO-independent
vasorelaxant response to carbachol in aortae from SHR rats.
4.2.3 Drugs and reagents
Carbenoxlone (3ǃ-Hydroxy-11-oxoolean-12-en-30-oic acid 3-
hemisuccinate), carbachol ((2-Hydroxyethyl) trimethylammonium
chloride carbamate), capsaicin (8-methyl-N-vanillyl-trans-6-
nonenamide), L-NAME (NG-Nitro-L-arginine methyl ester
hydrochloride), methoxamine (Į-(1-Aminoethyl)-2, 5-
dimethoxybenzyl alcohol hydrochloride), indomethacin (1-(4-
Chlorobenzoyl)-5-methoxy-2-methyl-3-indoleacetic acid) and
catalase were purchased from Sigma Chemical Co. (UK). Capsaicin
and indomethacin were dissolved in ethanol at stock concentrations
of 10mM. All other drugs were dissolved using distilled water.
Catalase and carbenoxolone were present in organ baths 1h prior to
the addition of methoxamine. L-NAME and indomethacin were
added approximately 20 minutes before methoxamine.
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4.2.4 Statistical analysis
All responses are expressed as mean percentage vasorelaxation with
the associated standard error of the mean (S.E.M). The GraphPad
Prism 5.0 software (San Diego, CA) was used to plot mean data as
sigmoidal concentration-response curves using a sigmoidal equation
[Y=Bottom+ (Top-Bottom)/(1+10((LogEC50-X)*Hillslope)), when
X=logarithm of agonist concentration and Y=response from Bottom
to Top in a sigmoidal shape]. The curves were used to determine
potency (pEC50) and maximal response (Rmax) values. Potency
(pEC50) is the negative log of agonist concentration that reduced
methoxamine-induced contraction by 50%. The maximal response
relates to the maximum percentage vasorelaxation of methoxamine-
induced pre-contraction. Statistical significance was determined
using two-tailed unpaired Students t-test between two data sets or
one-way ANOVA when comparing multiple data-sets. One-way
ANOVA was followed by a Bonferroni post hoc carried out as
appropriate. Statistical significance was determined using one-way
ANOVA unless stated otherwise in the figure legend. P-values <0.05
were considered significant.
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4.3 Results
4.3.1 Endothelium-dependent vasorelaxant responses to carbachol
in aortae from SHR and WKY rats
Carbachol caused concentration-dependent vasorelaxation in aortic
rings from both SHR and WKY rats. The maximal response
produced in SHR arteries (Rmax= 66.6±4.2%, n=10) was
significantly greater (P<0.001) compared to that in the WKY arteries
(Rmax=37.1±2.7%, n=10) (Figure 4.2). The potency of carbachol
was similar in the SHR and WKY arteries (pEC50=6.24±0.13, n=10
WKY rats; pEC50=6.54±0.14, n=10 SHR) (Figure 4.2)
Figure 4.2
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Figure 4.2 Vasorelaxant responses to carbachol in aortae from WKY
and SHR rats. Mean data with bars indicating S.E.M displayed.
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4.3.2 Effects of L-NAME on the vascular responses to endothelium-
dependent vasorelaxant carbachol in aortae from SHR and WKY rats
The vasorelaxant effects of carbachol were abolished in the presence
of 300µM L-NAME in aortae from WKY rats. The maximal response
to carbachol in SHR aortae was significantly (P<0.001) reduced in
the presence of 300µM L-NAME (Rmax=31.0±3.5%, n=6) (Figure
4.3).
Figure 4.3
Figure 4.3 Vasorelaxant responses to carbachol in the presence of L-
NAME (300µM) in aortae from WKY and SHR rats. Mean data with
bars indicating S.E.M displayed. Dashed lines represents SHR and
WKY control data taken from Figure 4.2.
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4.3.3 Effects of indomethacin on the vascular responses to carbachol
in aortae from SHR and WKY rats
The maximal relaxant response to carbachol (Rmax=87.1±3.3%, n=7
SHR; Rmax=67.3±4.2%, n=4 WKY) was significantly increased in the
presence of 10µM indomethacin in both SHR preparations
(Rmax=123±4.4%, n=7 SHR) (P<0.001) and WKY preparations
(Rmax=93.1±2.8%, n=5 WKY) (P<0.05) (Figure 4.4). However, the
potency of carbachol (pEC50=6.70±0.14, n=4 WKY;
pEC50=6.96±0.10, n=7 SHR) remained unaffected by the presence
of indomethacin in aortae from either WKY (pEC50=6.52±0.06, n=5)
and SHR rats (pEC50=6.79±0.09, n=7) (Figure 4.4).
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Figure 4.4
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Figure 4.4 Vasorelaxant responses to carbachol in the presence of
indomethacin (10µM) in aortae from WKY and SHR rats. Mean data
with bars indicating S.E.M displayed.
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4.3.4 Effects of capsaicin pre-treatment on the vascular responses
to endothelium-dependent vasorelaxant carbachol in aortae from
SHR and WKY rats
The vasorelaxant responses to carbachol were unaffected by a 1h
capsaicin (10µM) pre-treatment (with 20min washout) in both SHR
(Rmax=66.0±5.8%, pEC50=6.48±0.22, n=5) and WKY preparations
(Rmax=41.2±10.2%, pEC50=5.84±0.40, n=6) (Figure 4.5).
Figure 4.5
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Figure 4.5 Vasorelaxant responses to carbachol after a 1h pre-
treatment with capsaicin (10µM) of aortae from WKY and SHR rats.
Dashed lines display SHR and WKY control data from Figure 4.2.
Mean data with bars indicating S.E.M displayed.
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4.3.5 Effects of catalase, in the presence of L-NAME, on the
vasorelaxant responses to carbachol in aortae isolated from SHR
and WKY rats
The vasorelaxant responses to carbachol in aortae isolated from
WKY rats (Rmax=72.0±3.05%, pEC50=6.44±0.09, n=4) were
abolished by the combined presence of catalase and L-NAME. The
maximal vasorelaxant response to carbachol in aortae from SHR rats
(Rmax=89.0±3.5%, pEC50=6.81±0.09, n=4) was significantly
(P<0.001) reduced in the presence of L-NAME and catalase
(Rmax=32.5±5.2%, pEC50=7.33±0.52, n=4), however the response
were no different from those in the presence of L-NAME alone and
the residual relaxation remained. The potency of carbachol was
unaffected by the presence of catalase and L-NAME (Figure 4.6).
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Figure 4.6
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Figure 4.6 Vasorelaxant responses to carbachol in the presence of
catalase (1000 units/ml) and L-NAME in aortae from WKY and SHR
rats. Mean data with bars indicating S.E.M displayed.
4.3.6 Effects of L-NAME, capsaicin pre-treatment and high
extracellular potassium on the vasorelaxant responses to carbachol
in SHR aortae
The maximal vasorelaxant response to carbachol in the presence of
high extracellular K+ in aortae from SHR rats (Rmax=100.6±5.5%,
pEC50=6.76±0.14, n=3) was significantly (P<0.001) decreased by L-
NAME (Rmax=43.9±4.8%, pEC50=6.86±0.28, n=3), but the presence
of L-NAME in addition to pre-treatment of vessels with capsaicin had
no further effect on the vasorelaxant response to carbachol
(Rmax=26.4±3.6%, pEC50=6.86±0.37, n=3) (Figure 4.7).
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Figure 4.7
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Figure 4.7 Vasorelaxant responses to carbachol in the presence of
high extracellular K+ (60mM) and L-NAME (300µM) in aortae from
SHR rats. Contraction was iniatiated with High K+ (60mM). Mean
data with bars indicating S.E.M displayed.
4.3.7 Effects of the gap junction inhibitor, carbenoxolone, on the
vasorelaxant responses to carbachol in SHR aortae
The vasorelaxant responses to carbachol in SHR aortae
(Rmax=78.4±6.9%, pEC50=6.73±0.19, n=4) were unaffected by the
gap junction inhibitor carbenoxolone (Rmax=90.3±6.7,
pEC50=6.76±0.17, n=4). Similarly, the residual vasorelaxant
responses produced by carbachol in the presence of L-NAME
(Rmax=18.2%±3.2, pEC50=7.11±0.42, n=4) were unaffected by
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carbenoxolone (Rmax=26.2±4.4, pEC50=7.41±0.56, n=4) (Figure
4.8).
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Figure 4.8 Vasorelaxant responses to carbachol in the presence of
carbenoxolone (100µM) and L-NAME (300µM) from SHR rats. Mean
data with bars indicating S.E.M displayed.
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4.4 Discussion
This chapter demonstrates augmented endothelium-dependent
responses in SHR aortae to carbachol. Responses to carbachol were
sensitive to L-NAME in both strains. The enhanced endothelial
responses in SHR aortae contradicts early work that formed the
dogma that the SHR is associated with impaired endothelial function
(Luscher and Vanhoutte, 1986; Auch-Schwelk et al., 1990; Ito et al.,
1991; Ge et al., 1995; Yang et al., 2002; Gluais et al., 2005).
Luscher and Vanhoutte (1986) described an augmented
acetylcholine response in aortae from normotensive rats compared
to those from SHRs. Indomethacin enhanced vasorelaxation in
SHRs normalising the response in comparison to the control strain,
through the inhibition of a prostanoid endothelium-derived
contracting factor (EDCF). Therefore, the impaired endothelial
function in hypertension was thought to be due to the release of an
EDCF, which acts to blunt endothelium-dependent relaxations
(Luscher and Vanhoutte, 1986). Prostacyclin (Rapoport et al., 1996;
Gluais et al., 2005; 2007) and endoperoxides (Ito et al., 1991; Ge
et al., 1995) have been implicated as EDCFs. It is noteworthy that
COX-enzymes metabolise arachidonic acid into endoperoxides,
which are subsequently synthesised into a range of prostanoids.
EDCF-mediated responses are evoked by COX activation, possibly
mediated via oxygen-free radicals (Yang et al., 2002) and diffuse
from the endothelium (Yang et al., 2003) to activate smooth muscle
TP receptors (Auch-Schwelk et al., 1990; Yang et al., 2004) causing
contractile responses. However, in contrast to these reports the
present study demonstrates enhanced endothelial function in SHR
aortae. This finding is not without precedent as Wheal and Randall
(2009) reported similarly enhanced carbachol-induced responses in
SHR aortae, while other reports describe intact endothelium-
dependent responses (Pomposiello et al., 2001; Sandow et al., 2003;
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Ford and Rush, 2010). However, the discrepancies outlined
regarding endothelial dysfunction in hypertension are likely to reflect
age-related differences, Luscher and Vanhoutte (1986) used arteries
from rats at 30-34 weeks of age, while the present study used SHR
and WKY rats at 12-18 weeks and previous papers used SHRs at 12-
15 (Randall et al., 1991) and 20 weeks (Wheal and Randall, 2009).
Indeed, EDCF-mediated responses in SHR are positively correlated
with age (Koga et al., 1988; 1989) and there are also age-
dependent differences reported in the expression of aortic COX-
enzymes, prostanoid receptors and prostanoid synthases in SHR
rats (Tang and Vanhoutte, 2008) and this may cause the age-
related differences in endothelial function of SHR aortae. Radaelli et
al. (1998) demonstrated that NO activity in SHRs was intact at 12
weeks of age and may be enhanced as shown by augmented pressor
responses to NO synthase inhibition in vivo. The present study
describes enhanced endothelium-dependent responses during the
early stages of established hypertension, while previous research
reports an age-dependent endothelial dysfunction seen in the latter
stages of hypertension due to upregulated production of EDCFs.
The endothelium-dependent responses in the present study were
enhanced in aortae from both strains by the presence of
indomethacin. This may suggest that, in response to carbachol,
there is no difference in the production of EDCFs, and so are
enhanced by a similar magnitude by indomethacin. Alternatively,
indomethacin may be enhancing the carbachol responses by
different mechanisms. In WKY rats of the same age as used in the
present study, indomethacin was shown to increase acetylcholine-
induced responses by augmenting free-radical oxygen production,
namely ONOO- (De Angelis et al., 2004). The authors concluded
that this effect of indomethacin occurred independently of the COX
pathway as other COX inhibitors used failed to potentiate
vasorelaxant responses.
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There is evidence of enhanced endothelial function in models of
hypertension, including an upregulation in the NO system (Radaelli
et al., 1998; Chang et al., 2002). Radaelli et al. (1998) reported
that pressor responses to the inhibition of NO synthesis with NG-
monomethyl-L-arginine (L-NMMA) in SHR rats of 12 weeks of age in
comparison to normotensive controls. Wheal and Randall (2009)
demonstrated that enhanced vasorelaxation to anandamide in
aortae from SHR rats was abolished by removal of the endothelium.
In the present study, endothelium-dependent responses in the WKY
aorta were abolished by L-NAME and therefore mediated by NO.
However, in the SHR aorta there was a significant L-NAME
insensitive component with a residual relaxation of approximately
30%. This residual component could be responsible for the
augmented endothelial responses in SHR aortae. In an attempt to
elucidate the mechanisms underlying this component the
contributions of putative EDHF-type mechanisms such as gap
junctions and hydrogen peroxide were assessed as was sensory
nerve activity.
The residual relaxation to carbachol was not dependent on NO or
COX-mediated mechanisms and the hypothesis was that the residual
relaxation could be due to an EDHF component in SHR aortae.
EDHF-activity is usually associated with small resistance vessels
(Shimokawa et al., 1996; Tomioka et al., 1999) and was absent in
the WKY aorta. Hydrogen peroxide, K+ ions and electrical
communication between cells through myo-endothelial gap-junctions
have all been implicated in EDHF-mediated responses. The
involvement of K+ ion release (Edwards et al., 1996; Coleman et al.,
2001; Nelli et al., 2003; Torondel et al., 2004; McNeish et al., 2005)
and activation of hyperpolarising K+ channels (Corriu et al., 1996;
Zygmunt et al., 1997; Walker et al., 2001) is well documented in
EDHF-mediated responses. In this study the presence of High K+
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and L-NAME had no effect on the residual relaxation of SHR aortae
by carbachol. This appears to rule out EDHF-mediated responses as
high extracellular K+ would prevent activation of K+ channels and
therefore hyperpolarisation of smooth muscle cells.
Hydrogen peroxide has been implicated as an EDHF mediator (Beny
and von der Weid, 1991) due to reports that catalase, which inhibits
hydrogen peroxide production, abolishes EDHF-induced relaxations
in human mesenteric arteries (Matoba et al., 2002), mice
mesenteric arteries (Matoba et al., 2000) and in porcine and human
coronary microvessels (Matoba et al., 2003; Miura et al., 2003).
Hydrogen peroxide can be synthesised by endothelial cells (Matoba
et al., 2000) and can have a direct hyperpolarising effect on
vascular smooth muscle (Beny and Weid, 1991) and can cause
hyperpolarisation by activating a range of K+ channels (Wei et al.,
1996; Sobey et al., 1997; Barlow et al., 1998; Hayabuchi et al.,
1998) and by inducing the release of vasodilator prostacyclin via
COX-1 enzymes (Thengchaisri et al., 2003). Interestingly, Chaytor
et al. (2003) demonstrated that hydrogen peroxide causes
relaxation in the rabbit femoral artery and it was concluded that
hydrogen peroxide can be characterised as a relaxing factor distinct
from hyperpolarising mechanisms. In small mesenteric arteries
hydrogen peroxide mediates vasorelaxation elicited by anandamide
and N-oleoylethanolamine and the enhanced EDHF-type responses
in smaller mesenteric arteries (Wheal and Randall, 2012). However,
in the present study catalase had no effect on the residual relaxation
produced by carbachol in the presence of L-NAME. Thus, hydrogen
peroxide is not acting as an EDHF or a modulator of EDHF in the
aorta of the SHR.
Gap-junctions connecting endothelial cells and smooth muscle cells
are thought to play a role in propagating endothelium-dependent
vascular responses. Gap junctions are comprised of connexin
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proteins (Hill et al., 2002; Segretain et al., 2004) and can allow the
movement of ions and messengers between cells to elicit vascular
actions. Specific connexin knock-out animal models, including
connexin40, are characterised by decreased endothelium-dependent
vasodilatation (de Wit et al., 2003). However, the residual
relaxation to carbachol in SHR aortae was insensitive to a gap-
junction inhibitor, carbenoxolone. Therefore, the residual carbachol
response that could be contributing to the enhanced endothelial
function of SHR aortae does not involve gap-junctions.
Interestingly, in SHRs subjected to chronic activation of TRPV1 with
dietary capsaicin caused an increase in TRPV1-mediated NO
production and resulted in improved endothelium-dependent
vasorelaxation of mesenteric arteries (Yang et al., 2010). Capsaicin
pre-treatment did not affect the responses to carbachol in either
WKY or SHR aortae, ruling out sensory-nerve mediated activity in
endothelium-dependent relaxations. It also demonstrates that
capsaicin pre-treatment does not act as a general inhibitor of
vasorelaxant responses in the preparations used. It is a possibility
that this residual response to carbachol is due to the liberation of
stored NO in SHR aortae, while it has also been shown that certain
vessels can synthesise NO via an L-arginine independent pathway
(Kemp and Cocks, 1997). Any differences in endothelial function did
not account for the enhanced effects of endocannabinoids observed
in aortic rings from hypertensive rats reported in Chapter 3.
Responses to oleamide and anandamide were robust in endothelial
denuded vessels and insensitive to the presence of L-NAME.
In summary, this chapter describes increased endothelium-
dependent relaxations of SHR aortae compared to those from
normotensive animals. Initially, the enhanced endothelial responses
appeared contradictory to much of the literature, however as
discussed above this contradiction is probably due to age-related
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differences in endothelial function. Endothelium-dependent
relaxations in both SHR and WKY aortae were sensitive to the
presence of L-NAME, although a residual relaxant component
independent of NO existed in SHR vessels. This residual relaxation
was also independent of sensory nerve mediated activity, EDHF,
COX-enzymes, gap junctional communication and hydrogen
peroxide. Therefore, enhanced endothelial function may represent
an adaptive change in response to the early stages of established
hypertension in SHRs, which is followed by the accelerated loss of
endothelial function with aging.
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Chapter 5 Effects of oleamide and anandamide in small
mesenteric arteries from spontaneously hypertensive rats
5.1 Introduction
In chapter 3 it was demonstrated that both the endocannabinoid-
like substance oleamide and anandamide caused augmented
vasorelaxant effects in aortae isolated from the SHR model of
hypertension. The vasorelaxant effects of endocannabinoids have
previously been reported to be mediated by a variety of mechanisms
and exhibit tissue and species specificity (Randall et al., 2004).
Cannabinoid CB1 receptors, sensory nerve activation, nitric oxide,
the COX-pathway and EDHF have all been implicated in the vascular
responses to anandamide. These mechanisms of action are tissue
specific, for example, sensory nerve-mediated activity has been
heavily implicated in rat mesenteric arterial resistance vessel
responses to anandamide (Zygmunt et al., 1999; Ralevic et al.,
2000; Harris et al., 2002; OSullivan et al., 2004), while sensory-
nerve independent mechanisms mediate rat aortic responses and
those in the coronary vasculature of different species (White et al.,
2001; Ford et al., 2002; OSullivan et al., 2004). OSullivan et al.
(2004) described anandamide-induced vasorelaxation of mesenteric
arteries that occur through different mechanisms in conduit
compared to resistance vessels.
Considering the tissue-specific nature outlined above it is likely that
the effects of hypertension on vasorelaxant responses to
endocannabinoids may differ between arteries. Indeed, Wheal and
Randall (2009) demonstrated enhanced vasorelaxant effects to
anandamide in aortae from SHR rats, while anandamide was less
potent in the perfused mesenteric arterial bed. In light of this it is
important to investigate the effects of oleamide in the SHR in an
alternative arterial preparation. In Chapter 3 it was also reported
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that there was an upregulation of endothelium-dependent
vasorelaxation in aortae from hypertensive rats, which is contrary to
the dogma that hypertension is associated with endothelial
dysfunction. There are also a number of reports demonstrating
decreased endothelium-dependent relaxations in mesenteric arteries
from SHRs (Jameson et al., 1993). Therefore, it was of interest to
characterise these responses in another arterial preparation.
The principal aim of this study was to assess the vasorelaxant
responses to oleamide and anandamide in first order mesenteric
arteries from a rat model of hypertension. Endothelial function of
mesenteric arteries from SHR and WKY rats was also assessed by
determining endothelium-dependent relaxations to carbachol and
sensory nerve activity by responses to applied capsaicin.
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5.2 Methods and Materials
5.2.1 Animals
Male SHR and WKY rats (Charles River UK) (250-350g; aged 12-18
weeks) were used during this investigation. All rats used were
housed at the Biomedical Services Unit, University of Nottingham
with a 12h light/dark cycle and in temperature-controlled conditions.
5.2.2 Preparation of mesenteric arteries
After the rats were killed (as described in Chapter 3) the mesenteric
arterial bed was removed. First generation mesenteric arteries were
dissected under a light microscope and 4 segments were mounted in
a wire myograph (Danish Myo Technology) in modified Krebs-
Henseleit buffer solution (NaCl 118, KCl 4.7, MgSO4 1.2, KH4PO 4.2,
NaHCO3 25, D-glucose 10, CaCl2 2 (mM)) at 37°C and gassed
continuously (5% CO²/95% O²) (OSullivan et al., 2004) (Figure 5.1).
Vessels were equilibrated to 9.8mN of tension and subsequently
contracted with KCl (60mM) to check viability of vessels. Washout
was performed to return vessels to basal tone and re-equilibrated if
necessary. Vessels were pre-contracted with methoxamine.
Concentration-response curves were constructed for oleamide
(10nM-100µM), anandamide (1nM-10µM) (Figure 5.2), capsaicin
(10nM-10µM) and carbachol (10nM-10µM). Responses to
anandamide were also carried out in the presence of L-NAME
(300µM).
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Figure 5.1
Figure 5.1 Myograph set-up. A=transducer, B=Krebs filled organ
bath, C=micrometer screw, D=hook attached to micrometer screw,
E=hook attached to transducer and F=tissue segment.
Figure 5.2
Figure 5.2 Representative trace of the response to anandamide in a
mesenteric artery segment from a SHR rat. A=1nM, B=3nM,
C=10nM, D=30nM, E=100nM, F=300nM, G=1µM, H=3µM and
I=10µM.
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5.2.3 Drugs and reagents
Oleamide and anandamide were obtained from Tocris Co. (UK). All
other drugs used in this investigation were purchased from Sigma
Chemicals Co. (UK). Anandamide and capsaicin were dissolved in
ethanol at stock concentrations of 10 mM. DMSO was used to
dissolve oleamide. All other drugs were dissolved in distilled water.
L-NAME was incubated for approximately 20 minutes before pre-
contraction of vessels with methoxamine.
5.2.4 Statistical analysis
All responses are expressed as mean percentage vasorelaxation with
the associated standard error of the mean (S.E.M). The GraphPad
Prism 5.0 software (San Diego, CA) was used to plot mean data as
sigmoidal concentration-response curves using a sigmoidal equation
[Y=Bottom+ (Top-Bottom)/(1+10((LogEC50-X)*Hillslope)), when
X=logarithm of agonist concentration and Y=response from Bottom
to Top in a sigmoidal shape]. The curves were used to determine
potency (pEC50) and maximal response (Rmax) values. Potency
(pEC50) is the negative log of agonist concentration that reduced
methoxamine-induced contraction by 50%. The maximal response
relates to the maximum percentage vasorelaxation of methoxamine-
induced pre-contraction. Statistical significance was determined
using two-tailed unpaired Students t-test between two data sets or
one-way ANOVA when comparing multiple data-sets. One-way
ANOVA was followed by a Bonferroni post hoc carried out as
appropriate. Statistical significance was determined using one-way
ANOVA unless stated otherwise in the figure legend. P-values <0.05
were considered significant.
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5.3 Results
5.3.1 Vasorelaxant responses to oleamide in mesenteric arteries
isolated from SHR and WKY rats
Oleamide caused concentration-dependent vasorelaxation of
mesenteric arteries from both SHR (Rmax=33.9±4.6%,
pEC50=4.73±0.23, n=6) and WKY rats (Rmax=30.5±3.8%,
pEC50=4.85±0.24, n=6) (Figure 5.3) and these did not differ
between strains.
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Figure 5.3 Vasorelaxant responses to oleamide in mesenteric
arteries isolated from WKY and SHR rats. Mean data with bars
indicating S.E.M displayed. Experiments were analysed using
Students t-test.
Chapter 5 Effects of oleamide and anandamide in small mesenteric arteries
from spontaneously hypertensive rats
143
5.3.2 Vasorelaxant responses to anandamide in mesenteric arteries
isolated from SHR and WKY rats
Maximal vasorelaxant responses to anandamide were significantly
(P<0.001) enhanced in mesenteric arteries from SHR
(Rmax=28.1±3.3%, n=8 SHR) compared to WKY rats
(Rmax=12.9±3.1%, n=8) (Figure 5.4). However, the potency of
anandamide was similar in SHR and WKY preparations
(pEC50=6.81±0.62, n=8 WKY; pEC50=8.06±0.54, n=8 SHR).
Figure 5.4
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Figure 5.4 Vasorelaxant responses to anandamide in mesenteric
arteries isolated from WKY and SHR rats. Mean data with bars
indicating S.E.M displayed.
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5.3.3 Effects of L-NAME on the vasorelaxant responses to
anandamide in mesenteric arteries isolated from SHR and WKY rats
L-NAME did not affect the vasorelaxant response to anandamide in
mesenteric arteries from SHR rats (Rmax=19.8±1.9%,
pEC50=8.11±0.44, n=8 SHR). However, anandamide did not cause
vasorelaxation in the presence of L-NAME in WKY preparations
(Figure 5.5).
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Figure 5.5 Vasorelaxant responses to anandamide in the presence of
L-NAME (300µM) in mesenteric arteries isolated from WKY and SHR
rats. Mean data with bars indicating S.E.M displayed.
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5.3.4 Vasorelaxant responses to carbachol in mesenteric arteries
isolated from SHR and WKY rats
Carbachol caused vasorelaxation of mesenteric arteries from both
SHR (Rmax=83.4±2.7%, n=9) and WKY rats (Rmax=81.7±4.2%,
n=9), such that maximal responses were similar. However,
carbachol was significantly (P<0.001) more potent in SHR arteries
(pEC50=7.44±0.10, n=9) compared to normotensive controls
(pEC50=6.77±0.13, n=9) (Figure 5.6).
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Figure 5.6 Vasorelaxant responses to carbachol in mesenteric
arteries isolated from WKY and SHR rats. Mean data with bars
indicating S.E.M displayed. Experiments were analysed using
Students t-test.
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5.3.5 Vasorelaxant response to capsaicin in mesenteric arteries
isolated from SHR and WKY rats
Capsaicin caused comparable maximal vasorelaxant responses in
SHR (Rmax=40.0±3.4%, n=9) and WKY arterial preparations
(Rmax=38.8±5.1%, n=9). However, capsaicin was significantly
(P<0.001) more potent in mesenteric arteries from SHRs
(pEC50=7.77±0.33, n=9) compared to normotensive controls
(pEC50=5.95±0.25, n=9) (Figure 5.7).
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Figure 5.7 Vasorelaxant responses to capsaicin in mesenteric
arteries isolated from WKY and SHR rats. Mean data with bars
indicating S.E.M displayed. Experiments were analysed using
Students t-test.
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5.4 Discussion
The principal finding of Chapter 3 was that the vasorelaxant
responses to the endocannabinoid-like substance, oleamide are
substantially enhanced in the aorta isolated from the SHR model of
hypertension and that this may be related to alterations in
prostanoid metabolism. Having described the enhanced responses
in aortic rings from SHR rats, the vascular effects of oleamide and
anandamide in a different arterial preparation was investigated. The
primary finding of this chapter was that, in contrast to the
enhancement of responses in aortae from SHR rats, oleamide
caused comparable vasorelaxation of mesenteric arteries from both
strains. This is consistent with the literature showing oleamide to be
a vasodilator of rat mesenteric vasculature (Hoi and Hiley, 2006;
Sudhahar et al., 2009). The results also support the tissue specific
nature of oleamide-induced vasorelaxation in arteries isolated from
the SHR.
Endocannabinoid-induced responses in hypertension have previously
been demonstrated to be dependent on the arterial preparation used.
Wheal and Randall (2009) reported differential effects of
hypertension on vasorelaxation caused by anandamide in different
isolated arteries. Wheal and Randall (2009) investigated
anandamide-induced vasorelaxation of aortic rings and perfused
mesenteric arterial beds from two different models of hypertension;
the SHR model and in rats made hypertensive by chronic inhibition
of NO synthase with L-NAME. In the L-NAME model of hypertension
anandamide produced augmented responses in mesenteric arterial
preparations, while in aortic rings vasorelaxation was comparable to
normotensive controls (Tep-Areenan et al., 2002; Wheal and
Randall, 2009). Furthermore, anandamide caused increased
maximal relaxations in aortic rings from SHR rats, but in mesenteric
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arterial beds anandamide was actually less potent in beds from SHR
rats (Wheal and Randall, 2009). The literature demonstrates how
the vasorelaxant effects of endocannabinoids in hypertension are
dependent on the arterial bed used, possibly as a result of
differential effects of established hypertension on arteries, or due to
contrasting vasodilator mechanisms mediating responses in different
preparations. For example, in aortae from the Wistar rat
anandamide induced vasorelaxation via a Pertussis toxin-sensitive
mechanism and independently of sensory-nerve mediated activity,
while in perfused mesenteric arterial bed vasorelaxant responses to
anandamide involved sensory nerves (Harris et al., 2002; OSullivan
et al., 2005). Furthermore, in the larger mesenteric arteries the
responses to anandamide appear also most exclusively via sensory
nerves (OSullivan et al., 2004). Similar tissue specificity exists in
oleamide-induced vascular responses. Sudhahar et al., (2009)
described vasorelaxation to oleamide in small mesenteric resistance
arteries from Wistar rats that involved TRPV1 and CB1 receptors. In
contrast, Chapter 2 has shown TRPV1 and CB1 to be unimportant in
oleamide responses in Wistar aortae. This tissue specificity could
explain why the actions of oleamide are affected differently by
hypertension in aortae compared to mesenteric arteries.
In the present study, it was demonstrated that anandamide elicited
enhanced vasorelaxation of first order mesenteric arteries from SHR
rats compared to those from normotensive WKY rats. In Chapter 3,
it was discussed how anandamide similarly caused enhanced
responses in aortic rings from hypertensive rats. Indeed, the
magnitude of the vasorelaxant response to anandamide in aortae
from SHR rats was comparable between aortic rings and mesenteric
arteries, with approximately 30-40% relaxation of induced tone.
This is in contrast to Wheal and Randall (2009) who showed that
anandamide was less potent in smaller mesenteric arteries from
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SHR rats. However, the findings of the present chapter are
supported by reports in conscious SHRs, where methanandamide
produced enhanced depressor responses (Li et al., 2003). The
discrepancy described between the current study and Li et al.,
(2003) with Wheal and Randall (2009) is possibly a question of age.
Li et al., (2003) used rats aged 8-10 weeks, of age. The present
study used rats of approximately 12-18 weeks and it is possibly that
the discrepancies surrounding anandamide-induced vasorelaxation
in SHR is due to the effects of a longer period of established
hypertension on the mesenteric vasculature.
The decreased potency of anandamide in mesenteric arteries from
SHR rats reported elsewhere was associated with impaired NO-
dependent vasorelaxation (Wheal and Randall, 2009). However, the
current chapter describes increased potency of carbachol,
suggesting that endothelium-dependent vasorelaxation is actually
upregulated in mesenteric arteries. Previously, Randall et al. (1991)
reported intact endothelium-dependent vasodilatation of mesenteric
arterial beds in rats aged 12-15 weeks. Previous studies have
proposed a link between hypertension and upregulated NO-
dependent mechanisms in the mesenteric vasculature from SHR rats
(Marin et al., 2000; Chang et al., 2002). Chang et al. (2002)
investigated changes in the perfusion pressure of mesenteric arterial
beds of SHR and WKY rats using an in situ mesenteric system. It
was reported that endothelium-dependent vasodilatation induced by
acetylcholine was enhanced in SHR rats compared to normotensive
controls (Chang et al., 2002). In young SHR and WKY rats (4 weeks
old) endothelium-dependent relaxations of mesenteric resistance
arteries were comparable, however vasorelaxation to acetylcholine
is impaired in older SHR rats (16 and 28 weeks) (Jameson et al.,
1993). This chapter reports that carbachol is more potent in
mesenteric arteries from SHR rats, which is consistent with
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enhanced endothelium-dependent responses in hypertension
(Chapter 4). As discussed in Chapter 3 this is contradictory to the
established dogma that the SHR model of hypertension is associated
with endothelial dysfunction, however it is argued that endothelial
dysfunction in SHR rats is positively correlated with age and thus
the duration of established hypertension. Furthermore,
experimental and physiological conditions may affect whether
endothelium-dependent relaxation of hypertensive arteries is
impaired or not (Li and Bukoski, 1993). Li and Bukoski (1993)
demonstrated impaired relaxations to acetylcholine of mesenteric
resistance arteries from SHR rats aged 12-15 weeks. However,
endothelial dysfunction was only apparent in arteries pre-contracted
with noradrenaline. The authors concluded that endothelial
dysfunction occurred in SHR rats due to increased endothelium-
derived contracting factor (EDCF) elicited during pre-contraction by
noradrenaline. Endothelium-dependent relaxations were equal in
arteries from both hypertensive and normotensive strains after pre-
contraction with vasopressin and in the presence of indomethacin in
noradrenaline contracted vessels (Li and Bukoski, 1993). However,
it is also possible that vasopressin was causing the release of
endothelium-derived relaxing factors resulting in normalised
endothelium-dependent relaxation between strains and so masking
differences in endothelial function (Katusic et al., 1984; Randall et
al., 1988; Suzuki et al., 1989). Indeed, in the rat isolated superior
mesenteric arterial bed responses to vasopressin were modulated by
an endothelium-derived relaxing factor (Randall et al., 1988). In
human mesenteric arteries, vasopressin caused the release of
endothelium-derived vasodilator prostaglandins (Martinez et al.,
1994). Therefore, while agonist choice for pre-contraction may
affect endothelial-dysfunction, it is possible that vasopressin,
through the release of endothelial factors, masks any underlying
differences in endothelial function. Moreover, differences in
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endothelial function have also been described in vessels pre-
contracted with serotonin and prostaglandin (Luscher and Vanhoutte,
1986; Tesfamariam and Halpern, 1988). In addition, Vindis et al.,
(2009) reported endothelial dysfunction in third order mesenteric
arteries from SHR rats in experiments where concentrations of
noradrenaline were used that elicited the same level of contraction
in vessels form both hypertensive and normotensive strains.
In the present chapter, it was demonstrated that capsaicin is a more
potent vasorelaxant in mesenteric arteries from SHR rats. In
Chapter 3 it was described how in aortic segments capsaicin-induced
responses were equal between the strains. This suggests that in
mesenteric vasculature there may be alterations in sensory-nerve
mediated activity in hypertension but not in the aortic. In addition
an alternative mechanism of action of capsaicin-induced
vasorelaxation has been identified in Chapter 5. Li et al. (2003)
reported enhanced hypotensive effects of methanandamide and
capsaicin in SHR rats, which were sensitive to the presence of
capsazepine. The authors proposed that sensory-nerve activity was
upregulated in hypertension. Wheal and Randall (2009) reported
that in mesenteric arterial beds from the L-NAME-induced model of
hypertension capsaicin caused enhanced vasorelaxation in a manner
sensitive to capsaicin pre-treatment. The increased sensory-nerve
mediated activity associated with mesenteric beds from
hypertension was responsible for augmented vasorelaxation to
anandamide (Wheal and Randall, 2009). Furthermore, the authors
described comparable vasorelaxation to anandamide in aortae from
L-NAME-induced hypertensive and normotensive rats, which
correlated with comparable sensory nerve mediated activity in
aortae from hypertensive and normotensive rats. It was also
demonstrated that the mesenteric vasculature of the SHR was
associated with increased expression of the CGRP receptor (Li et al.,
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2003). It is possible that mesenteric arteries from SHR rats are
more sensitive to capsaicin, due to the release of the neuropeptide
CGRP and its effects at the upregulated CGRP receptor.
Enhanced blood pressure decreases to both anandamide and
capsaicin in rats made hypertensive by a high-salt diet are blocked
by capsazepine (Wang et al., 2005). In addition, Wang and Wang
(2007) reported that methanandamide caused greater release of
CGRP in high-salt hypertensive rats compared to normotensive
controls and that mesenteric expression of CGRP receptor was
upregulated. Interestingly, hypertension elicited by high salt
resulted in augmented production of anandamide (Wang et al.,
2007). Therefore, in the high-salt model of hypertension, increased
anandamide production acting at upregulated sensory-nerve
mediated mechanisms may be an adaptive change to regulate high
blood pressure. This regulation or blunting of hypertension through
sensory-nerve mediated pathways is further supported by the fact
that capsazepine caused enhanced pressor responses in
hypertensive rats compared to normotensive controls (Wang and
Wang, 2007). Similarly, this chapter reports enhanced sensory-
nerve mediated activity in mesenteric arteries from SHR rats that
correlates with augmented anandamide-induced vasorelaxation.
Therefore, augmented sensory-nerve activity could underpin the
increased vasorelaxation to anandamide in mesenteric arteries of
SHR rats and may represent a physiological limit on blood pressure
increases. In contrast, oleamide-induced responses are comparable
between SHR and WKY mesenteric arteries and so are unaffected by
the differential sensory-nerve mediated activity. This suggests that
vasorelaxation to oleamide of mesenteric arteries from WKY and
SHR functions independently of sensory nerves.
Interestingly, in SHRs subjected to chronic activation of TRPV1 with
dietary capsaicin mean arterial pressure was lowered (Yang et al.,
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2010). This was associated with increases in nitrite levels, an
indication of enhanced NO production, and it was also demonstrated
that dietary capsaicin improved endothelial function of mesenteric
arteries from SHRs (Yang et al., 2010). Thus, the authors
concluded that long-term activation of TRPV1 restored endothelial
function through upregulated NO release, which was supported by
observations in a mouse model. Chronic activation of TRPV1 in mice
augmented eNOS levels in endothelial cells and mesenteric arteries,
and this effect was absent in TRPV1 knockout mice (Yang et al.,
2010). In the high salt model of hypertension, Wang et al. (2007)
described enhanced production of anandamide. Taken together it is
therefore possible that increased plasma levels of anandamide in
response to hypertension and possible increases in TRPV1
expression could result in augmented long-term activation of these
receptors in hypertensive animals. This presents a theoretical
mechanism for improved endothelial function in arteries from
younger SHR rats.
In summary, this chapter demonstrates that oleamide caused
comparable vasorelaxant responses in mesenteric arteries from
hypertensive and normotensive rats. This is in contrast to
oleamide-induced vasorelaxation of aortic segments, which was
augmented in hypertension. This interestingly illustrates a tissue
specific nature of the effects of hypertension on oleamide-induced
vasorelaxation. However, anandamide elicited enhanced
vasorelaxant responses in both aortae and mesenteric arteries from
SHR rats in comparison to normotensive controls. The augmented
responses to anandamide in mesenteric arteries were not due to
differences in NO-dependent mechanisms. Mesenteric arteries from
SHR rats demonstrated increased sensitivity to capsaicin, possibly
due to alterations in sensory-nerve mediated mechanisms.
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Chapter 6 Vasorelaxation to capsaicin and its effects on
calcium influx in arteries
6.1 Introduction
Capsaicin is the active component of hot chilli peppers and has been
shown to induce a range of pharmacological effects by activating the
TRPV1 receptor (Caterina et al., 1997; Gunthorpe et al., 2002;
Szallasi et al., 2006). In addition, chronic capsaicin exposure is a
commonly used pharmacological tool for desensitising perivascular
sensory nerves by exhausting neuropeptides stores.
TRPV1 is a non-selective cation channel (Caterina et al., 1997)
which regulates permeability to Ca2+ and can be activated by a
range of endogenous agonists including vanilloids (for review;
Sterner and Szallasi, 1999), endocannabinoids (Zygmunt et al.,
1999; Smart et al., 2000), lipoxygenase products (Hwang et al.,
2000) as well as physical stimuli. The activation of TRPV1 receptors
by agonists causes an increase in intracellular Ca2+ which results in
the release of neuropeptides such as calcitonin gene related-peptide
(CGRP), substance P and tachykinins (Saria et al., 1986; Franco-
Cereceda et al., 1987; Geppetti et al., 1988; Mayer et al., 1990;
Patacchini et al., 1999; Dunn et al., 2003). These neuropeptides
can regulate vascular smooth muscle, for example CGRP causes
hyperpolarisation of smooth muscle by activating K+ channels (Dunn
et al., 2003).
Capsaicin and its derivatives have been shown to induce blood
pressure decreases in rats (Lo et al., 2003; Li et al., 2003; Li and
Wang, 2003; Wang and Wang et al., 2007). Also, the chronic
activation of TRPV1 in SHRs through dietary capsaicin decreased
arterial blood pressure (Yang et al., 2010). The vasodilator nature
of capsaicin has been demonstrated in a number of isolated blood
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vessels and the release of vasoactive neuropeptides has been
implicated in capsaicin-induced vasorelaxation (Franco-Cereceda et
al., 1987; Franco-Cereceda and Rudehill, 1989; Jansen et al., 1990;
Holzer, 1992; Li and Wang, 2003). Pre-treatment of cerebral
arteries, dura matter and primary sensory nerves with capsaicin
depleted stores of substance P, Neurokinin A and CGRP, hence the
use of capsaicin as a pharmacological tool to desensitise sensory
nerves (Gamse et al., 1981; Saito and Goto, 1986; Dux et al.,
2003).
Studies have also demonstrated the involvement of nitric oxide (NO)
in capsaicin-induced responses. In the perfused coronary circulation
of rabbits, capsaicin elicited relaxations that were sensitive to both
NOS inhibition and CGRP-receptor inhibition (Mitchell et al., 1995).
Yang et al., (2010) demonstrated that chronic activation of TRPV1
by dietary capsaicin caused increased activity of endothelial NOS in
mouse mesenteric arteries. The effects of capsaicin were absent in
TRPV1 knockout mice demonstrating the involvement of these
receptors. The authors proposed that long-term TRPV1 activation
on endothelial cells resulted in calcium influx causing the
phosphorylation of protein kinase A (PKA) and subsequent activation
of NOS (Yang et al., 2010).
Previous chapters have shown that a 1h pre-treatment of aortae
from Wistar rats with capsaicin abolishes responses to oleamide.
Moreover, capsaicin pre-treatment reduces the enhanced
vasorelaxation of SHR aortae by anandamide and oleamide to levels
produced in normotensive vessels. Taken on its own this suggests
that oleamide and anandamide responses are driven by sensory-
nerve mediated activity. However, the vasorelaxant responses to
oleamide and anandamide were insensitive to the TRPV1 antagonist,
capsazepine, and the cation channel blocker ruthenium red. Thus,
anandamide and oleamide are exerting effects independently of
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TRPV1 but in a manner sensitive to capsaicin pre-treatment. This
would suggest that capsaicin can function by mechanisms that are
distinct from sensory-nerve activity to cause vasorelaxation and
affect the vasorelaxant responses to oleamide and anandamide.
According to the literature this could be mediated by the direct
action of capsaicin on ion channels. It is therefore necessary to
investigate further the mechanisms of actions involved in the
vascular effects of capsaicin.
Recent studies have demonstrated that capsaicin can also affect
vascular control by mechanisms distinct from activation of TRPV1 on
sensory nerves. In rat aortic smooth muscle cells the inhibition of
L-type Ca2+ channels was identified as the mechanism underlying
capsaicin-induced relaxations (Lo et al., 1995). In addition,
potassium channel activation has also been implicated (Ellis et al.,
1997; Zhu et al., 1997; Yeon et al., 2001; Fujimoto et al., 2006).
Also involved in the capsaicin relaxation is COX-2. In vivo
experiments involving human mucosal vascular beds have
demonstrated that 10µM capsaicin elicits vasodilatation which is
insensitive to capsazepine and the CGRP receptor antagonist
CGRP8-37 (Van Crombruggen et al., 2011). The vascular response
to capsaicin was attenuated by an EP1 prostanoid receptor
antagonist and by inhibition of COX-2 with NS398, indicating
capsaicin decreased the production of the vasoconstrictor
prostanoids. Therefore, authors concluded that capsaicin induced
TRPV1-independent vasodilatation by reducing production of PGE2
via COX-2 activity. The endocannabinoid system has been
implicated in regulating capsaicin-induced bronchospasm in guinea
pigs (Calignano et al., 2000).
In light of the involvement of TRPV1-independent mechanisms in
capsaicin-induced vasorelaxation, and capsaicins importance as a
pharmacological tool in desensitising perivascular sensory nerves,
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this chapter aimed to characterise the vascular actions of capsaicin
in isolated arteries. In particular, the roles of TRPV1 receptors and
the effects of calcium influx in capsaicin-induced vasorelaxation of
rat isolated aortae and porcine coronary arteries were examined.
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6.2 Methods and Materials
6.2.1 Animals
Male Wistar rats were killed and aortae removed and set-up
following the protocols outlined in Chapter 2. Porcine hearts were
obtained from a local abattoir and transported in ice-cold Krebs-
Henseleit buffer solution (NaCl 118, KCl 4.7, MgSO4 1.2, KH4PO 4.2,
NaHCO3 25, D-glucose 10, CaCl2 2 (mM)). Proximal coronary
arteries were removed from the hearts and stored in a refrigerator
at approximately 4°C in pre-gassed Krebs-Henseleit buffer solution
having been cleaned thoroughly of connective tissue by blunt
dissection and cut into segments of 3-5mm.
6.2.2 The vascular response to capsaicin in aortic rings and porcine
coronary artery
Aortic rings and porcine coronary arteries were placed onto two
metal wires, with one being fixed and the other attached via thread
to an isometric transducer measuring tension and placed into 50ml
organ baths. The organ baths were filled with modified Krebs-
Henseleit buffer solution at 37°C and gassed steadily (5% CO²/95%
O²). The aortic rings were allowed to equilibrate to 9.8mN of
tension and coronary arteries were equilibrated to 49mN. Tension
was measured by a Leitica force transducer coupled to an
ADInstruments MacLab recording system.
Aortic vessels were pre-contracted with the Į1-adrenoceptor agonist
methoxamine (10µM) prior to the addition of capsaicin (1nM-10µM),
which was added cumulatively at 5 minute intervals to construct
concentration-response curves. Porcine coronary arteries were pre-
contracted with U46619 (1-70nM), a thromboxane mimetic, prior to
the construction of capsaicin concentration-response curves (1nM-
100µM) (Figure 6.1) to achieve a submaximal contraction of 50-
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80% of maximal KCl (60mM) response. To investigate the role of
sensory nerves, some vessels were subjected to pre-treatment with
10µM capsaicin for 1h (Zygmunt et al., 1999). Capsaicin pre-
treatment was followed by a 20min wash-out period, prior to pre-
contraction. In aortic rings, concentration-responses curves to
capsaicin were also constructed in the presence of capsazepine
(1µM), a TRPV1 antagonist (White et al., 2001) and ruthenium red
(10µM), a cation channel blocker (Harris et al., 2002).
Figure 6.1
Figure 6.1 Representative trace of the response to capsaicin in the
porcine coronary artery. A=1nM, B=3nM, C=10nM, D=30nM,
E=100nM, F=300nM, G=1µM, H=3µM, I=10µM, J=30µM and
K=100µM.
6.2.3 The effect of capsaicin on contractile responses to calcium re-
introduction
Aortae were equilibrated to 9.8mN and porcine coronary arteries to
49mN for 1h in Ca²+ free Krebs-Henseleit buffer. After equilibration
in Ca²+-free, high K+ buffer (NaCl 62.5, KCl 59.4, MgSO4 1.2, KH4PO
1.2, NaHCO3 25, D-glucose 10 (mM)) capsaicin (either 1 µM, 3 µM
or 10 µM) was added to vessels with others being used as controls.
Concentration-response curves for the re-introduction of calcium
(10nM-3mM) (Figure 6.2) were constructed to test the effects of
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capsaicin on calcium-influx induced contraction. Some experiments
were performed in the presence of capsazepine (10µM) to assess
the potential involvement of TRPV1 receptors. Other experiments
were carried out in the presence of oleamide (10µM) and
anandamide (10µM) in order to characterise the effects of
endocannabinoids on calcium influx. Concentration-response curves
were also constructed in porcine coronary arteries to Bay-K 8644
(1nM-3µM), an L-type Ca2+ channel agonist. In preliminary
experiments Bay-K 8644 did not produce a vasoconstrictor effect in
the rat isolated aorta.
Figure 6.2
Figure 6.2 Representative trace of the contractile response to
calcium in the porcine coronary artery. A=10nM, B=30nM,
C=100nM, D=300nM, E=1µM, F=3µM, G=10µM, H=30µM, I=100µM,
J=300µM, K=1mM and L=3mM.
6.2.4 Drugs and reagents
Capsaicin (8-Methyl-N-vanillyl-trans-6-nonenamide), capsazepine
(N-[2-(4-chlorophenyl)ethyl]-1,3,4,5-tetrahydro-7,8-dihydroxy-2H-
2-benzazepine-2-carbothioamide), methoxamine hydrochloride (Į-
(1-Aminoethyl)-2,5-dimethoxybenzyl alcohol hydrochloride),
U46619 (9,11-Dideoxy-9a,11a-methanoepoxy prostaglandin F2Į),
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ruthenium red (ammoniated ruthenium oxychloride) and Bay-K
8644 (1,4-Dihydro-2,6-dimethyl-5-nitro-4-[2-
(trifluoromethyl)phenyl]-3-pyridinecarboxylic acid, methyl ester)
were purchased from Sigma Chemicals Co. (UK). Oleamide (cis-9-
Octadecenoamide) and anandamide (arachidonylethanolamide) were
purchased from Tocris Co. (UK). Capsaicin, capsazepine,
anandamide and Bay-K 8644 were dissolved in ethanol at stock
concentrations of 10mM. Methoxamine hydrochloride and
ruthenium red were dissolved in water at a stock concentration of
100mM and 10mM. U46619 and oleamide were dissolved in DMSO
(Dimethyl sulfoxide). Capsazepine was added 20 minutes prior to
the addition of contractile agents. Ruthenium red was present 30
minutes before pre-contraction.
6.2.5 Statistical analysis
All responses are expressed as mean percentage vasorelaxation with
the associated standard error of the mean (S.E.M). The GraphPad
Prism 5.0 software (San Diego, CA) was used to plot mean data as
sigmoidal concentration-response curves using a sigmoidal equation
[Y=Bottom+ (Top-Bottom)/(1+10((LogEC50-X)*Hillslope)), when
X=logarithm of agonist concentration and Y=response from Bottom
to Top in a sigmoidal shape]. The curves were used to determine
potency (pEC50) and maximal response (Rmax) values. Potency
(pEC50) is the negative log of agonist concentration that reduced
methoxamine-induced contraction by 50%. The maximal response
relates to the maximum percentage vasorelaxation of methoxamine-
induced pre-contraction. Statistical significance was determined
using two-tailed unpaired Students t-test between two data sets or
one-way ANOVA when comparing multiple data-sets. One-way
ANOVA was followed by a Bonferroni post hoc carried out as
appropriate. Statistical significance was determined using one-way
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ANOVA unless stated otherwise in the figure legend. P-values <0.05
were considered significant.
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6.3 Results
6.3.1 Vascular responses to capsaicin in rat isolated aortae
Capsaicin caused concentration-dependent vasorelaxation of the
aortic rings (Rmax=25.1±3.3%, pEC50=6.29±0.26, n=7), which was
significantly (P<0.001) greater than the small vasorelaxant
response caused by the vehicle control (0.15% of final bath volume)
(Rmax=5.5±1.4%, n=7) alone (Figure 6.3).
Figure 6.3
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Figure 6.3 Vasorelaxant responses to capsaicin and the vehicle
control (ethanol) in aortic rings pre-contracted with methoxamine
from Wistar rats. Mean data with bars indicating S.E.M are
displayed.
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6.3.2 Effects of capsaicin pre-treatment on capsaicin-induced
vasorelaxation of rat isolated aortae
Capsaicin-induced vasorelaxation of the rat aorta was unaffected by
a 1h capsaicin (10µM) pre-treatment (Rmax=27.4±1.9%,
pEC50=6.42±0.14, n=7) (Figure 6.4).
Figure 6.4
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Figure 6.4 Vasorelaxant responses to capsaicin in rat isolated aortae
pre-contracted with methoxamine after a 1h capsaicin (10µM) pre-
treatment. Mean data with bars indicating S.E.M are displayed.
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6.3.3 Involvement of TRPV1 receptors in capsaicin-induced
vasorelaxation of rat isolated aortae
The vasorelaxant responses to capsaicin (Rmax=30.4±2.8%,
pEC50=6.57±0.25, n=8) were also unaffected by the presence of
capsazepine (1µM) (Rmax=32.6±3.2%, pEC50=6.44±0.24, n=8)
(Figure 6.5). V
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Figure 6.5 Vasorelaxant responses to capsaicin in rat isolated aortae
pre-contracted with methoxamine in the presence of capsazepine
(1µM). Mean data with bars indicating S.E.M are displayed.
Experiments were analysed using Students t-test.
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6.3.4 Effects of ruthenium red on vasorelaxant responses to
capsaicin in the rat isolated aorta
Similarly, responses to capsaicin (Rmax=21.2±2.6%,
pEC50=6.1±0.20, n=6) were unaffected by 10µM ruthenium red
(Rmax=28.0±7.5%, pEC50=5.85±0.37, n=6) (Figure 6.6).
Figure 6.6
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Figure 6.6 Vasorelaxant responses to capsaicin in rat isolated aortae
pre-contracted with methoxamine in the presence of ruthenium red.
Mean data with bars indicating S.E.M are displayed. Experiments
were analysed using Students t-test.
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6.3.5 Effects of capsaicin on the contractile responses to calcium re-
introduction in rat isolated aortae
The re-introduction of calcium into a calcium-free, high potassium
buffer caused concentration-dependent contraction of the rat aortic
rings (Figure 6.7). The contractile response caused by calcium re-
introduction was significantly (P<0.001) reduced in the presence of
30µM capsaicin, such that at 3mM calcium the increase in tone was
5.6±1.0mN (n=12) compared to a control response of 15.6±2.4mN
(n=10) in its absence (Figure 6.7).
Figure 6.7
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Figure 6.7 Contractile responses in aortic rings from Wistar rats to
Ca2+ re-introduction in a Ca2+ free, high K+ buffer in the presence of
30µM capsaicin. Mean data with bars indicating S.E.M are displayed.
Experiments were analysed using Students t-test.
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6.3.6 Vascular effects of capsaicin in the porcine isolated coronary
artery
Capsaicin caused a concentration-dependent vasorelaxation of
porcine coronary arteries that was significantly (P<0.05) greater
than responses to the vehicle control (ethanol), such that at 100µM
capsaicin the relaxation was 98.5±9.9% (n=6) compared to a
vehicle response of 49.1±13.8% (n=6) (Figure 6.8).
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Figure 6.8 Vasorelaxant responses to capsaicin and the vehicle
control (ethanol) in porcine isolated coronary arteries pre-contracted
with U46619. Mean data with bars indicating S.E.M are displayed.
Experiments were analysed using Students t-test.
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6.3.7 Involvement of TRPV1 receptors in capsaicin-induced
vasorelaxation of porcine isolated coronary artery
Vasorelaxant responses to capsaicin in the porcine coronary artery
were unaffected by the presence of the TRPV1 receptor antagonist
capsazepine (10µM). At 100µM capsaicin the maximal relaxation
was 115 ± 5% (n=6) compared to 108±7% (n=6) in the presence
of capsazepine (10µM) (Figure 6.9).
Figure 6.9
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Figure 6.9 Vasorelaxant responses to capsaicin in porcine coronary
artery pre-contracted with U46619 in the presence of capsazepine
(10µM). Mean data with bars indicating S.E.M are displayed.
Experiments were analysed using Students t-test.
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6.3.8 Effects of capsaicin on the contractile response to calcium re-
introduction in porcine isolated coronary artery
The re-introduction of Ca2+ into a Ca2+ free, high K+ environment
caused contraction of porcine coronary arterial segments
(Rmax=110.1±5.6mN, pEC50=3.88±0.10, n=6) (Figure 6.10). The
contractile responses remained intact in the presence of 1µM
(Rmax=100.9±4.5mN, pEC50=3.91±0.09, n=6) and 10µM capsaicin
(Rmax=106.0±5.9mN, pEC50=3.64±0.09, n=6) (Figure 6.10).
However, the presence of 30µM capsaicin caused a significant
(P<0.0001) decrease in both the maximal contractile response
(Rmax=46.5±5.8mN, n=6) and its potency (pEC50=3.21±0.15, n=6)
(P<0.01) (Figure 6.10).
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Figure 6.10
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Figure 6.10 Contractile responses in segments of porcine coronary
artery to Ca2+ re-introduction in a Ca2+ free, high K+ buffer in the
presence of 1µM, 10µM and 30µM capsaicin. Mean data with bars
indicating S.E.M are displayed.
6.3.9 Effects of 100µM capsaicin and the presence of vehicle on the
contractile response to calcium re-introduction in porcine isolated
coronary artery
The maximal contractile response (P<0.001) and potency (P<0.01)
of responses to Ca2+ re-introduction in the presence of 30µM
(Rmax=69.6±7.0mN, pEC50=3.12±0.13, n=6) were both significantly
reduced compared to the contractile responses in the presence of
the vehicle control (Rmax=131.7±8.1mN, pEC50=3.85±0.12, n=6)
(Figure 6.11). In the presence of 100µM capsaicin the contractile
response to Ca2+ was completely abolished (n=5) (Figure 6.11).
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Figure 6.11
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Figure 6.11 Contractile responses in segments of porcine coronary
artery to Ca2+ re-introduction in a Ca2+ free, high K+ buffer in the
presence of vehicle control, 30µM and 100µM capsaicin. Mean data
with bars indicating S.E.M are displayed.
6.3.10 Involvement of TRPV1 receptors in the effects of capsaicin on
the contractile responses to calcium re-introduction
The contractile responses to Ca2+ re-introduction were abolished by
the presence of 30µM capsaicin and 10µM capsazepine. In the
presence of 30µM capsaicin alone calcium re-introduction caused a
small maximal contractile response, such that the maximal response
to 3mM Ca2+was 17.7±4.9mN (n=6) (Figure 6.12).
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Figure 6.12
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Figure 6.12 Contractile responses in segments of porcine coronary
artery to Ca2+ re-introduction in a Ca2+ free, high K+ buffer in the
presence of 30µM capsaicin and 10µM capsazepine. Mean data with
bars indicating S.E.M are displayed.
6.3.11 Effects of capsaicin on contractile responses to the L-type
calcium channel activator Bay-K 8644
The L-type calcium channel activator caused concentration-
dependent vasoconstriction of porcine isolated coronary arteries
(Rmax=60.0±3.9mN, pEC50=7.15±0.16, n=9) (Figure 6.13). The
vasoconstrictor responses to Bay-K 8644 were unaffected by the
presence of either 1µM (Rmax=65.0±4.8mN, pEC50=7.27±0.19, n=6)
or 3µM capsaicin (Rmax=42.1±11.9mN, pEC50=6.57±0.49, n=6)
(Figure 6.13). However, in the presence of 10µM capsaicin the
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maximal contractile response to Bay-K 8644 was significantly
(P<0.05) reduced (Rmax=25.8±5.0mN, pEC50=6.52±0.33, n=6)
(Figure 6.13). Vasoconstrictor responses to Bay-K 8644 were
completely abolished in the presence of 30µM capsaicin (n=6)
(Figure 6.13).
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Figure 6.13 Contractile responses of the porcine isolated coronary
arteries to the L-type calcium channel activator Bay-K 8644 in
presence of 1µM, 3µM, 10µM and 30µM capsaicin. Mean data with
bars indicating S.E.M are displayed.
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6.3.12 Effects of oleamide on the contractile response to calcium re-
introduction in porcine isolated coronary artery
The contractile response to Ca2+ re-introduction (Rmax=12.3±0.8mN,
pEC50=3.57±0.09, n=8) was unaffected by 10µM oleamide
(Rmax=14.7±1.4, pEC50=3.54±0.14, n=6) (Figure 6.14).
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Figure 6.14 Contractile response in segments of porcine coronary
artery to Ca2+ re-introduction in a Ca2+ free, high K+ buffer in the
presence of 10µM oleamide. Mean data with bars indicating S.E.M
are displayed.
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6.3.13 Effects of anandamide on the contractile response to calcium
re-introduction in porcine isolated coronary artery
The contractile responses to Ca2+ re-introduction (Rmax=12.3±0.8mN,
pEC50=3.57±0.09, n=8) were unaffected by 10µM anandamide
(Rmax=10.8±0.7mN, pEC50=3.58±0.09, n=8) (Figure 6.15).
Figure 6.15
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Figure 6.15 Contractile responses in segments of porcine coronary
artery to Ca2+ re-introduction in a Ca2+ free, high K+ buffer in the
presence of 10µM anandamide. Mean data with bars indicating
S.E.M are displayed
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6.4 Discussion
A major finding of this investigation is that capsaicin induces
concentration-dependent vasorelaxation of the rat isolated aorta
through mechanisms distinct from TRPV1 receptors and, by
implication, sensory nerves. In addition, the results suggest an
alternative mechanism of action for capsaicin that could drive
relaxant responses in both rat aortae and porcine coronary arteries.
Capsaicin caused concentration-dependent vasorelaxation of both
rat aortae and porcine coronary arteries. The relaxant responses in
rat aortae were unaffected by the TRPV1 receptor antagonist
capsazepine. Similarly, the presence of the cation-channel blocker
ruthenium red had no effect on vascular responses to capsaicin.
Pre-treatment of aortae with capsaicin, which is designed to deplete
perivascular sensory nerves of vasoactive neuropeptides (Zygmunt
et al., 1999), did not alter the vasorelaxation to capsaicin.
Furthermore, the vasorelaxant responses to capsaicin were
insensitive to both capsazepine and ruthenium red. These findings
suggest that capsaicin-induced vasorelaxation of the rat aorta and
porcine coronary artery does not involve TRPV1 receptors. These
findings are consistent with other investigations demonstrating non-
TRPV1 mechanisms of action for capsaicin. Expression of TRPV1 has
previously been detected in aortic smooth muscle cells from male
Wistar rats (Yang et al., 2006). Vanilloid receptor activation on
vascular smooth muscle is more likely to induce vasoconstriction,
whereas activation of endothelial expression receptors is likely to
elicit vasorelaxation (reviewed in Firth et al., 2007). For example,
endocannabinoid-induced TRPV1-mediated relaxation of the rat
mesenteric bed is correlated with endothelial TRPV1 expression
(Poblete et al., 2005).
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The findings of a capsaicin-induced vasorelaxation which is
insensitive to TRPV1 antagonism has been reported elsewhere in the
literature. Gupta et al. (2007) described capsaicin-induced
vasorelaxation in both human and porcine coronary arteries which
was similarly insensitive to both capsazepine and ruthenium red. In
addition, responses were unaffected by CGRP receptor blockade
(Gupta et al., 2007). However, in contrast Bratz et al. (2008)
described a capsaicin-induced relaxation of porcine coronary arteries
that was partially inhibited by capsazepine. This study examined an
impaired vasorelaxant response to capsaicin in a model of the
metabolic syndrome, which was associated with a decreased
expression of TRPV1 expression in vasculature from the metabolic
syndrome model (Bratz et al., 2008).
Several other studies have also demonstrated non-sensory nerve
mediated relaxations to capsaicin in rabbit coronary arteries, guinea
pig ileum, equine smooth muscle and human nasal vasculature
(Yeon et al., 2001; Zhu et al., 1997; Fujimoto et al., 2006; Van
Crombruggen et al., 2011). Although, Gupta et al. (2007) described
TRPV1-independent relaxation of human and porcine coronary
arteries, they were unable to elucidate the specific mechanisms
underlying the responses to capsaicin. In addition to being TRPV1-
independent, responses were distinct from CGRP, NO, K+ channels,
cAMP and calcium channels (Gupta et al., 2007).
Previous studies have shown that capsaicin inhibits calcium entry via
channels in the rat aorta. Monsereenusorn and Kongsamut (1985)
described a dose-dependent inhibition of radioactive calcium-45
uptake by capsaicin in cultured smooth muscle cells from rat aorta.
To build on this Lo et al. (1995) demonstrated that capsaicin
inhibited L-type Ca2+ channels in cultured rat aortic smooth muscle.
These results suggested that L-type Ca2+ channel inhibition may be
involved in the vascular actions of capsaicin in the rat aorta. In
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support of this, the present study shows that the presence of
capsaicin inhibits the contractile response caused by calcium re-
introduction in aortae in a high K+ (60mM) calcium-free buffer,
consistent with interference with calcium influx. Therefore,
capsaicin-induced vasorelaxation of rat aorta and porcine coronary
arteries are mediated via inhibition of calcium influx.
In the present study, capsaicin produced concentration-dependent
vasorelaxant responses in porcine isolated coronary arteries. The
magnitude of the vasorelaxant response was comparable to
capsaicin-induced relaxations reported elsewhere (Gupta et al.,
2007). Capsaicin-induced vasorelaxation of porcine coronary
arteries was insensitive to capsazepine (10µM). This clearly
demonstrates that vasorelaxation of coronary arteries and rat aortae
in response to capsaicin are mediated independently of TRPV1
receptors. This is in accordance with Gupta et al. (2007), who
described capsazepine-insensitive vasorelaxation of human and
porcine coronary arteries. In contrast, Bratz et al. (2008) reported
capsaicin driven vasorelaxation of porcine coronary arteries that was
partially mediated by TRPV1 receptors, in an endothelial-dependent
mechanism, together with nitric oxide and K+ channels. The
differences in the literature could reflect differences in the strain of
swine used. Bratz et al. 2008 examined capsaicin-induced
responses in coronary arteries from obese male Ossabaw miniature
swine compared to lean controls. They described an impaired
response to capsaicin in coronaries from obese swine compared to
lean controls, which was associated with a decreased expression of
TRPV1. The capsaicin-induced relaxation of coronary arteries from
lean pigs was normalised by capsazepine to that of arteries from
obese swine (Bratz et al., 2008). However, there was still a large
residual response to capsaicin in arteries from lean pigs in the
presence of TRPV1 antagonist. The vasorelaxant effects of capsaicin
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in lean coronary arteries was sensitive to L-NAME, iberiotoxin and
also TEA, implicating both NO and K+ channels (Bratz et al., 2008).
After all treatments a large residual relaxant effect remained and it
was unclear if the involvement of NO and K+ channels may be
mediated by the upstream activation of TRPV1 receptors. Bratz et
al. 2008, using Fura2 imaging, demonstrated calcium-influx via
TRPV1 receptors in response to capsaicin in endothelial cells from
coronary arteries. Elsewhere, it has been shown that an increase in
intracellular Ca2+ through TRPV1 activation by capsaicin results in
upregulated NOS activity via phosphorylation by PKA (Yang et al.,
2010). It is also possible that TRPV1-induced Ca2+ influx in the
endothelial cells mediated the release of EDHF, although this is less
likely in larger conduit vessels. Alternatively, several studies have
described the direct actions of capsaicin at K+ channels on smooth
muscle (Zhu et al., 1997; Yeon et al., 2001; Fujimoto et al., 2006).
In light of capsaicin-induced, capsazepine insensitive relaxation of
the porcine coronary artery it was necessary to characterise the role
of calcium channels in this preparation. The contractile responses
induced by calcium re-introduction was significantly reduced by the
presence of 30µM capsaicin and completely abolished by the
presence of 100µM capsaicin. These results demonstrate that
capsaicin is interfering with calcium entry into smooth muscle. One
hypothesis is that activation of TRPV1 results in the downstream
inhibition of L-type Ca2+ channels and so mediates decreased
calcium entry. Indeed, it has previously been reported that CGRP
can inhibit calcium currents in rat paracervical ganglion neurons and
also modify L-type Ca2+ channel currents in the smooth muscle of
rat vas deferens (Nakazawa et al., 1992; Cohen et al., 1996).
However, the inhibitory effects of capsaicin on calcium influx were
not inhibited by the presence of a TRPV1 competitive antagonist,
indicated that it is not coupled to TRPV1 receptor activation.
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Capsaicin has previously been reported to block calcium-uptake in
smooth muscle cells from rat aorta (Monsereenusorn and
Kongsamut, 1985; Lo et al., 1995).
Having demonstrated that capsaicin inhibits calcium-influx into
vascular smooth muscle the effects of capsaicin on L-type Ca2+
channels were investigated. Bay-K 8644 (Bay-K) is an L-type Ca2+
channel activator that increases Ca2+-influx (Takasu et al., 1987;
Triggle and Rampe, 1989) and caused a concentration-dependent
vasoconstriction of porcine coronary arteries. The presence of 10µM
capsaicin significantly inhibited the maximal contractile response
caused by Bay-K 8644. Interestingly, the presence of 30µM
capsaicin completely abolished the contractile response to Bay-K
8644. These results suggest that capsaicin can directly inhibit L-
type Ca2+ channel activation on vascular smooth muscle. The
concentrations of capsaicin used to block the effects of Bay-K are
within the range that causes capsaicin-induced vasorelaxation. Thus,
it is possible that the direct inhibition of L-type Ca2+ channels is a
mechanism of action driving vascular responses to capsaicin. This is
consistent with the involvement of Ca2+ channels in the relaxant
effect of capsaicin in smooth muscle from rat aorta (Lo et al., 1995).
Similarly, DAlonzo et al. (1995) showed that capsaicin had anti-
arrhythmic and anti-ischaemic activity in perfused isolated hearts
from guinea pigs and these effects were attributed to the blocking of
voltage-gated Ca2+ channels. It was concluded that capsaicin
caused effects similar to those of Ca2+ channel antagonists in
perfused hearts (DAlonzo et al., 1995).
In light of the effects of capsaicin on calcium influx in the rat aortae
the effects of oleamide and anandamide on calcium-influx were
investigated. This was because the literature shows that
endocannabinoids can act directly to inhibit a number of ion
channels. Chemin et al. (2001) demonstrated that 1µM anandamide
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can block T-type calcium channel current in a receptor independent
manner. Anandamide and 2-AG (IC50 2.7µM) have been reported to
directly block Shaker-related Kv1.2 potassium channels (Poling et
al., 1996). Indeed anandamide, 2-AG, N-palmitoylethanolamine and
N-oleoylethanolamine directly blocked human cardiac kv1.5
channels (Barana et al., 2010). Zhang et al., (2000) described a
similar effect of 10µM arachidonic acid on T-type Ca2+ channels.
Arachidonic acid can also inhibit the contractility of ventricular
myocytes by inhibiting L-type Ca2+ channels in a concentration-
dependent manner (IC50 8.5µM) (Liu et al., 2007). In feline cerebral
arterial smooth muscle anandamide inhibited L-type Ca2+ channels
(Gebremedhin et al., 1999). The authors proposed that inhibition of
L-type Ca2+ channels occurred via CB1 receptors as the inhibitory
effect of anandamide was sensitive to both pertusis toxin and
rimonabant, while correlating with smooth muscle expression.
Similar effects of anandamide via CB1 receptors on Ca
2+ channels
were present in the rat myocardium (Li et al., 2009). Although the
literature documents that endocannabinoids can both directly and
indirectly block ion channel function, the present chapter
demonstrated that the presence of oleamide and anandamide had
no effect on calcium influx in rat aortae.
A number of recent studies have described non-TRPV1 mediated
capsaicin-induced relaxations. Capsaicin appears to be able to
induce relaxations by a variety of mechanisms that appear to differ
between tissues. Several studies have implicated the activation of
different K+ channels in relaxant responses to capsaicin (Zhu et al.,
1997; Yeon et al., 2001; Fujimoto et al., 2006). Sim et al. (2001)
demonstrated that capsaicin concentration-dependently relaxed
antral circular myocytes from the guinea-pig stomach. It was also
shown that capsaicin produced similar inhibitory effects to calcium
channel antagonists and caused relaxations by blocking voltage
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operated calcium channels (Sim et al., 2001). It was concluded that
capsaicin was acting on intracellular stores of calcium. Relaxant
responses to capsaicin have also shown to be mediated by NO in
human sigmoid colon circular muscle (Bartho et al., 2002) and by
COX-2 in human nasal vasculature (Van Crombruggen et al., 2011).
The present chapter, in addition to other non-sensory nerve
mediated mechanisms detailed in the literature, has outlined a
possible mechanism of action underlying the vascular responses to
capsaicin. This helps supports the findings of Chapters 2 and 3
where capsaicin exposure was shown to inhibit the vasorelaxation of
aortic segments from Wistar and SHR rats to oleamide and
anandamide in a manner distinct from sensory-nerves. It is possible
that aortic segments lack TRPV1 expression and that capsaicin
exposure causes changes to ion channels that prevent anandamide
and oleamide elicited vasorelaxation. It is also possible that
capsaicin persists even after the 20 minute wash-out periods and so
directly affects ion channels in aortic segments. The possibility that
capsaicin may be interfering with a novel CB cannabinoid receptor,
which is distinct from the classical cannabinoid receptors, in order to
inhibit aortic relaxation to oleamide and anandamide should not be
ignored. Indeed, Hoi and Hiley (2006) proposed that in small
mesenteric rat arteries oleamide and anandamide may be acting at
novel cannabinoid receptor that is sensitive to rimonabant and O-
1918 and coupled to a Gi/o protein.
In summary, the present chapter has demonstrated that capsaicin
causes concentration-dependent vasorelaxation of both the rat
isolated aorta and the porcine coronary artery. The vascular actions
of capsaicin in the rat aorta were mediated by mechanisms distinct
from TRPV1 receptors. It has also been shown that capsaicin can
block the contractile responses produced by calcium re-introduction
in both the rat aorta and porcine coronary arteries. In addition,
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capsaicin blocked the contractile effects of Bay-K 8644, an L-type
Ca2+ channel activator, in porcine coronary arteries. Thus, we have
provided evidence that suggests capsaicin can inhibit calcium-
uptake by blocking L-type Ca2+ channels in arteries. In conclusion,
we have suggested a mechanism of action for capsaicin driving its
vascular responses that is distinct from TRPV1 receptor activation.
These results also have implications for experimental pharmacology,
namely that treatment with capsaicin should be interpreted with
care and that relaxant responses to capsaicin do not necessarily
imply a role for sensory nerves.
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Chapter 7 Investigating the effects of oleamide in the
perfused mesenteric arterial bed
7.1 Introduction
As discussed in Chapter 1, the endothelium releases vasoactive
mediators that are important in the control of vascular tone. Nitric
oxide and prostacyclin are well characterised endothelium-derived
vasodilators and account for endothelium-dependent relaxations to
agonists such as acetylcholine and bradykinin and to physical stimuli
like shear stress. It has been uncovered that an additional
endothelium-derived relaxant exists independently of NO and
prostacyclin. This additional relaxant is characterised by
endothelium-dependent hyperpolarisation of underlying vascular
smooth muscle and its effects are abolished by Ca2+-activated K+-
channels and hyperpolarising concentrations of extracellular K+ and
is termed endothelium-derived hyperpolarising factor (EDHF) (Taylor
and Weston, 1988).
The relative importance of EDHF versus NO appears to be
dependent upon vessel size. EDHF-mediated mechanisms appear
more important to endothelium-dependent relaxation as vessel size
gets smaller, with NO contribution being more important in conduit
vessels (Shimokawa et al., 1996; Tomioka et al., 1999).
Shimokawa et al. (1996) demonstrated endothelium-dependent
vasorelaxation to acetylcholine in the rat isolated aorta and in the
proximal and distal mesenteric arteries. The importance of NO to
vasorelaxation decreased as vessel size decreased and correlated
with lower basal release of NO in resistance vessels and decreased
expression of eNOS. Contribution of EDHF-mediated mechanisms
was greatest in the relaxation of distal mesenteric arteries.
McCulloch et al. (1997) demonstrated that EDHF-mediated
Chapter 7 Investigating the effects of oleamide in the perfused mesenteric
arterial bed
188
mechanisms may be upregulated in order to compensate for the loss
of NO.
EDHF-mediated relaxations to agonists involve an increase in
endothelial calcium, causing the activation of Ca2+-activated K+-
channels. The resulting efflux of K+ hyperpolarises endothelial cells
and this hyperpolarisation is transmitted to the vascular smooth
muscle by the generation of an EDHF. A number of different
mechanisms have been implicated as EDHFs. It has been
demonstrated that communication through myoendothelial gap-
junctions plays an important role in transmitting this
hyperpolarisation to the smooth muscle. A host of studies using
gap-junction blockers and connexin-mimetic peptides have
implicated gap junctions in mediating EDHF-type endothelium-
dependent relaxations (Chaytor et al., 1998; 2001; 2003; Taylor et
al., 1998; Edwards et al., 1999; Griffith and Taylor, 1999; De Vriese
et al., 2002; Griffith et al., 2002).
The connexin-mimetic peptide, Gap27, inhibited EDHF-mediated
relaxations to acetylcholine in rabbit mesenteric arteries (Chaytor et
al., 1998). EDHF-mediated relaxation of rabbit mesenteric arteries
is also sensitive to glycyrrhetinic acid derived gap junction blockers
(Taylor et al., 1998; Griffith and Taylor, 1999; Chaytor et al., 2000).
A range of other connexin-mimetic peptides, each one inhibiting a
specific connexin, confirmed the role of gap junctional
communication in EDHF-mediated relaxation of the rat hepatic
artery and rabbit iliac artery (Chaytor et al., 2001; Griffith et al.,
2002).
The EDHF-mediated vasorelaxant effect of carbachol in the perfused
rat arterial mesenteric bed was inhibited by the gap-junction blocker
18-Į glycyrrhetinic acid (Harris et al., 2000). Palmitoleic acid,
clotrimazole and ouabain also attenuated EDHF-type responses in
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the mesenteric arterial bed and were shown to blunt cell-to-cell
transfer of Lucifer yellow dye (Harris et al., 2000). In the same
tissue preparation, Harris et al. (2002) implicated gap-junctional
communication in anandamide-induced vasorelaxation. Previously,
vasorelaxation of rabbit mesenteric arteries to anandamide was
shown to be partially dependent on functioning gap junctions
(Chaytor et al., 1999). Interestingly, an extensive body of research
has shown that oleamide can block gap-junctional communication
(Guan et al., 1997; Boger et al., 1998; Bannerman et al., 2000;
Nagasawa et al., 2006). Oleamide (20µM) completely blocked gap-
junctional communication in rat glial cells, similarly anandamide
(5µM) acted as a gap junction blocker in striatal astrocytes
(Venance et al., 1995; Boger et al., 1998).
The aim of this chapter is to characterise the effects of oleamide on
the endothelium-dependent relaxation induced by carbachol in the
perfused rat mesenteric arterial bed. Since oleamide has been
shown to inhibit gap-junctional communication its effects against
EDHF-mediated responses were assessed. In light of the fact that
anandamide relaxes the rat mesenteric arterial bed (Harris et al.,
2002) and oleamide causes vasorelaxation of isolated mesenteric
arteries from the rat (Hoi and Hiley, 2006; Sudhahar et al., 2009) it
is clearly important to characterise responses to oleamide in the
same vessel bed
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7.2 Methods
7.2.1 Animals
Male Wistar rats (200-400g) were stunned with a blow to the head
and killed by exsanguination. The rats were dissected with a mid-
line incision to reveal the superior mesenteric artery, which was
ligated and cleaned of fatty tissue with blunt dissection. A small
incision was made in the artery and a cannula (internal diameter
0.58mm; outer diameter 0.96mm) was inserted and ligated below
the insertion point. The intestinal wall was carefully cut away from
the mesenteric arterial bed. All rats used were housed at the
Biomedical Services Unit, University of Nottingham with a 12 h
light/dark cycle and in temperature-controlled conditions.
7.2.2 Perfused rat mesenteric arterial bed
The mesenteric arterial bed was then removed and attached to a
perfusion system and suspended in a heated jacketed organ-bath.
The isolated arterial bed was perfused at 5ml/min with gassed (5%
CO2/95% O2) Krebs-Henseleit solution (NaCl 118, KCl 4.7, MgSO4
1.2, KH4PO 4.2, NaHCO3 25, D-glucose 10, CaCl2 2 (mM)). Pressure
was measured by a pressure transducer coupled to a MacLab 4e
system.
The isolated arterial bed was allowed to equilibrate for 30 minutes
and the Į1- adrenoceptor, methoxamine (1-10µM), was initially
added to the perfusion buffer to increase pressure. Methoxamine
was present throughout the experiment. After established tone had
stabilised, vasorelaxant responses to oleamide (355pmol-3.52µmol)
(Figure 7.1) and carbachol (5.48pmol-54.8nmol) were assessed by
constructing dose-response curves by administering doses by bolus
injections (30µL-330µL) via an injection port in the perfusion system.
In order to examine the role of sensory nerves in vasorelaxant
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responses to oleamide, arterial beds were perfused with buffer
containing capsaicin (10µM) for 1h followed by a 30min washout
period. This chronic exposure to capsaicin was designed to exhaust
sensory nerves of vasoactive neuropeptides (Zygmunt et al., 1999).
The role of NO in relaxant responses to oleamide and carbachol was
characterised by the addition of L-NAME (300µM), an inhibitor of
nitric oxide synthase, to the perfusion fluid. In addition, L-NAME
was present in all other experiments. The importance of K+-
channel-dependent mechanisms of vasorelaxation was assessed by
constructing dose-response curves in arterial beds being perfused
with a high K+ buffer (NaCl 62.5, KCl 59.4, MgSO4 1.2, KH4PO 1.2,
NaHCO3 25, D-glucose 10, CaCl2 2 (mM)) (Wheal et al., 2010).
Experiments were also performed in the presence of carbenoxolone
(100µM), to assess the importance of gap junctional communication
in mediating vasorelaxation to carbachol and oleamide (Davidson et
al., 1986). In addition, the effect of oleamide (20µM) on the
vasorelaxant responses to carbachol was investigated. Dose-
response curves to sodium nitroprusside (SNP) (336fmol-1.01nmol),
an NO donor, were constructed in the presence of oleamide (20µM),
to assess if oleamide affected NO-mediated relaxation or relaxation
per se.
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Figure 7.1
Figure 7.1 Representative trace of the relaxant response to doses of
oleamide. A=107nmol, B=355nmol, C=1.07µmol and D=3.52µmol.
7.2.3 Drugs
Carbenoxlone (3ǃ-Hydroxy-11-oxoolean-12-en-30-oic acid 3-
hemisuccinate), carbachol (2-Hydroxyethyl) tri-methylammonium
chloride carbamate Carbachol Carbamylcholine chloride), capsaicin
(8-methyl-N-vanillyl-trans-6-nonenamide), L-NAME (NG-Nitro-L-
arginine methyl ester hydrochloride), methoxamine (Į-(1-
Aminoethyl)-2, 5-dimethoxybenzyl alcohol hydrochloride) and SNP
(Nitroprusside sodium SNP Sodium nitroferricyanide Sodium
pentacyanonitrosylferrat) were purchased from Sigma Chemical Co.
(UK). Oleamide (cis-9 10 octadecenoamide) was supplied by Tocris
Co. (UK). Carbenoxolone, carbachol, L-NAME and methoxamine
were all dissolved in distilled water. Capsaicin was dissolved in
ethanol and oleamide was dissolved in DMSO (Dimethyl sulfoxide).
7.2.4 Statistical analysis
All responses are expressed as mean data with the associated
standard error of the mean (S.E.M). The GraphPad Prism 5.0
Chapter 7 Investigating the effects of oleamide in the perfused mesenteric
arterial bed
193
software (San Diego, CA) was used to plot mean data as sigmoidal
concentration-response curves using a sigmoidal equation
[Y=Bottom+ (Top-Bottom)/(1+10((LogEC50-X)*Hillslope)), when
X=logarithm of agonist concentration and Y=response from Bottom
to Top in a sigmoidal shape]. The curves were used to determine
potency (pED50 which is the negative log of the dose causing 50% of
the maximal relaxation) and maximal response (Rmax) values.
Statistical significance was determined using one-way ANOVA when
comparing multiple data-sets. One-way ANOVA was followed by a
Bonferroni post hoc carried out as appropriate. P-values <0.05 were
considered significant.
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7.3 Results
7.3.1 Vasorelaxant effects of oleamide in the perfused rat
mesenteric arterial bed
Oleamide caused dose-dependent vasorelaxation of perfused
mesenteric arterial beds isolated from Wistar rats (Rmax=57.6±3.9%,
pED50=6.73±0.08, n=3-5) (Figure 7.2). The vasorelaxant effect of
oleamide was unaffected by L-NAME (Rmax=78.3±16.3%,
pED50=6.40±0.24, n=4) (Figure 7.2).
Figure 7.2
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Figure 7.2 Vasorelaxation to oleamide in the rat mesenteric arterial
bed contracted with methoxamine in the presence of L-NAME and in
the combined presence of L-NAME and carbenoxolone. Mean data
with bars indicating S.E.M are displayed.
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7.3.2 Involvement of gap-junctions in the vasorelaxant response to
oleamide in the perfused rat mesenteric arterial bed
The vasorelaxant responses to oleamide (Rmax=57.6±3.9%,
pED50=6.73±0.08, n=3) were also unaffected in the presence of
both L-NAME and carbenoxolone (Rmax=65.9±6.6%,
pED50=7.23±0.17, n=4) (Figure 7.2).
7.3.3 The involvement of potassium channels in the vasorelaxant
response to oleamide in the perfused rat mesenteric arterial bed
The contraction of mesenteric arterial beds with high extracellular
potassium in the presence of L-NAME abolished vasorelaxant
responses to oleamide at doses below (1.07µmole) (Figure 7.3).
Whereas, the relaxant response in methoxamine pre-contracted
arterial beds was 57.0±11.2% (n=5) in the presence of L-NAME
(Figure 7.3). Only at the highest dose of oleamide was there a
relaxant response of 30.7±23.1% (n=4) in the presence of high
extracellular potassium.
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Figure 7.3
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Figure 7.3 Vasorelaxation to oleamide in the rat mesenteric arterial
bed after a 1h pre-treatment with capsaicin and after contraction
with high extracellular potassium in the presence of L-NAME. Mean
data with bars indicating S.E.M are displayed.
7.3.4 Involvement of sensory nerves in the vasorelaxant responses
to oleamide in the perfused rat mesenteric arterial bed
The vasorelaxant effects of oleamide were unaffected by 1h
capsaicin (10µM) pre-treatment (Rmax=58.2±3.9%,
pED50=6.62±0.08, n=4) (Figure 7.3).
7.3.5 Endothelium-dependent vasorelaxant of the perfused rat
mesenteric arterial bed
Carbachol caused a dose-dependent vasorelaxation of perfused
mesenteric arterial beds (Rmax=85.4±34.4%, pED50=9.69±1.00,
n=4) (Figure 7.4). The presence of 300µM L-NAME caused a
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significant (P<0.05) decrease in the vasorelaxant response to
carbachol, such that at 54.75nmol, vasorelaxation was decreased
from 81.5±5.9% (n=4) to 44.7±7.2% (n=4) (Figure 7.4). The
presence of both 20µM oleamide and 300µM L-NAME further
decreased (P<0.05) the vasorelaxant response to carbachol, such
that at 54.75nmol, vasorelaxation was 10.6±7.2% (n=5) (Figure
7.4). Similarly, the presence of both 100µM carbenoxolone and
300µM L-NAME abolished the vasorelaxant response to carbachol
(Figure 7.4).
Figure 7.4
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Figure 7.4 Endothelium-dependent vasorelaxation to carbachol in
the rat mesenteric arterial bed contracted with methoxamine in the
presence of L-NAME, both L-NAME and carbenoxolone, and both L-
NAME and oleamide. Mean data with bars indicating S.E.M are
displayed.
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7.3.6 Endothelium-independent vasorelaxation of the perfused rat
mesenteric arterial bed
Vasorelaxation caused by SNP in the presence of L-NAME was
unaffected by the presence of oleamide. Vasorelaxation to the
maximum concentration of SNP used was 85.5±9.2% (n=3),
compared to 65.5±5.2% (n=3) in the presence of oleamide (20µM)
(Figure 7.5).
Figure 7.5
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Figure 7.5 Endothelium-independent vasorelaxation to SNP in the
rat mesenteric arterial bed contracted with methoxamine in the
presence of L-NAME and oleamide. Mean data with bars indicating
S.E.M are displayed. Experiments were analysed using Students t-
test.
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7.4. Discussion
One of the principal findings of the present chapter is that the
endocannabinoid-like substance, oleamide, induces vasorelaxation
of the rat mesenteric arterial bed. This supports previous reports
showing oleamide to be a potent vasodilator of small resistance
mesenteric arteries (Hoi and Hiley, 2006; Sudhahar et al., 2009).
The current set of experiments also demonstrated that oleamide
significantly attenuated the endothelium-dependent relaxation of the
rat mesenteric arterial bed. The present study shows that oleamide
had comparable effects to carbenoxolone at inhibiting carbachol-
induced relaxation of the mesenteric arterial bed. Carbenoxolone is
a glycyrrhetinic acid derivative that blocked gap-junctional
communication in human fibroblast mutant cells in a manner that
was not connexion specific (Davidson et al., 1986; Davidson and
Baumgarten, 1988). Communication through gap junctions has
been reported in a number of EDHF-mediated responses (Yamamoto
et al., 1998; 1999; Harris et al., 2000; Coleman et al., 2001).
Previously, Harris et al. (2000) described carbachol-induced EDHF-
mediated relaxation of the rat isolated mesenteric arterial bed. The
EDHF-mediated responses were inhibited by the gap-junction
blockers 18 Į-glycyrrhetinic acid, palmitoleic acid and clotrimazole
(Harris et al., 2000). The previous work by Harris et al. (2000)
implicated gap junctional communication in EDHF-type relaxations.
This was confirmed in this chapter but, more importantly, it was also
found that oleamide specifically interfered with EDHF-type responses
whilst leaving nitric oxide-mediated responses unaffected.
Oleamide has been shown to elicit inhibitory effects on gap-junction
communication in a number of tissues; including, rat glial cells
(Guan et al., 1997; Boger et al., 1998), neural crest cells (Huang et
al., 1998; Bannerman et al., 2000), tracheal epithelial cells (Boitano
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and Evans, 2000), somniferous tubule cells (Decrouy et al., 2004),
endothelial cells of the blood brain barrier (Nagasawa et al., 2006),
osteoblasts (Schiller et al., 2001) and osteocytes (Ishihara et al.,
2012). Guan et al. (1997) reported that oleamide (50µM)
completely blocked gap junction communication in rat glial cells,
demonstrated through the inhibition of Lucifer yellow dye transfer
and electrical conductance. Oleamide blocked gap junctions in a
non-specific manner, inhibiting both Į1 and ǃ1 connexin subtypes
(Guan et al., 1997). Boger et al. (1998) reported a similar effect
of oleamide on gap junctions in the same cell type. In addition, it
was demonstrated that oleamide (50µM) inhibited neural crest cell
migration in mice embryonic cells, a process regulated by gap-
junction communication (Huang et al., 1998). Interestingly,
oleamide (25-100µM) inhibited the function of endothelial cells from
the blood brain barrier, mimicking the effects of the well known gap
junction blocker 18ǃ-glycyrrhetinic acid (Nagasawa et al., 2006
The vasorelaxant effect of oleamide in the rat mesenteric arterial
bed was reduced after contraction with high extracellular K+ (60mM)
instead of methoxamine. This suggests a role for K+-channels in
oleamide-induced vasorelaxation, possibly through EDHF-mediated
mechanisms. However, the responses to oleamide were unaffected
by carbenoxolone, which, as discussed above, interferes with EDHF-
type responses. Therefore, these findings suggest that, in the
mesenteric arterial bed, oleamide does not act via EDHF release and
its effects against carbachol-induced relaxation would suggest that it
interferes with EDHF. So the present findings do not identify a
mechanism of relaxation to oleamide but it would appear to be
independent of nitric oxide and sensory nerves. The findings with
high extracellular potassium may implicate a K+ channel-dependent
mechanism and further experiments using selective K+ channel
inhibitors are required to establish this.
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Harris et al. (2002) characterised the vasorelaxation of the rat
mesenteric arterial bed to the prototypical endocannabinoid,
anandamide. Anandamide, similarly to oleamide in the present
study, caused vasorelaxation independently of NO production (Harris
et al., 2002). In contrast, Hoi and Hiley, (2006) had reported a NO-
dependent component of oleamide-induced vasorelaxation.
Anandamide caused relaxation that was sensitive to the presence of
18Į-glychrrhetinic acid, possibly implicating gap junctions in the
response (Harris et al., 2002). Anandamide has previously been
demonstrated to interact with gap junctions in striatal astrocytes
(Venance et al., 1995). However, anandamide-induced
vasorelaxation was insensitive to both carbenoxolone and
palmitoleic acid (Harris et al., 2002). The authors postulated that
responses to anandamide may have involved the sodium pump and
not gap junctions as ouabain also had an inhibitory effect.
Endocannabinoids can also act as TRPV1 agonists, activating the
release of neuropeptides, such as CGRP, from perivascular sensory
nerves (Zygmunt et al., 1999). Sensory-nerve mediated activity
has been implicated in oleamide-induced relaxation of isolated
mesenteric arteries (Hoi and Hiley, 2006; Sudhahar et al., 2009).
Sudhahar et al. (2009) demonstrated that the presence of
capsazepine, a TRPV1 antagonist, reduced the potency of oleamide
and that mesenteric arteries were associated with the expression of
TRPV1. Vasorelaxant responses to anandamide in the rat
mesenteric arterial bed were attenuated by capsaicin pre-treatment
and in the presence of ruthenium red (Harris et al., 2002). It was
therefore hypothesised that oleamide was causing vasorelaxation
through sensory-nerve mediated activity. However, this proposal
can be rejected as a chronic pre-treatment of the mesenteric arterial
bed with capsaicin had no effect on oleamide-induced responses.
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This chapter presents evidence demonstrating oleamide to be a
potent vasorelaxant of the rat mesenteric arterial bed. However, its
key vascular effect could be via its ability to impair endothelium-
dependent relaxations, possibly via inhibition of gap junctions. This
could be of significance as endogenous oleamide might regulate
endothelial function and this could be relevance to vascular
pathology. For example under pathological conditions when levels of
oleamide are increased or following inhibition of FAAH there may be
inhibition of EDHF-type responses.
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Chapter 8 General Discussion
8.1 General Discussion
This study aimed to characterise the vascular actions of the
endocannabinoid-like mediator oleamide, making a comparison with
the actions of the prototypical endocannabinoid anandamide. This
thesis investigated the effects of oleamide in large conduit vessels in
both health and disease, providing insights into the mechanisms of
action. This study also characterised the properties of oleamide in a
whole arterial bed and its effects on endothelium-dependent
relaxation.
8.1.1 Oleamide as a vasorelaxant
The vascular actions of oleamide have received relatively little
interest, especially in comparison to the cardiovascular effects of
anandamide. One of the major aims of this thesis was to build on
previous research demonstrating the potent vasorelaxant properties
of oleamide in small resistance mesenteric arteries (Hoi and Hiley,
2006; Sudhahar et al., 2009). Chapter 2 aimed to characterise and
compare the vascular actions of oleamide and anandamide in larger
conduit vessels.
An initial finding of this study was the small vasorelaxant effect of
oleamide in the rat isolated aorta. Oleamide induced approximately
20% relaxation, which is comparable to the effect of other
cannabinoid compounds in the same preparation (OSullivan et al.,
2005). In the present study anandamide failed to elicit any
response in aortae, contradictory to the small vasorelaxation
reported elsewhere. The vasorelaxant effect of oleamide was found
to be tissue dependent, as oleamide did not induce responses in
porcine isolated coronary and mesenteric arteries. Anandamide, in
contrast, evoked relaxation of mesenteric arteries in a NO-
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dependent manner. Therefore, this study demonstrates clear
differences in the mechanisms of action between oleamide and
anandamide.
Oleamide-induced vasorelaxation was abolished by capsaicin pre-
treatment independently of sensory-nerve mediated activity.
Results in Chapter 5 demonstrate that capsaicin can affect vascular
control by mechanisms distinct from sensory-nerve activation.
Hence, the results suggest that oleamide may have an additional
unidentified capsaicin-sensitive site of action. This action may also
play an important role in the enhanced effects of oleamide and
anandamide in aorta from hypertension.
Building on previous work by others using the rat isolated
mesenteric artery, this thesis demonstrated that oleamide caused a
large vasorelaxant effect in the rat perfused mesenteric arterial bed.
This response was diminished by a depolarising concentration of
high extracellular K+, possibly implicating the involvement of K+-
channels and/or EDHF-mediated activity. This provides supporting
evidence for previous reports demonstrating the sensitivity of the
oleamide response in rat mesenteric arteries to a combination of
apamin and charybdotoxin and also to high extracellular K+ (Hoi and
Hiley, 2006).
8.1.2 Alternative mechanism of action for capsaicin
As discussed in Chapter 6, capsaicin has been shown to be a potent
agonist of TRPV1 receptors, through which it can exert a range of
pharmacological effects. The activation of TRPV1 on perivascular
sensory nerves by capsaicin can result in the release of vasoactive
neuropeptides causing vasorelaxation. Thus, chronic exposure of
isolated vessels to capsaicin is a routinely used pharmacological tool
to exhaust neuropeptide stores and desensitise sensory nerves to
TRPV1 activation. For example, Zygmunt et al. (1999) pre-treated
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isolated arteries with capsaicin to help implicate the involvement of
sensory-nerves in anandamide-induced vasodilation. Therefore, this
study similarly exposed arteries to capsaicin in order to characterise
the involvement of sensory nerves in responses to oleamide and
anandamide. This thesis demonstrates the capsaicin-sensitive
nature of both oleamide-induced vasorelaxation of isolated rat
aortae and in the enhanced effects of oleamide in aortae from
hypertension. Similarly, the augmented effect of anandamide in
aortae from SHR rats was normalised by capsaicin pre-treatment.
However, it was demonstrated that the vascular effects of oleamide
and anandamide were insensitive to TRPV1 antagonism with
capsazepine and ruthenium red. This suggested that capsaicin,
and therefore oleamide and anandamide, were eliciting vascular
effects independently of TRPV1 and sensory nerves. This prompted
the investigation into the mechanisms of action of capsaicin in the
rat aorta and in the porcine coronary artery.
Other studies demonstrated that capsaicin can induce changes in
vascular tone by mechanisms distinct from TRPV1 receptors, by
acting directly on ion channels (Lo et al., 1995; Ellis et al., 1997;
Zhu et al., 1997; Yeon et al., 2001; Fujimoto et al., 2006). This
thesis contributes further evidence demonstrating that capsaicin
evokes vasorelaxation via mechanisms independent of sensory
nerves. It was shown that capsaicin-induced vasorelaxation of both
rat aortae and porcine coronary arteries was insensitive to the
presence of capsazepine and ruthenium red. In both porcine
coronary arteries and rat aortae the presence of capsaicin inhibited
the contractile response caused by the re-introduction of calcium. It
was also demonstrated that the vasoconstrictor properties of Bay-k
8644, a L-type calcium channel activator, in porcine coronary
arteries was blocked by capsaicin. Thus this thesis presents an
alternative mechanism of action for capsaicin in affecting arterial
tone and substantiates previous work in which capsaicin inhibited
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calcium-influx in vascular smooth muscle from rat aortae
(Monsereenusorn and Kongsamut, 1985; Lo et al., 1995).
The demonstration of an alternative mechanism of action for
capsaicin helps validate results in Chapter 2 and 3 in which capsaicin
pre-treatment attenuated vasorelaxation by anandamide and
oleamide. How capsaicin and its newly defined ability to either
directly or indirectly block L-type calcium channels can interfere with
endocannabinoid-induced effects is not completely understood.
There are a number of possible explanations however. Firstly,
capsaicin may persist after the washout period and act directly at
ion channels to interfere with endocannabinoid-induced responses.
Secondly, capsaicin may interact with a novel, as yet unidentified,
CB or TRPV receptor to attenuate relaxation evoked by oleamide and
anandamide. Another alternative is that capsaicin is interfering with
an ion channel that is a downstream target of a novel CB receptor.
Importantly, this thesis provides results which have some
implications for experimental pharmacology. Most notably that
capsaicin may stimulate effects in tissue lacking TRPV1 receptors
and sensory-nerve innervation and so experiments utilising chronic
capsaicin pre-treatment should validate results using TRPV1
antagonists.
8.1.3 Effect of hypertension on oleamide-induced responses
A major focus of this thesis was to examine the effects of
hypertension on oleamide-induced vasorelaxation. Having
demonstrated a small vasorelaxant response to oleamide in normal
Wistar aortae in Chapter 2 and in light of the enhanced
cardiovascular effects of anandamide in hypertension reported
elsewhere, the present study aimed to characterise the effects of
oleamide in aortae from the SHR model of hypertension. The
principal finding of Chapter 3 was that oleamide-induced
vasorelaxation was greatly augmented in aortae from hypertension
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compared to those from normotensive controls. This augmented
response in hypertension is related to differences in the COX-
pathway. This conclusion was based upon the observation that the
presence of indomethacin potentiated the relaxant effects of
oleamide in aortae from the normotensive strain to a level
comparable to arteries from hypertension. This thesis also describes
upregulated responses to anandamide in SHR aortae, consistent
with responses reported by Wheal and Randall (2009). However,
alterations in prostanoid metabolism were not responsible for the
elevated vasorelaxation caused by anandamide in hypertension.
The augmented responses to oleamide and anandamide in aortae
from hypertension were both normalised to levels comparable to
those from normotensive controls by chronic exposure to capsaicin.
Similarly to the capsaicin-sensitive nature of oleamide-induced
relaxation in Wistar aortae, enhanced responses to oleamide and
anandamide are independent of TRPV1 activity.
Another interesting point of discussion is the effect of indomethacin
on oleamide-induced relaxations in different tissues. In WKY aorta
indomethacin enhanced responses to oleamide. Therefore, in the
WKY control an alteration to the COX-pathway exists that is not
present in the SHR. Similarly, this effect of indomethacin on
oleamide responses was not present in the normal Wistar aorta,
suggesting that the Wistar and SHR may be more similar than the
SHR and WKY control. This opens up the debate whether the
alteration in the COX pathway is lost in SHR rats as an adaptive
change to hypertension or if it is due to the WKY being an
inappropriate control animal. Indeed, whether or not the WKY is an
appropriate control has been discussed by others in greater detail.
It has been demonstrated that SHR and WKY rats are genetically
quite different and in genes unrelated to hypertension, which is
probably due to random genetic drift (St. Lezin et al., 1992). In the
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future it would be useful to investigate the effects of oleamide using
transgenic models of hypertension.
Having described enhanced responses in aortae from hypertension,
the focus of Chapter 5 was to examine the vascular effects of
anandamide and oleamide in a different arterial preparation. In
contrast to augmented responses in aortic rings from SHR rats,
oleamide caused similar vasorelaxation in mesenteric arteries from
both healthy and diseased rats. Thus, this thesis demonstrates the
tissue specific nature of the effects of hypertension on oleamide-
induced responses. The enhanced vasorelaxant effect of
anandamide in hypertension was however also observed in
mesenteric arteries.
This study also documents differences in endothelial function
between vessels from hypertensive and normotensive rats, although
underlying differences in endothelial function did not account for the
enhanced effects of oleamide and anandamide in SHR aortae.
Chapter 4 demonstrates greater endothelium-dependent relaxations
in aortae from SHR rats. This thesis therefore presents results that
are contradictory to earlier work suggesting that hypertension is
associated with impaired endothelial function (Luscher and
Vanhoutte, 1986). A substantial amount of research showed
diminished responses to endothelium-dependent relaxants and the
production of prostanoid-derived EDCFs in SHR aortae. As
discussed in Chapter 4, the contradictory nature of these results
may reflect age-related changes in endothelial function. It is
possible that enhanced endothelial function could represent an
adaptive change in the early stages of established hypertension. In
both SHR and WKY aortae carbachol-induced relaxations were
inhibited by L-NAME, however a small residual component of
endothelium-dependent relaxation in SHR aortae was insensitive to
L-NAME. This residual component of endothelium-dependent
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relaxation was also independent of sensory nerves, EDHF, COX-
pathway, gap-junctions and hydrogen peroxide. Chapter 5 provides
further evidence for augmented endothelial function in the early
stages of established hypertension in the SHR, carbachol was
identified to be a more potent vasorelaxant of SHR mesenteric
arteries versus those from WKY rats.
8.1.4 Effect of oleamide on EDHF-mediated vasorelaxation
Gap-junctional communication was originally implicated in EDHF-
mediated endothelium-dependent vasorelaxation by Chaytor et al.
(1998). The role of gap junctions in EDHF-type responses is
discussed in detail in Chapter 7. Indeed, the endothelium-
dependent relaxation induced by carbachol in the perfused rat
mesenteric arterial bed was sensitive to gap-junction inhibition by
18-Į glycyrrhetinic acid, palmitoleic acid, clotrimazole, ouabain and
rimonabant (Harris et al., 2000). This thesis provides results that
confirm the findings of Harris et al. (2000) and the role of gap-
junctions in EDHF-mediated relaxation. The presence of
carbenoxolone, a glycyrrhetinic acid derived gap-junction blocker, in
combination with L-NAME completely blocked the relaxant actions of
carbachol in the perfused rat mesenteric arterial bed. This study
also provided evidence substantiating the ability of oleamide to act
as a gap-junction blocker. Guan et al. (1997) originally described
oleamides ability to inhibit gap-junctional communication in rat glial
cells, subsequent groups used oleamide as a tool to study the role of
gap-junctions in physiological processes. The present study
suggests that oleamide can act at gap junctions expressed in the
vasculature and function to block EDHF-type relaxations. Oleamide
replicated the effects of carbenoxolone in the presence of L-NAME,
in blocking vasorelaxant response to carbachol in the perfused
mesenteric arterial bed. Further studies should include the effects
of oleamide on Lucifer dye transfer in vascular tissue. Future
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investigations elucidating the specific-gap junctions involved in
EDHF-mediated relaxation of rat mesenteric arterial bed and the
connexins expressed in this tissue should help identify the specific
gap junction complexes at which oleamide acts.
8.1.5 Conclusions
This thesis contributes to existing literature demonstrating the
vasorelaxant properties of oleamide. The investigation shows that
oleamide exerts a small vasorelaxant effect in the rat isolated aorta,
which is not as large or as potent an effect reported elsewhere in rat
mesenteric resistance arteries (Hoi and Hiley, 2006; Sudhahar et al.,
2009). However, in porcine coronary and mesenteric arteries
oleamide did not demonstrate vasorelaxant properties. This clearly
shows a tissue and species dependent nature of the vasodilator
effects of oleamide. Results presented here suggest that oleamide
is less effective in conduit vessels compared to resistance vessels.
Oleamide elicited a large vasorelaxant response in the rat perfused
mesenteric arterial bed, building on work by other research groups
describing relaxation of isolated mesenteric arteries to oleamide.
A major finding of this study was the greatly enhanced response to
both anandamide and oleamide in aortae from hypertensive rats
compared to those from normotensive controls. The COX-pathway
was shown to be an important component in regulating oleamide-
induced responses in aortae for normotensive WKY rats. The
limiting effect of the COX-pathway on oleamide responses was
absent in hypertension and it is possible that this represents an
adaptive change in the early stages of established hypertension.
This thesis also highlights the tissue specific nature of the effect of
hypertension on oleamide-induced vasorelaxation, with oleamide-
induced relaxation of mesenteric arteries being equal between the
two strains of rat.
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The augmented responses to both oleamide and anandamide were
sensitive to capsaicin pre-treatment but were shown to be
independent of sensory-nerve mediated activity. Vasorelaxation of
normal Wistar aortae was also abolished by capsaicin. This thesis
provides a capsaicin-sensitive mechanism, independent from
sensory-nerves and neuropeptide release, which can mediate
vascular responses to endocannabinoids in conduit arteries. The
nature of this novel mechanism of action remains to be elucidated.
In summary, oleamide has been found to exert significant vascular
effects, both directly and indirectly by interfering with EDHF. The
enhanced responses to oleamide and endothelium-dependent
relaxations found in early hypertension may represent an important
adaptive mechanism to modulate cardiovascular control in
hypertension.
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Figure 8.1
Figure 8.1 Potential vascular mechanisms of action of oleamide.
Oleamide may act to inhibit EDHF-mediated endothelium-dependent
vasorelaxation by blocking myoendothelial gap junctions. Oleamide
may also be able to cause vasorelaxation via K+ channels, which
may also involve EDHF-mediated mechanisms. The cyclooxygenase
(COX) pathway can play an important role in regulating the
vasorelaxant effect of oleamide. Oleamide and anandamide induce
capsaicin-sensitive vasorelaxation, which may point to the existence
of a capsaicin-sensitive novel CB-receptor, most likely located on
the vascular smooth muscle. It has been demonstrated that
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capsaicin can block Ca2+-uptake through L-type calcium channels on
vascular smooth muscle.
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9. Appendices
9.1 Appendix 1
9.1.1 Pre-contraction data for Chapter 2
Figure Treatment Basal tone
(g)
Induced
tone
(g)
2.4 oleamide
(n=10)
0.96±0.02 1.20±0.10
2.4 DMSO (n=6) 1.03±0.02 0.98±0.03
2.5 + high K+
(n=8)
1.00±0.01 0.87±0.08
2.6 control
(n=11)
0.97±0.01 0.89±0.08
2.6 + capsaicin
pre-
treatment
(n=11)
1.01±0.01 1.09±0.13
2.7 control
(n=10)
0.96±0.02 1.20±0.10
2.7 + 5µM
capsazepine
(n=7)
0.82±0.13 1.12±0.15
2.8 control
(n=7)
1.00±0.02 0.80±0.06
2.8 + ruthenium
red (n=7)
1.03±0.02 0.84±0.06
2.9 + control
(n=8) 0.98±0.01
1.10±0.08
2.9 + indometh
(n=8) 0.94±0.02
0.87±0.06
2.10 control
(n=6) 0.94±0.02
1.46±0.13
2.10 + minus
endothelium
(n=6)
1.02±0.02 1.53±0.15
2.11 control
(n=7)
1.02±0.02 1.12±0.09
2.11 + URB97
(n=8)
1.02±0.03 1.17±0.06
2.12 control
(n=7)
0.98±0.02 0.85±0.07
2.12 + AM251
(N=6)
0.99±0.03 0.90±0.06
2.13 anandamide
(n=8)
1.01±0.03 1.41±0.15
2.14 oleamide
(n=6)
5.01±0.04 5.90±0.86
2.14 DMSO (n=6) 5.03±0.07 8.30±0.87
2.15 anandamide
(n=5)
4.95±0.06 7.23±1.04
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2.16 oleamide
(n=10)
4.82±0.10 5.85±0.90
2.16 DMSO
(n=10)
4.61±0.19 5.76±0.87
2.17 anandamide
(n=6)
4.87±0.03 3.87±0.28
2.17 EtOH (n=5) 4.11±0.14 6.35±1.21
2.18 control
(n=8)
4.34±0.17 7.21±1.72
2.18 + L-NAME
(n=8)
4.89±0.40 10.20±1.81
2.19 control
(n=10)
4.19±0.12 5.90±0.87
2.19 + indometh
(n=10)
4.51±0.13 6.47±1.17
2.20 control
(n=6)
4.23±0.14 6.26±0.63
2.20 + capsaicin
pre-
treatment
(n=6)
4.11±0.14 6.35±1.21
2.21 control
(n=7)
4.69±0.26 8.50±0.68
2.21 + minus
endothelium
(n=8)
4.58±0.18 8.42±1.26
Values are mean±S.E.M, with n values stated in brackets.
9.1.2 Pre-contraction data for Chapter 3
Figure Treatment Basal tone
(g)
Induced
tone (g)
3.2 WKY-
oleamide
(n=5)
0.96±0.02 1.00±0.11
3.2 SHR-
oleamide
(n=6)
1.03±0.04 1.22±0.17
3.3 WKY-
anandamide
(n=10)
1.05±0.02 0.92±0.08
3.3 SHR-
anandamide
(n=10)
1.05±0.02 0.94±0.09
3.4 WKY-
oleamide
(n=6)
0.97±0.02 1.63±0.13
3.4 +AM251
(n=4)
0.95±0.04 1.38±0.29
3.4 SHR-
oleamide
(n=8)
0.94±0.03 1.18±0.25
3.4 + AM251 0.89±0.04 1.73±0.18
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(n=6)
3.5 WKY-
anandamide
(n=6)
0.86±0.03 1.27±0.18
3.5 + AM251
(n=6)
0.94±0.04 1.42±0.07
3.5 SHR-
anandamide
(n=6)
1.07±0.05 1.08±0.17
3.5 + AM251
(n=6)
0.99±0.06 0.92±0.12
3.6 WKY-
oleamide
(n=6)
0.97±0.02 1.63±0.13
3.6 + minus
endothelium
(n=6)
0.98±0.03 1.30±0.31
3.6 SHR-
oleamide
(n=8)
0.94±0.03 1.18±0.25
3.6 + minus
endothelium
(n=9)
1.00±0.03 0.84±0.14
3.7 WKY-
oleamide
(n=5)
0.96±0.02 1.00±0.11
3.7 + L-NAME
(n=6)
1.05±0.03 1.60±0.11
3.7 SHR-
oleamide
(n=6)
1.03±0.04 1.22±0.17
3.7 + L-NAME
(n=6)
1.22±0.07 1.23±0.21
3.8 WKY-
anandamide
(n=5)
0.93±0.05 1.66±0.31
3.8 + minus
endothelium
(n=6)
0.95±0.01 1.47±0.11
3.8 SHR-
anandamide
(n=7)
0.97±0.03 1.21±0.18
3.8 + minus
endothelium
(n=7)
0.95±0.02 0.99±0.13
3.9 WKY-
anandamide
(n=10)
1.05±0.02 0.92±0.11
3.9 + L-NAME
(n=6)
1.00±0.04 0.86±0.05
3.9 SHR-
anandamide
(n=10)
1.05±0.02 0.94±0.09
3.9 + L-NAME
(n=7)
1.03±0.02 0.70±0.07
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3.10 WKY-
oleamide +
indometh
(n=7)
1.00±0.02 0.64±0.06
3.10 SHR-
oleamide +
indometh
(n=6)
0.80±0.02 1.01±0.11
3.11 WKY-
oleamide
(n=6)
0.92±0.04 0.91±0.08
3.11 + niflumic
acid (n=6)
0.90±0.04 0.62±0.05
3.11 SHR-
oleamide
(n=6)
0.92±0.01 0.69±0.09
3.11 + niflumic
acid (n=5)
0.94±0.03 1.18±0.25
3.12 WKY-
anandamide
(n=6)
0.86±0.03 1.27±0.18
3.12 +
indomethacin
(n=6)
0.92±0.07 0.89±0.16
3.12 SHR-
anandamide
(n=6)
1.07±0.65 1.08±0.17
3.12 +
indomethacin
(n=6)
0.85±0.04 1.34±0.22
3.13 WKY-
oleamide
(n=6)
0.93±0.05 1.36±0.17
3.13 + indometh
+minus
endothelium
(n=6)
0.81±0.04 1.31±0.16
3.14 WKY-
oleamide
(n=6)
0.95±0.01 0.76±0.08
3.14 + URB597
(n=7)
0.93±0.07 0.82±0.06
3.14 SHR-
oleamide
(n=6)
1.04±0.03 0.95±0.12
3.14 + URB597
(n=6)
1.00±0.03 0.94±0.05
3.15 WKY-
anandamide
(n=8)
1.00±0.04 0.74±0.03
3.15 + URB597
(n=8)
0.99±0.03 0.80±0.07
3.15 SHR-
anandamide
(n=6)
0.82±0.12 0.97±0.12
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3.15 + URB597
(n=6)
0.78±0.10 0.76±0.09
3.16 WKY-
oleamide +
capsaicin
pre-treat
(n=6)
0.92±0.03 0.97±0.10
3.16 SHR-
oleamide +
capsaicin
pre-treat
(n=5)
0.97±0.02 1.39±0.23
3.17 WKY-
anandamide
+capsaicin
pre-treat
(n=7)
1.03±0.01 0.69±0.04
3.17 SHR-
anandamide
+capsaicin
pre-treat
(n=7)
1.05±0.01 0.59±0.06
3.18 WKY-
capsaicin
(n=8)
1.02±0.01 0.94±0.12
3.18 SHR-
capsaicin
(n=9)
1.01±0.02 1.08±0.13
3.19 WKY-
oleamide
(n=7)
0.95±0.01 0.76±0.08
3.19 +
capsazepine
(n=6)
0.97±0.02 0.84±0.09
3.19 SHR-
oleamide
(n=6)
1.04±0.03 0.95±0.11
3.19 +
capsazepine
(n=6)
1.01±0.02 0.72±0.06
3.20 WKY-
oleamide
(n=7)
0.95±0.01 0.76±0.08
3.20 + ruthenium
red (n=7)
1.01±0.06 1.10±0.13
3.20 SHR-
oleamide
(n=6)
1.04±0.03 0.95±0.11
3.20 + ruthenium
red (n=6)
1.08±0.05 0.91±0.08
3.21 WKY-
anandamide
(n=8)
1.00±0.04 0.74±0.03
3.21 +
capsazepine
1.02±0.02 0.55±0.03
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(n=7)
3.21 SHR-
anandamide
(n=6)
0.82±0.12 0.97±0.12
3.21 +
capsazepine
(n=5)
0.77±0.12 0.72±0.13
3.22 WKY-
anandamide
(n=8)
1.00±0.04 0.74±0.03
3.22 + ruthenium
red (n=7)
1.06±0.04 0.95±0.18
3.22 SHR-
anandamide
(n=7)
0.82±0.12 0.97±0.12
3.22 + ruthenium
red (n=5)
0.79±0.12 0.78±0.05
Values are mean±S.E.M, with n values stated in brackets.
9.1.3 Pre-contraction data for Chapter 4
Figure Treatment Basal tone
(g)
Induced
tone (g)
4.2 WKY-
carbachol
(n=10)
1.00±0.01 0.97±0.07
4.2 SHR-
carbachol
(n=10)
1.02±0.02 0.92±0.10
4.3 WKY + L-
NAME (n=6)
1.00±0.02 0.78±0.08
4.3 SHR + L-
NAME (n=6)
0.99±0.01 0.63±0.08
4.4 WKY (n=4) 1.01±0.07 1.54±0.30
4.4 WKY +
indometh
(n=5)
0.94±0.04 0.97±0.10
4.4 SHR (n=7) 1.04±0.04 1.56±0.20
4.4 SHR +
indometh
(n=7)
0.85±0.04 0.88±0.11
4.5 WKY +
capsaicin pre-
treat (n=6)
1.03±0.01 0.65±0.07
4.5 SHR +
capsaicin pre-
treat (n=5)
1.03±0.02 0.53±0.04
4.6 WKY (n=4) 1.01±0.07 0.79±0.07
4.6 WKY +
catalase + L-
NAME (n=4)
1.08±0.09 0.94±0.18
4.6 SHR (n=4) 0.98±0.05 0.91±0.09
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4.6 SHR +
catalase + L-
NAME (n=4)
1.18±0.13 1.11±0.21
4.7 SHR + high
K+ (n=3)
1.03±0.04 1.06±0.17
4.7 + L-NAME +
high k+ (n=3)
1.01±0.03 1.11±0.09
4.7 capsaicin pre-
treat + L-
NAME +high
K+ (n=3)
0.98±0.04 1.05±0.11
4.8 SHR (n=4) 1.01±0.01 1.08±0.17
4.8 + L-NAME
(n=4)
1.09±0.06 1.09±0.06
4.8 +
carbenoxolone
(n=4)
0.98±0.04 0.93±0.10
4.8 + L-NAME +
carbenoxolone
(n=4)
0.88±0.02 1.16±0.25
Values are mean±S.E.M, with n values stated in brackets.
9.1.4 Pre-contraction data for Chapter 5
Figure Treatment Basal tone
(g)
Induced
tone (g)
5.3 WKY-
oleamide
(n=6)
1.03±0.03 0.98±0.12
5.3 SHR-
oleamide
(n=6)
1.10±0.04 0.98±0.16
5.4 WKY-
anandamide
(n=8)
0.97±0.01 1.02±0.06
5.4 SHR-
anandamide
(n=8)
0.96±0.02 1.16±0.10
5.5 WKY + L-
NAME (n=7)
1.05±0.04 1.10±0.22
5.5 SHR + L-
NAME (n=8)
1.02±0.04 1.13±0.24
5.6 WKY-
carbachol
(n=9)
0.93±0.02 0.83±0.15
5.6 SHR-
carbachol
(n=9)
0.96±0.01 1.35±0.14
5.7 WKY-
capsaicin
(n=9)
0.94±0.01 0.98±0.19
5.7 SHR-
capsaicin
0.97±0.01 1.33±0.18
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(n=8)
Values are mean±S.E.M, with n values stated in brackets.
9.1.5 Pre-contraction data for Chapter 6
Figure Treatment Basal tone
(g)
Induced
tone (g)
6.3 capsaicin
(n=6)
0.98±0.02 1.17±0.06
6.3 EtOH (n=7) 0.97±0.03 1.37±0.08
6.4 + capsaicin
pre-
treatment
(n=7)
1.02±0.01 1.08±0.09
6.4 control
(n=8)
0.97±0.01 0.86±0.07
6.5 +
capsazepine
(n=8)
1.01±0.02 0.89±0.08
6.5 control
(n=6)
0.99±0.01 1.07±0.13
6.6 + ruthenium
red (n=6)
1.01±0.01 0.94±0.06
6.9 capsaicin
(n=6)
5.14±0.14 6.17±0.68
6.9 +
capsazepine
(n=6)
4.97±0.04 4.26±0.62
Values are mean±S.E.M, with n values stated in brackets.
9.1.6 Pre-contraction data for Chapter 7
Figure Treatment Basal tone
(mmHg)
Induced
tone
(mmHg)
7.2 control (n=3-
5)
32.89±2.49 61.75±11.86
7.2 + L-NAME
(n=4)
34.94±1.75 99.72±14.36
7.2 +
carbenoxolone
+L-NAME
(n=4)
44.19±5.00 37.44±6.30
7.3 + capsaicin
pre-treatment
(n=4)
31.67±2.79 73.00±8.16
7.3 + L-NAME +
High K+ (n=4)
54.49±16.26 73.66±21.37
7.4 control (n=4) 32.81±3.22 77.36±17.25
7.4 + L-NAME
(n=4)
34.94±1.75 95.24±5.41
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7.4 + oleamide +
L-NAME (n=5)
44.67±2.79 99.17±16.32
7.4 +
carbenoxolone
+ L-NAME
(n=5)
44.19±5.00 40.66±7.65
7.5 control (n=3) 41.40±4.06 56.21±8.19
7.5 + oleamide
(n=3)
42.34±3.54 58.30±11.33
Values are mean±S.E.M, with n values stated in brackets.
